<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003046.pub2" GROUP_ID="LIVER" ID="852300021113091087" MERGED_FROM="" MODIFIED="2013-12-18 14:28:18 +0000" MODIFIED_BY="Dimitrinka Nikolova" REVIEW_NO="02" REVMAN_SUB_VERSION="5.2.7 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<TITLE MODIFIED="2013-10-27 15:29:50 +0100" MODIFIED_BY="[Empty name]">Radiofrequency (thermal) ablation versus no intervention or other interventions for hepatocellular carcinoma</TITLE>
<CONTACT>
<PERSON ID="35735DBF82E26AA200DA2AF314340255" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sebastian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sebastian.weis@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology</DEPARTMENT>
<ORGANISATION>University of Leipzig</ORGANISATION>
<ADDRESS_1>Liebigstrasse 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 34 19 71 2200</PHONE_1>
<PHONE_2/>
<FAX_1>+49 34 19 7 12 259</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<PERSON ID="35735DBF82E26AA200DA2AF314340255" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Sebastian</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Weis</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>sebastian.weis@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology</DEPARTMENT>
<ORGANISATION>University of Leipzig</ORGANISATION>
<ADDRESS_1>Liebigstrasse 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 34 19 71 2200</PHONE_1>
<PHONE_2/>
<FAX_1>+49 34 19 7 12 259</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="53895579224828069557090904133706" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Annegret</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Franke</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>afranke@zks.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Zentrum für Klinische Studien (ZKS) Leipzig</DEPARTMENT>
<ORGANISATION>Universität Leipzig</ORGANISATION>
<ADDRESS_1>Haertelstrasse 16-18</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04107</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BCF0937282E26AA20144426C33405746" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Joachim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mössner</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION>Head of Department</POSITION>
<EMAIL_1>moej@medizin.uni-leipzig.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Division of Gastroenterology and Rheumatology Department of Internal Medicine, Neurology and Dermatology</DEPARTMENT>
<ORGANISATION>University of Leipzig</ORGANISATION>
<ADDRESS_1>Liebigstrasse 20</ADDRESS_1>
<ADDRESS_2/>
<CITY>Leipzig</CITY>
<ZIP>04103</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 341 97 109 ext: 12200</PHONE_1>
<PHONE_2/>
<FAX_1>+49 341 97 12209</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="06606975239186546212100225134955" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Janus</FIRST_NAME>
<MIDDLE_INITIALS>C</MIDDLE_INITIALS>
<LAST_NAME>Jakobsen</LAST_NAME>
<SUFFIX/>
<POSITION>Medical Doctor, PhD</POSITION>
<EMAIL_1>jcj@ctu.dk</EMAIL_1>
<EMAIL_2>janusjakobsen@mac.com</EMAIL_2>
<URL/>
<MOBILE_PHONE>+4526186242</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>The Cochrane Hepato-Biliary Group</DEPARTMENT>
<ORGANISATION>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet</ORGANISATION>
<ADDRESS_1>Blegdamsvej 9</ADDRESS_1>
<ADDRESS_2/>
<CITY>Copenhagen</CITY>
<ZIP>DK-2100</ZIP>
<REGION>Sjælland</REGION>
<COUNTRY CODE="DK">Denmark</COUNTRY>
<PHONE_1>+45 26186242</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="BCF0913F82E26AA20144426C4B3B780B" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Konrad</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Schoppmeyer</LAST_NAME>
<SUFFIX>MD</SUFFIX>
<POSITION/>
<EMAIL_1>konrad.schoppmeyer@euregio-klinik.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Internal Medicine</DEPARTMENT>
<ORGANISATION>Euregio-Klinik GmbH</ORGANISATION>
<ADDRESS_1>Albert-Schweitzer-Str. 10</ADDRESS_1>
<ADDRESS_2/>
<CITY>Nordhorn</CITY>
<ZIP>48529</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 5921 84 1660</PHONE_1>
<PHONE_2/>
<FAX_1>+49 5921 84 1664</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2012-09-18 12:23:43 +0200" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="19" MONTH="9" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="3" MONTH="9" YEAR="2012"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2014"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2001"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2004"/>
</DATES>
<WHATS_NEW MODIFIED="2013-12-17 15:59:17 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2013-12-17 15:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="19" MONTH="9" YEAR="2013"/>
<DESCRIPTION>
<P>The conclusions of the previous published review were:</P>
<P>"Radiofrequency thermal ablation seems a potentially promising technique for the treatment of small hepatocellular carcinoma. However, more randomised clinical trials are needed."</P>
<P>The conclusions reached in this second update are:</P>
<P>"The effects of RFA versus no intervention, chemotherapeutic treatment, or liver transplantation are unknown. We found moderate-quality evidence that hepatic resection is superior to RFA regarding survival. However, RFA might be associated with fewer complications and a shorter hospital stay than hepatic resection. We found moderate-quality evidence showing that RFA seems superior to percutaneous ethanol injection regarding survival. There were too sparse data to recommend or refute ablation achieved by techniques other than RFA. More randomised clinical trials with low risk of bias and low risks of random errors assessing the effect of RFA are needed."</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-12-17 15:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="18" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>This is the second update of a review originally published in 2002 (<LINK REF="REF-Galandi-2002" TYPE="REFERENCE">Galandi 2002</LINK>) and then updated in 2004 (<LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>). Since 2004, 10 new randomised trials comparing radiofrequency ablation (RFA) with other interventions have been published. These trials account for a substantial increase in the available data and were included in the current review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-12-17 15:59:17 +0100" MODIFIED_BY="Dimitrinka Nikolova">
<DATE DAY="18" MONTH="6" YEAR="2013"/>
<DESCRIPTION>
<P>The review was revised following the latest Cochrane methodology as well as Cochrane Hepato-Biliary Group methodological guidelines.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2011-05-08 21:37:15 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT MODIFIED="2013-12-17 16:37:08 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES MODIFIED="2013-12-17 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-12-17 16:36:54 +0100" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2013-12-17 16:37:08 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2013-12-17 16:37:08 +0100" MODIFIED_BY="[Empty name]">
<NAME>None</NAME>
<COUNTRY CODE="NONE">Not specified</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-12-18 15:25:43 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-12-18 15:21:13 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2012-11-04 13:09:37 +0100" MODIFIED_BY="[Empty name]">Radiofrequency ablation for the treatment of liver cancer (hepatocellular carcinoma)</TITLE>
<SUMMARY_BODY MODIFIED="2013-12-18 15:21:13 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Background</B>
</P>
<P>Liver cancer (hepatocellular carcinoma) is the fifth most common cancer worldwide. In the majority of patients, hepatocellular carcinoma is diagnosed at advanced stages of the disease and is mostly accompanied by liver cirrhosis. To date, there is no medical cure for patients with hepatocellular carcinoma, and treatment aims to slow tumour growth. In high-income countries, about 30% of patients present with the more favourable early hepatocellular carcinoma. For these patients, percutaneous ablation techniques (destruction of the cancer cells by heat, cold, or chemical substances such as ethanol), surgical resection (removal of part of the liver), and liver transplantation (which is limited by organ donor shortage) are currently considered potentially curative treatments. Radiofrequency (thermal) ablation (RFA) is the most elaborated of the percutaneous interventions, so far. Heat caused by alternating electric current is administered by probes that are inserted through the skin (percutaneously).</P>
<P>
<B>Study characteristics</B>
</P>
<P>The review authors searched the medical literature in order to clarify the role of RFA for the treatment of hepatocellular carcinoma and to compare its benefits and harms with no treatment, placebo (a pretend treatment), or other treatments (such as hepatic resection, percutaneous ethanol injection (PEI), percutaneous acetic acid injection (PAI), laser or microwave ablation, and liver transplantation). We looked for randomised clinical trials (where people were allocated at random to one of two or more treatments groups) of people with hepatocellular carcinoma who were able to receive RFA. Evidence is current to September 2013.</P>
<P>
<B>Key results and quality of evidence</B>
</P>
<P>We found no trials comparing RFA versus no intervention, placebo, chemotherapy, or liver transplantation.</P>
<P>The review authors found moderate-quality evidence from two trials with low risk of bias (where there was a low risk of a flaw in study design, method of collecting or interpreting results) randomising 578 patients suggesting that hepatic resection yielded better results regarding overall survival (the length of time that the patient remains alive), event-free survival (time that the person remains free of cancer or a certain symptom relating to cancer), and progression (time that the patient lives with cancer without it getting worse) compared with RFA. However, as resection is a more invasive procedure, resection has an eight times higher risk of major complications compared with RFA. Resected patients stayed twice as long in the hospital as the RFA patients. Moderate-quality evidence suggested that RFA prolongs survival and decreases recurrences (where the cancer returns) compared with PEI or PAI. This conclusion was based on data from six randomised clinical trials with 1088 participants. Some patients developed side effects such as fever, rash, and pain. These occurred at the same frequency in both treatment groups. We calculated the number of patients that would be required to judge a relative risk reduction (relative risk is a comparison of the risk of an event happening for one treatment group compared with another treatment group) for survival of 20%. The review authors found that for both comparisons, that is RFA versus PEI or PAI, and RFA versus resection, the number of patients in the included trials was too low to reach valid conclusions. No firm conclusion can be drawn from the comparison of RFA against other interventional techniques or combination approaches. The information provided by the single trials was limited. More randomised clinical trials with low risks of bias (that is low risks of systematic errors, leading to overestimation of benefits and underestimation of harms) and low risk of play of chance (that is random errors, leading to overestimation or underestimation of benefits and harms) are required.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-12-18 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2013-11-30 21:49:58 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatocellular carcinoma is the fifth most common cancer worldwide. Percutaneous interventional therapies, such as radiofrequency (thermal) ablation (RFA), have been developed for early hepatocellular carcinoma. RFA competes with other interventional techniques such as percutaneous ethanol injection, surgical resection, and liver transplantation. The potential benefits and harms of RFA compared with placebo, no intervention, chemotherapy, hepatic resection, liver transplantation, or other interventions are unclear.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2013-12-17 15:59:38 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of RFA versus placebo, no intervention, or any other therapeutic approach in patients with hepatocellular carcinoma.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-12-17 15:59:37 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Central Register of Controlled Trials (CENTRAL)<I>, </I>MEDLINE, EMBASE, and ISI Web of Science to September 2012. We handsearched meeting abstracts from ASCO, ESMO, AASLD, EASL, APASL, and references of articles. We also contacted researchers in the field (last search September 2012).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2013-10-11 13:07:41 +0200" MODIFIED_BY="[Empty name]">
<P>We considered for inclusion randomised clinical trials investigating the effects of RFA versus placebo, no intervention, or any other therapeutic approach on hepatocellular carcinoma patients regardless of blinding, language, and publication status.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2013-12-17 15:59:37 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors independently performed the selection of trials, assessment of risk of bias, and data extraction. We contacted principal investigators for missing information. We analysed hazard ratios (HR) as relevant effect measures for overall survival, two-year survival, event-free survival, and local recurrences with 95% confidence intervals (CI). In addition, we analysed dichotomous survival outcomes using risk ratios (RR). We used trial sequential analysis to control the risk of random errors ('play of chance').</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-12-18 15:22:53 +0100" MODIFIED_BY="[Empty name]">
<P>We identified no trials comparing RFA versus placebo, no intervention, or liver transplantation. We identified and included 11 randomised clinical trials with 1819 participants that included four comparisons: RFA versus hepatic resection (three trials, 578 participants); RFA versus percutaneous ethanol injection (six trials, 1088 participants) including one three-armed trial that also investigated RFA versus acetic acid injection; RFA versus microwave ablation (one trial, 72 participants); and RFA versus laser ablation (one trial, 81 participants). Ten of the eleven included trials reported on the primary outcome of this review, overall survival. Rates of major complications or procedure-related deaths were reported in 10 trials. The overall risk of bias was considered low in five trials and high in six trials. For a subgroup analysis, we included only low risk of bias trials. Regarding the comparison RFA versus hepatic resection, there was moderate-quality evidence from two low risk of bias trials that hepatic resection seems more effective than RFA regarding overall survival (HR 0.56; 95% CI 0.40 to 0.78) and two-year survival (HR 0.38; 95% CI 0.17 to 0.84). However, if we included a third trial with high risk of bias, the difference became insignificant (overall survival: HR 0.71; 95% CI 0.44 to 1.15). With regards to the outcomes event-free survival and local progression, hepatic resection also yielded better results than RFA. However, the number of complications was higher in surgically treated participants (odds ratio (OR) 8.24; 95% CI 2.12 to 31.95). RFA seemed superior to percutaneous ethanol or acetic acid injection regarding overall survival (HR 1.64; 95% CI 1.31 to 2.07). The RR for mortality was also in favour of RFA, but did not reach statistical significance (150/490 (30.6%) people in the percutaneous ethanol or acetic acid group versus 119/496 (24.0%) people in the RFA group; RR 1.76; 95% CI 0.97 to 3.22). The proportion of adverse events did not differ significantly between RFA and percutaneous ethanol or acetic acid injection (HR 0.70; 95% CI 0.33 to 1.48). Trial sequential analyses revealed that the number of participants in the included trials was insufficient and that more trials are needed to assess the effects of RFA versus other interventions.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-12-17 15:59:37 +0100" MODIFIED_BY="[Empty name]">
<P>The effects of RFA versus no intervention, chemotherapeutic treatment, or liver transplantation are unknown. We found moderate-quality evidence that hepatic resection is superior to RFA regarding survival. However, RFA might be associated with fewer complications and a shorter hospital stay than hepatic resection. We found moderate-quality evidence showing that RFA seems superior to percutaneous ethanol injection regarding survival. There were too sparse data to recommend or refute ablation achieved by techniques other than RFA. More randomised clinical trials with low risk of bias and low risks of random errors assessing the effect of RFA are needed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-12-18 15:25:43 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-12-18 15:21:27 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2013-12-17 16:00:06 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Epidemiology and risk factors</HEADING>
<P>Hepatocellular carcinoma (liver cancer) is the fifth most common cancer worldwide (<LINK REF="REF-El-Serag-2007" TYPE="REFERENCE">El Serag 2007</LINK>). The highest incidence of hepatocellular carcinoma is found in regions with endemic hepatitis B virus (HBV) such as Eastern Asia and Central Africa. A rising incidence of hepatocellular carcinoma in high-income countries has been reported, along with a decrease in high-incidence areas (<LINK REF="REF-El-Serag-1999" TYPE="REFERENCE">El Serag 1999</LINK>; <LINK REF="REF-El-Serag-2007" TYPE="REFERENCE">El Serag 2007</LINK>; <LINK REF="REF-Jepsen-2007" TYPE="REFERENCE">Jepsen 2007</LINK>). This might be caused by differences in hepatitis C virus (HCV) prevalence (e.g. increase in the USA) (<LINK REF="REF-Jepsen-2007" TYPE="REFERENCE">Jepsen 2007</LINK>), and increased HBV vaccination rates (e.g. decrease in China) (<LINK REF="REF-El-Serag-2007" TYPE="REFERENCE">El Serag 2007</LINK>). Overall, 75% to 80% of patients with primary liver cancer are attributable to persistent viral infections with either HBV (50% to 55%) or HCV (25% to 30%). High consumption of alcohol; cumulative amount of aflatoxins in the liver over time; and metabolic disorders such as non-alcoholic fatty liver disease, haemochromatosis, and alpha-1-antitrypsin deficiency are further risk factors for the development of cirrhosis and subsequent hepatocellular carcinoma (<LINK REF="REF-S_x00f8_rensen-2003" TYPE="REFERENCE">Sørensen 2003</LINK>; <LINK REF="REF-Bosch-2004" TYPE="REFERENCE">Bosch 2004</LINK>; <LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). Associations of primary liver cancer with diabetes (<LINK REF="REF-El-Serag-2004" TYPE="REFERENCE">El Serag 2004</LINK>), obesity (<LINK REF="REF-Calle-2003" TYPE="REFERENCE">Calle 2003</LINK>), and syndromes related to insulin resistance are subject of ongoing research, but their impact is currently unclear.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Prognosis</HEADING>
<P>Liver cancer carries high mortality. In Europe and USA, the five-year survival is below 10% (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>). In most patients, hepatocellular carcinoma is diagnosed at late stages of the disease and is mostly accompanied by liver cirrhosis. In high-income countries, only about 30% of patients present with the more favourable early hepatocellular carcinoma (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>). Percutaneous ablation techniques, surgical resection, and liver transplantation are currently considered potentially curative treatments for early hepatocellular carcinoma.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Diagnosis</HEADING>
<P>Due to the neovascularity of hepatocellular carcinoma and its characteristic arterial hypervascularity and venous/late phase washout (so-called hepatocellular carcinoma radiological hallmark) in rapid-sequence cross-sectional imaging, an accurate diagnosis of hepatocellular carcinoma lesions larger than 2 cm in diameter can be made non-invasively in patients with cirrhosis. According to the current guidelines of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>), non-invasive diagnostic criteria for patients with cirrhosis and hepatocellular carcinoma are:</P>
<UL>
<LI>for lesions larger than 2 cm: one positive imaging technique (four-phase computed tomography or dynamic contrast enhanced magnetic resonance imaging (MRI))</LI>
<LI>for lesions from 1 to 2 cm: two coincidental techniques (computed tomography, MRI, or contrast-enhanced ultrasound.</LI>
</UL>
<P>Image-guided biopsies of the tumour are common practice in cases of inconclusive radiological findings, that is, a lesion between 1 and 2 cm in diameter identified by only one imaging modality and such biopsies are mandatory for tumours in non-cirrhotic livers (<LINK REF="REF-Takamori-2000" TYPE="REFERENCE">Takamori 2000</LINK>; <LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). Elevated serum levels of alpha-fetoprotein (AFP) that were proposed in addition to one typical radiological finding at the beginning of the century (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>) have been discarded from the diagnostic scheme by the American Association for the Study of Liver Disease (AASLD) (<LINK REF="REF-Bruix-2005" TYPE="REFERENCE">Bruix 2005</LINK>). Conversely, it is still regarded to be useful by EASL and EORTC (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>).</P>
</SUBSECTION>
</CONDITION>
<INTERVENTION MODIFIED="2013-12-17 16:00:21 +0100" MODIFIED_BY="[Empty name]">
<P>Ablation techniques rely on the possibility to induce cell death by thermal or chemical means. The aim of the ablation is to completely destroy all tumour cells and thus provide cure of the cancer. The underlying liver disease (e.g. cirrhosis or hepatitis) is not affected by the treatment.</P>
<P>
<I>Radiofrequency ablation or radiofrequency thermal ablation (RFA) </I>uses frictional heat to induce cell death from coagulation necrosis. After local anaesthesia of the skin, an RFA-electrode is placed into the liver lesion under the guidance of magnetic resonance tomography, computed tomography, or ultrasound (<LINK REF="REF-Goldberg-2000" TYPE="REFERENCE">Goldberg 2000</LINK>). A radiofrequency-current-generator is connected to the needle and a zero-electrode is fixed onto the patient's back. Under short-term analgesia-sedation, energy is applied for a few minutes leading to spheric lesions of about 3 to 5 cm in diameter. When temperatures pace 60 °C, a coagulation necrosis is induced (<LINK REF="REF-Minami-2010" TYPE="REFERENCE">Minami 2010</LINK>; <LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). Several investigations have shown the efficacy and the safety of the procedure (<LINK REF="REF-Rossi-1996" TYPE="REFERENCE">Rossi 1996</LINK>; <LINK REF="REF-Rossi-1998" TYPE="REFERENCE">Rossi 1998</LINK>; <LINK REF="REF-Allgaier-1999" TYPE="REFERENCE">Allgaier 1999</LINK>; <LINK REF="REF-Curley-1999" TYPE="REFERENCE">Curley 1999</LINK>; <LINK REF="REF-Francia-1999" TYPE="REFERENCE">Francia 1999</LINK>; <LINK REF="REF-Goldberg-2000" TYPE="REFERENCE">Goldberg 2000</LINK>; <LINK REF="REF-Grasso-2000" TYPE="REFERENCE">Grasso 2000</LINK>; <LINK REF="REF-Livraghi-2000" TYPE="REFERENCE">Livraghi 2000</LINK>; <LINK REF="REF-Nicoli-2000" TYPE="REFERENCE">Nicoli 2000</LINK>). If necessary, the procedure can be repeated to treat larger lesions or patients with more than one liver tumour.</P>
<P>
<I>Surgical resection</I> demands a radical resection of the tumours. This is often not feasible due to the impairment of liver function caused by the underlying cirrhosis. Local recurrence and de novo hepatocellular carcinoma at other locations within the liver are about 50% at three years and 70% at five years (<LINK REF="REF-Arii-2000" TYPE="REFERENCE">Arii 2000</LINK>; <LINK REF="REF-Bismuth-2000" TYPE="REFERENCE">Bismuth 2000</LINK>; <LINK REF="REF-Llovet-2000" TYPE="REFERENCE">Llovet 2000</LINK>).</P>
<P>
<I>Orthotopic liver transplantation</I> is an alternative approach for selected patients with small hepatocellular carcinoma. The beneficial removal of liver cirrhosis as a predisposing factor for hepatocellular carcinoma is, however, often counterbalanced by progression of the tumour while the patient is waiting for a new organ. Moreover, organ shortage is a major factor limiting the availability of this procedure. The Milan criteria (one tumour of 5 cm or less in diameter, or three tumours with a diameter of 3 cm or less each) are the broadly accepted standard to identify patients suitable for liver transplantation (<LINK REF="REF-Mazzaferro-1996" TYPE="REFERENCE">Mazzaferro 1996</LINK>). Percutaneous techniques are used with increasing frequency to bridge the waiting time until transplantation (<LINK REF="REF-Dubay-2011" TYPE="REFERENCE">Dubay 2011</LINK>).</P>
<P>
<I>Medical treatment options</I>:<I> </I>Sorafenib, a multi-kinase inhibitor improved median survival by 2.8 months in one trial (<LINK REF="REF-Llovet-2008" TYPE="REFERENCE">Llovet 2008</LINK>), and was approved for treatment of advanced hepatocellular carcinoma in 2007 (<LINK REF="REF-W_x00f6_rns-2009" TYPE="REFERENCE">Wörns 2009</LINK>). Sorafenib has not yet been compared to other interventions for hepatocellular carcinoma in randomised trials.</P>
<P>
<I>Percutaneous ethanol injection (PEI) </I>causes dehydration and necrosis of tumour cells, accompanied by small vessel thrombosis, leading to tumour ischaemia and destruction. PEI is usually carried out under ultrasound guidance with repeated injections of ethanol on separate days. Best results for PEI are achieved in single hepatocellular carcinoma lesions of less than 3 cm in diameter, for which complete remission rates of 70% can be expected. Lower occurrences of complete remission have been observed in larger and multinodular tumours (<LINK REF="REF-Livraghi-1995" TYPE="REFERENCE">Livraghi 1995</LINK>; <LINK REF="REF-Lencioni-1997" TYPE="REFERENCE">Lencioni 1997</LINK>). In one Cochrane review with meta-analysis, we concluded that there was insufficient evidence to determine whether PEI or segmental liver resection was more effective (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>). In a recent up-date of the <LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK> review, no additional information could be added and there is little evidence to expect such evidence within the next years (<LINK REF="REF-Weis-2013" TYPE="REFERENCE">Weis 2013</LINK>).</P>
<P>
<I>Percutaneous acetic acid injection</I> (PAI) has been used as an alternative for ethanol in percutaneous treatment (<LINK REF="REF-Ohnishi-1998" TYPE="REFERENCE">Ohnishi 1998</LINK>). Contraindications for PEI and PAI are cirrhosis with poor liver function (Child C cirrhosis), complete portal vein thrombosis, and massive ascites. We chose to analyse data from trials using PEI and PAI together because of the similarities between these two interventions in contrast to other treatment modalities. However, when results from individual trials are reported, we will report if PEI or PAI was used. In subgroup analysis, we will assess if there seems to be a difference in the overall survival in trials comparing RFA versus PEI or PAI.</P>
<P>
<I>Other interventions</I>:<I> </I>Percutaneous cryoablation or interstitial laser photocoagulation are not yet routine clinical practice.</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2013-12-18 15:21:27 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment options of hepatocellular carcinoma have substantially increased since the introduction of ablation therapies in the 1990ies. While PEI was still the preferred treatment option at the beginning of the century (<LINK REF="REF-Bruix-2001" TYPE="REFERENCE">Bruix 2001</LINK>), contradicting results have been reported in recently performed trials. Some were in favour of RFA (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>, while others showed no differences in the outcome between RFA and PEI (<LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). In addition, the effects of RFA compared with hepatic resection for hepatocellular carcinoma are unclear. The current recommendations by the EASL and the EORTC are to use hepatic resection as a primary treatment and to use RFA when surgery is not possible (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). As new trials have been published, we thought that this might change the evidence.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-12-17 16:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the beneficial and harmful effects of RFA versus placebo, no intervention, or any other therapeutic approach in patients with hepatocellular carcinoma.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-12-17 16:00:36 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2013-12-17 16:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised clinical trials, irrespective of publication status or blinding. We applied no language limitations.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2013-12-17 16:00:29 +0100" MODIFIED_BY="[Empty name]">
<P>All patients with hepatocellular carcinoma without contraindications for RFA (e.g. too many or too large tumours, extrahepatic malignant manifestation).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2013-11-30 21:52:57 +0100" MODIFIED_BY="[Empty name]">
<P>RFA compared with placebo, no intervention, or any other intervention.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-12-17 16:00:36 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<UL>
<LI>Overall survival.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcomes</HEADING>
<UL>
<LI>Two-year survival.</LI>
<LI>Event-free survival concerning local recurrences, distant recurrence, de novo (a new) carcinoma, death.</LI>
<LI>Local progression/recurrences.</LI>
<LI>Frequency of complications/serious adverse events. Serious adverse events: Number of participants with serious adverse events defined as "any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalisation or prolongation of existing hospitalisation, results in persistent or significant disability/incapacity". All other adverse events were be considered as non-serious (<LINK REF="REF-ICH_x002d_GCP-1997" TYPE="REFERENCE">ICH-GCP 1997</LINK>).</LI>
<LI>Quality of life.</LI>
<LI>Duration of hospital stay/health economics.</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Electronic searches</HEADING>
<P>We performed electronic searches in the Cochrane Hepato-Biliary Group Controlled Trials Register (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>)<I>, </I>the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and ISI Web of Science (Science Citation Index Expanded) (<LINK REF="REF-Royle-2003" TYPE="REFERENCE">Royle 2003</LINK>) to 3 September 2012. We did not update searches in CancerLit and Current Contents as well as searches of the journals (<I>Zeitschrift für Gastroenterologie</I> (suspended in 2000) and <I>Endoskopie Heute</I> (suspended in 1999). CancerLit is no longer updated and Current Contents has merged into ISI Web of Science. We used the search strategies with the time spans shown in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, which ended September 2012.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Searching other resources  </HEADING>
<P>We also handsearched proceedings of conferences of five oncological and hepatological societies (ASCO, ESMO, AASLD, EASL, APASL), as well as references of articles. We contacted researchers in the field and companies producing RFA equipment for information on further (unpublished) trials.</P>
</SUBSECTION>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-12-17 16:01:40 +0100" MODIFIED_BY="[Empty name]">
<P>We performed this systematic review according to a peer-reviewed, published protocol (<LINK REF="REF-Galandi-2001" TYPE="REFERENCE">Galandi 2001</LINK>), and followed the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and the Cochrane Hepato-Biliary Group Module (<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>). We performed the analyses using Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Selection of studies</HEADING>
<P>One review author (SW) collected the publications of all trials potentially relevant for this review. Two review authors (SW, KS) independently selected trials for inclusion.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data extraction and management</HEADING>
<P>Two review<B> </B>authors (SW, AF) independently extracted the data from all trials. We included data from the first versions of the review by Galandi (<LINK REF="REF-Galandi-2002" TYPE="REFERENCE">Galandi 2002</LINK>; <LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>). We contacted the principal authors of the trials to retrieve missing data. Where there were missing data for an appropriate judgement of the risk of bias, we judged the risk of bias as 'high'. We accepted the original trials' definitions for all beneficial and harmful outcomes although we attempted to extract information on all outcomes specified for this review. We resolved disagreements by discussion. We extracted type and number of serious adverse events, length of hospitalisation, and quality of life if available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of risk of bias in included studies</HEADING>
<P>Two review authors (SW, KS) assessed the risk of bias of all trials included in this review, following the risk of bias domains, with definitions presented below (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995;</LINK> <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998;</LINK> <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001;</LINK> <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008;</LINK> <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>; <LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Allocation sequence generation</HEADING>
<UL>
<LI>Low risk of bias: sequence generation was achieved using computer random number generation or a random number table. Drawing lots, tossing a coin, shuffling cards, and throwing dice were adequate if performed by an independent research assistant not otherwise involved in the trial.</LI>
<LI>Uncertain risk of bias: the method of sequence generation was not specified.</LI>
<LI>High risk of bias: the sequence generation method was not random.<I> </I>
</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Allocation concealment</HEADING>
<UL>
<LI>Low risk of bias: the participant allocations could not have been foreseen in advance of, or during, enrolment. Allocation was controlled by a central and independent randomisation unit. The allocation sequence was unknown to the investigators (e.g. if the allocation sequence was hidden in sequentially numbered, opaque, and sealed envelopes).</LI>
<LI>Uncertain risk of bias: the method used to conceal the allocation was not described so that intervention allocations may have been foreseen in advance of, or during, enrolment.</LI>
<LI>High risk of bias: the allocation sequence was likely to be known to the investigators who assigned the participants.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Blinding of participants, personnel, and outcome assessors</HEADING>
<UL>
<LI>Low risk of bias: blinding was performed adequately, or the assessment of outcomes was not likely to be influenced by lack of blinding.</LI>
<LI>Uncertain risk of bias: there was insufficient information to assess whether blinding was likely to induce bias on the results.</LI>
<LI>High risk of bias: no blinding or incomplete blinding, and the assessment of outcomes were likely to be influenced by lack of blinding.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Incomplete outcome data</HEADING>
<UL>
<LI>Low risk of bias: missing data were unlikely to make treatment effects depart from plausible values. Sufficient methods, such as multiple imputation, had been employed to handle missing data.</LI>
<LI>Uncertain risk of bias: there was insufficient information to assess whether missing data in combination with the method used to handle missing data were likely to induce bias on the results.</LI>
<LI>High risk of bias: the results were likely to be biased due to missing data.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Selective outcome reporting</HEADING>
<UL>
<LI>Low risk of bias: all outcomes were pre-defined (e.g. in a published protocol) and reported, or all clinically relevant (e.g. overall survival, event-free survival, or adverse events) were reported.</LI>
<LI>Uncertain risk of bias: it was unclear whether all pre-defined and clinically relevant outcomes were reported.</LI>
<LI>High risk of bias: one or more clinically relevant outcomes were not reported, and data on these outcomes were likely to have been recorded.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Vested interest bias</HEADING>
<UL>
<LI>Low risk of bias: the trial appeared to be free of other components (should be listed, e.g. industry bias, academic bias, etc.) that could put it at risk of bias.</LI>
<LI>Uncertain risk of bias: it was unclear whether the trial was at risk of vested interest bias.</LI>
<LI>High risk of bias: there were other factors in the trial that could put it at risk of bias (e.g. for-profit involvement, study authors had conducted trials on the same topic, etc.).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other bias</HEADING>
<UL>
<LI>Low risk of bias: no other potential source of bias could be detected.</LI>
<LI>Uncertain risk of bias: potential sources of bias could not be ruled out (e.g. missing outcome definition, unclear baseline differences, etc.).</LI>
<LI>High risk of bias: other relevant sources of bias were present (e.g. small cohorts, significant baseline differences, etc.).</LI>
</UL>
<P>A trial was considered with a low risk of bias, if it was assessed with low risk of bias in all of the specified bias risk domains, and a trial was considered with high risk of bias, if one or more of the specific domains were assessed to be unclear or with high risk of bias.</P>
<P>We solved disagreements by discussion, or by contacting the Cochrane Hepato-Biliary Group in Copenhagen.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Units of analysis issues</HEADING>
<P>We did not include cluster randomised trials. We did not expect or identify cross-over trials due to the nature of the disease and the interventions investigated. We included trials with three or more treatment groups if pair-wise comparison of a single intervention versus RFA was possible and if inclusion criteria of both intervention groups fulfilled the inclusion criteria. In order to exclude analysis bias by multiple counting of the shared intervention group, the shared intervention group was split into a corresponding number of subgroups with smaller sample size. We analysed and included each pair-wise comparison separately. We measured two survival outcomes. We analysed recurrence-free survival and overall survival separately.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Dealing with missing data</HEADING>
<P>We considered missing data in the judgement of selective and incomplete reporting bias. In case of missing data that prevented trials from being included, we contacted trialists and requested missing data. In addition, we aimed to obtain hazard ratios (HRs) and standard deviations or Kaplan Meier survival plots for the survival outcome measures when these were not available from the original publication.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of heterogeneity  </HEADING>
<P>We performed analyses of heterogeneity between trials by calculating the Chi<SUP>2</SUP> statistic using Review Manager 5 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). In addition, we assessed heterogeneity by calculating the I<SUP>2</SUP> statistic (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), measuring the inconsistency among the trials and describing the percentage of variability in effect estimates that occurred due to heterogeneity rather than chance. For I<SUP>2</SUP> statistics, the following thresholds were applied: 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of reporting biases</HEADING>
<P>We planned to do funnel plots if more than 10 trials were identified to give an overview regarding potential reporting bias and other bias sources (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Data synthesis</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Meta-analysis</HEADING>
<P>We performed the meta-analyses according to the recommendations of The Cochrane Collaboration (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>), and the Cochrane Hepato-Biliary Group Module<I> (</I>
<LINK REF="REF-Gluud-2013" TYPE="REFERENCE">Gluud 2013</LINK>
<I>)</I>. We extracted HRs as relevant effect measures for overall survival, two-year survival, event-free survival, and local recurrences with 95% confidence intervals (CI) from publications. Alternatively, we estimated HRs from log rank Chi<SUP>2</SUP> statistics, log rank P values and given (total or group-wise) numbers of events, observed-to-expected event ratios, or Kaplan-Meier curves with patients at risk given, using methods presented by <LINK REF="REF-Machin-1997" TYPE="REFERENCE">Machin 1997</LINK> and <LINK REF="REF-Parmer-1998" TYPE="REFERENCE">Parmer 1998</LINK>. In addition, we calculated risk ratios (RR) together with their 95% CIs for survival. We used odds ratios (OR) together with their 95% CIs to characterise effect differences between RFA and other interventions regarding dichotomous outcomes such as complication rates and the inverse-variance method for measures on metric scale according to the protocol.</P>
<P>We assigned trials to subcategories according to their type of control intervention. We presented pooled effects within each subcategory and as overall estimate of effects. We analysed trials comparing RFA versus two other interventions within a three-armed design in that both comparisons were included independently within the respective subcategory using the given - or estimated - effect differences. The sample size or events or both, observed in the RFA group, allowed only once for the overall analysis to maintain the total sample sizes or events.</P>
<P>We used random-effects models to analyse the effect sizes (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>). In comparison to fixed-effect model meta-analyses, these are more conservative and result in wider CIs of the meta-analysed effect estimates, in order to avoid over-optimistic significances. In contrast, random-effects models put too much weight on small trials (which are often more biased). Therefore, we also conducted fixed-effect model meta-analysis and reported results from both models if the results differed. In the absence of relevant heterogeneity, both models will result in nearly identical effect estimations.</P>
<P>For all available outcomes, we presented data tables or forest plots. The risk of bias within the trials was considered a potential source of heterogeneity, and, therefore, it was assessed in detail according to the methodology described above. We intended to perform a subgroup analysis to compare trials with low risk of bias with the overall evidence received from all suitable trials.</P>
<P>We performed statistical analyses using Review Manager 5 Software (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Trial sequential analysis</HEADING>
<P>We applied trial sequential analysis (<LINK REF="REF-CTU-2011" TYPE="REFERENCE">CTU 2011</LINK>; <LINK REF="REF-Thorlund-2011" TYPE="REFERENCE">Thorlund 2011</LINK>) because cumulative meta-analyses are at risk of producing random errors due to sparse data and repetitive testing of the accumulating data (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>).<SUP> </SUP>To minimise random errors, we calculated the required information size (i.e. the number of participants needed in a meta-analysis to detect or reject a certain intervention effect) (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>). The required information size calculation should also account for the heterogeneity or diversity present in the meta-analysis (<LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>). In our meta-analysis, the required information size was based on the event proportion in the control group; assumption of a plausible RR reduction of 20%, or on the RR reduction observed in the included trials with low risk of bias; a risk of type I error of 5%; a risk of type II error of 20%; and the assumed diversity of the meta-analysis (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>, <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). The underlying assumption of trial sequential analysis was that testing for significance may be performed each time a new trial is added to the meta-analysis. We have added the trials according to the year of publication, and if more than one trial has been published in a year, we added trials alphabetically according to the last name of the first author. Based on the required information size, we constructed trial sequential monitoring boundaries (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>). These boundaries determined the statistical inference one may draw regarding the cumulative meta-analysis that has not reached the required information size; if the trial sequential monitoring boundaries were crossed before the required information size was reached, firm evidence may perhaps be established and further trials may turn out to be superfluous. In contrast, if the boundaries were not surpassed, it was most probably necessary to continue doing trials in order to detect or reject a certain intervention effect if the trial sequential monitoring boundaries for futility were not crossed. If the latter was the case, futility could be declared (<LINK REF="REF-Brok-2008" TYPE="REFERENCE">Brok 2008</LINK>; <LINK REF="REF-Wetterslev-2008" TYPE="REFERENCE">Wetterslev 2008</LINK>; <LINK REF="REF-Brok-2009" TYPE="REFERENCE">Brok 2009</LINK>; <LINK REF="REF-Thorlund-2009" TYPE="REFERENCE">Thorlund 2009</LINK>; <LINK REF="REF-Wetterslev-2009" TYPE="REFERENCE">Wetterslev 2009</LINK>; <LINK REF="REF-Thorlund-2010" TYPE="REFERENCE">Thorlund 2010</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Summary of findings tables</HEADING>
<P>We summarised the evidence in the 'Summary of findings' tables using GRADEpro (<A HREF="http://ims.cochrane.org/revman/other-resources/gradepro">ims.cochrane.org/revman/other-resources/gradepro</A>). We used the GRADE classification in order to judge the quality of evidence.</P>
</SUBSECTION>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-12-18 15:25:43 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-12-17 19:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>See: <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<SEARCH_RESULTS MODIFIED="2013-12-17 16:01:48 +0100" MODIFIED_BY="[Empty name]">
<P>Our literature search revealed 2008 references. We removed 718 duplicates. From the remaining 1290 references, we identified 11 randomised clinical trials that fulfilled our inclusion criteria (<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). We identified no additional trials from other sources. Two trials still await classification with insufficient information that were reported in meeting abstracts available to date and with no additional information from the study authors (<LINK REF="STD-Di-Costanzo-2011" TYPE="STUDY">Di Costanzo 2011</LINK>; <LINK REF="STD-Kuansheng-2011" TYPE="STUDY">Kuansheng 2011</LINK>; <LINK TAG="CHARACTERISTICS_OF_AWAITING_STUDIES" TYPE="SECTION">Characteristics of studies awaiting classification</LINK>). One trial was still ongoing (<LINK REF="STD-NCT00814242" TYPE="STUDY">NCT00814242</LINK>; <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK>). We excluded 23 studies due to insufficient design or lack of relevant information (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-12-17 16:30:58 +0100" MODIFIED_BY="[Empty name]">
<P>We included and analysed 11 trials in this review. The trials included 1819 randomised participants. We found no trials comparing RFA versus placebo, no intervention, chemotherapy, or liver transplantation.</P>
<P>Three trials with 578 participants compared RFA versus hepatic resection (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>).</P>
<P>Six trials with 1088 participants compared RFA versus PEI (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). Two of the trials with 344 participants randomised participants to three intervention groups (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI-hd)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>). In one trial, RFA was compared with a standard dose of PEI (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>), and versus a high dose of PEI (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI-hd)</LINK>). In the other trial, RFA was compared with PEI (<LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>) and versus PAI (<LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>).</P>
<P>One trial each compared RFA versus microwave ablation (n = 72 participants) (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>) and versus laser ablation (n = 81 participants) (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>).</P>
<P>Regarding the comparison of RFA versus other interventions, 10 out of 11 comparisons (including also the two three-armed trials) reported on the primary outcome, overall survival (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). Two-year survival could be extracted from seven trials (with nine comparisons) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Data on event-free survival were available from eight trials and on local progression were available from six trials (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). Rates of major complications or procedure-related deaths, or both, were reported in all trials.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-12-17 19:10:43 +0100" MODIFIED_BY="[Empty name]">
<P>Reasons for excluding identified studies were as follows: one trial compared RFA alone with RFA plus hepatic arterial occlusion (<LINK REF="STD-Kobayashi-2007" TYPE="STUDY">Kobayashi 2007</LINK>), one with RFA plus PEI (<LINK REF="STD-Zhang-2007" TYPE="STUDY">Zhang 2007</LINK>), and two with RFA plus transarterial chemo-embolisation (TACE) (<LINK REF="STD-Morimoto-2010" TYPE="STUDY">Morimoto 2010</LINK>; <LINK REF="STD-Morimoto-2011" TYPE="STUDY">Morimoto 2011</LINK>). Ten studies were not randomised clinical trials (<LINK REF="STD-Buscarini-1996" TYPE="STUDY">Buscarini 1996</LINK>; <LINK REF="STD-Goldberg-1998" TYPE="STUDY">Goldberg 1998</LINK>; <LINK REF="STD-Cuschieri-1999" TYPE="STUDY">Cuschieri 1999</LINK>; <LINK REF="STD-Jiao-1999" TYPE="STUDY">Jiao 1999</LINK>; <LINK REF="STD-Livraghi-1999" TYPE="STUDY">Livraghi 1999</LINK>; <LINK REF="STD-Kurokohchi-2005" TYPE="STUDY">Kurokohchi 2005</LINK>; <LINK REF="STD-Zhang-2005" TYPE="STUDY">Zhang 2005</LINK>; <LINK REF="STD-L_x00fc_-2006" TYPE="STUDY">Lü 2006</LINK>; <LINK REF="STD-Khan-2007" TYPE="STUDY">Khan 2007</LINK>; <LINK REF="STD-Ohmoto-2009" TYPE="STUDY">Ohmoto 2009</LINK>). Five studies were retrospective cohort studies (<LINK REF="STD-Amarnath-2006" TYPE="STUDY">Amarnath 2006</LINK>; <LINK REF="STD-Ueno-2009" TYPE="STUDY">Ueno 2009</LINK>; <LINK REF="STD-Opocher-2010" TYPE="STUDY">Opocher 2010</LINK>; <LINK REF="STD-Sreenivasan-2010" TYPE="STUDY">Sreenivasan 2010</LINK>; <LINK REF="STD-Gory-2012" TYPE="STUDY">Gory 2012</LINK>). One publication was retracted (<LINK REF="STD-Cheng-2008" TYPE="STUDY">Cheng 2008</LINK>). One study did not include patient data but was a Markov model analysis (<LINK REF="STD-Cho-2010" TYPE="STUDY">Cho 2010</LINK>). Akamatsu et al switched patients from PEI to RFA during the study (<LINK REF="STD-Akamatsu-2004" TYPE="STUDY">Akamatsu 2004</LINK>). It was unclear whether randomisation was performed in two trials (<LINK REF="STD-Gan-2004" TYPE="STUDY">Gan 2004</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>). We contacted the study authors but they did not reply and, therefore, we did not include the trials (<LINK REF="STD-Gan-2004" TYPE="STUDY">Gan 2004</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>). RFA was also used to treat portal vein thrombosis in one study and, therefore, the effects of RFA on tumour growth could not be extracted (<LINK REF="STD-Giorgio-2011a" TYPE="STUDY">Giorgio 2011a</LINK>). Peng et al only included patients with recurrent hepatocellular carcinoma. As this cohort displays differences to patients with newly diagnosed hepatocellular carcinoma, we did not include this trial (<LINK REF="STD-Peng-2012" TYPE="STUDY">Peng 2012</LINK>). One trial used laparoscopic RFA and was excluded (<LINK REF="STD-Santambrogio-2012" TYPE="STUDY">Santambrogio 2012</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-12-17 16:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>Overall, risk of bias was low in six trials and high in five trials. We only included the low risk of bias trials in the subgroup analysis.</P>
<ALLOCATION MODIFIED="2013-12-17 16:02:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Generation of allocation sequence and allocation concealment</HEADING>
<P>Allocation generation was done by a computer in seven trials, by random numbers in three trials (<LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>), and the method of the allocation generation was not reported in one trial (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>). The Shibata trial was described as a randomised trial. However, we were unable to obtain the missing information on allocation generation by the study authors. Concealed allocation was ensured by using a computer-based procedure in six trials, by sealed envelopes in three trials (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>), and by a coded list in one trial (<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). For the remaining trial, the study authors did not describe if allocation concealment was performed (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>).</P>
</SUBSECTION>
</ALLOCATION>
<BLINDING MODIFIED="2013-12-17 16:02:11 +0100" MODIFIED_BY="[Empty name]">
<P>Our most important outcomes were survival and tumour recurrence, which are unlikely to be significantly influenced by lack of blinding of both participants and outcome assessors. Moreover, as treatment modalities such as RFA and hepatic resection differ substantially with regard to the degree of invasiveness, procedure performance, etc., reasonable blinding to the treatment of an investigator or an informed patient is unlikely. Objective outcomes such as adverse events were blinded in one trial only and, therefore, only this trial was judged as a low risk of bias trial (<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>); all other trials had a high risk of bias (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-12-17 16:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>An intention-to-treat (ITT) analysis was explicitly stated in five trials (<LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>). Chen et al reported on 19 patients randomised to RFA who had later been subjected to resection (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>). These participants were excluded from the primary analysis. Results were adequately presented for both the ITT and the per-protocol analysis. The ITT results were considered for the meta-analysis of the data. Similarly, in <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>, seven patients were switched from RFA to the resection group on their own decision but were analysed according to ITT (used in this review) and per-protocol. In two trials, it was unclear whether incomplete outcome data had been adequately addressed (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>; <LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2013-12-17 16:02:19 +0100" MODIFIED_BY="[Empty name]">
<P>Ten trials were free of selective outcome reporting bias as the most relevant clinical outcome (overall survival was not reported in <LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>). The other 10 trials reported outcomes in a sufficiently detailed manner to allow estimations of HR based on Parmar's method (<LINK REF="REF-Parmer-1998" TYPE="REFERENCE">Parmer 1998</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">Vested interest bias</HEADING>
<P>Relevant vested interest bias such as industry funding or relevant academic bias was unclear in two trials (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>; <LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>), and not present in any of the trials as stated in the manuscript or directly by the study authors. Lin et al. performed two randomised clinical trials during the same time period. Patients were assigned to one of the trials according to their hospital admission week (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>) However, we judged this to have low risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Other source of bias</HEADING>
<P>Other sources of bias, namely possible premature stopping (<LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>), an unusual high number of patients switching groups (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>) or undefined outcomes (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>) were present in three trials and we judged them to have an unclear risk of bias.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Overall bias risk assessment</HEADING>
<P>Overall risk of bias was low in five trials and high in six trials (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>). For a subgroup analysis, we only included low risk of bias trials.</P>
</SUBSECTION>
</SELECTIVE_REPORTING>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-12-18 15:25:43 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Radiofrequency ablation versus hepatic resection</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for efficacy outcomes</HEADING>
<P>Three randomised clinical trials were identified that compared RFA versus hepatic resection (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>), of which two had low risk of bias (<LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>), and one had high risk of bias (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>). Analysing the results from all three trials using a random-effects model showed no significant difference between the compared interventions regarding overall survival (HR 0.71; 95% CI 0.44 to 1.15) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and two-year survival (HR 0.51; 95% CI 0.24 to 1.08) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>). Meta-analysis using a fixed-effect model showed a result in favour of hepatic resection compared with RFA on overall survival (HR 0.76; 95% CI 0.58 to 1.00) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In addition to the calculation of the HR, dichotomous outcomes on overall survival could be extracted from the two trials with low risk of bias (<LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>; <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). In concordance with the HR analysis, resection yielded statistically significant improved survival both using the fixed-effect and random-effects model meta-analyses (RR fixed 0.61; 95% CI 0.44 to 0.82 and RR random 0.60; 95% CI 0.44 to 0.82).</P>
<SUBSECTION>
<HEADING LEVEL="5">Trial sequential analysis</HEADING>
<P>Heterogeneity was present (I<SUP>2</SUP> = 67%, P value = 0.05). The diversity-adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the resection group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. This diversity may be an underestimation of the diversity of both the present and future meta-analyses, but has the advantage of narrowing the distance between the accrued and the required information size. Trial sequential analysis was only possible for two trials (<LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>), as we could not calculate dichotomous outcomes for the third trial (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>). Calculating the number of patients needed in order to judge an RRR of 20%, 2455 participants would need to be recruited. Even with the patients of the third trial, only 578 patients were randomised to RFA versus resection. Therefore, no firm evidence for benefit or harm has been reached yet (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). As can be seen from the figure, the cumulative Z-score did not cross the trial sequential monitoring boundaries and did reach the area of futility.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>In a subgroup analysis that included low-risk of bias trials only, results indicated that hepatic resection yields better results than RFA regarding overall survival (HR 0.56; 95% CI 0.40 to 0.78) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>) and two-year survival (HR 0.38; 95% CI 0.17 to 0.84) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>). Regarding event-free survival, the results indicated that hepatic resection seemed better than RFA (HR 0.70; 95% CI 0.54 to 0.91) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>). Only one trial reported on local progression and found hepatic resection was superior to RFA (HR 0.48; 95% CI 0.28 to 0.82) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>Major complications (including one procedure-related death) were only reported in 55% of patients in the surgery arm of one trial (OR 8.24; 95% CI 2.12 to 31.95) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>) (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcomes</HEADING>
<P>Our results show that RFA was associated with shorter duration of hospital stay compared with surgery (standardised mean difference 2.18 days; 95% CI 1.97 to 2.39).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Radiofrequency ablation versus percutaneous ethanol injection/percutaneous acetic acid injection</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for efficacy outcomes</HEADING>
<P>Six trials compared RFA with PEI of which four had a low risk of bias (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>) and two had a high risk of bias (<LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). The overall effects of RFA seemed superior to PEI regarding overall survival (HR 1.64; 95% CI 1.31 to 2.07) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), two-year survival (HR 1.82; 95% CI 1.34 to 2.47) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>), event-free survival (HR 1.55; 95% CI 1.31 to 1.85) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), and local progression (HR 2.44; 95% CI 1.71 to 3.49) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). No significant difference was found if only the result from the four trials with low risk of bias were meta-analysed (overall survival: HR 1.19; 95% CI 0.79 to 1.77). One trial compared the two interventions for single and very small (2 cm or less) hepatocellular carcinoma and found no differences in overall survival (<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
<P>In addition to the calculation of the HR, dichotomous outcomes (RR) on overall survival were calculated from all six trials. There was no significant difference between the RFA group versus the PEI/PAI group (RR 1.76; 95% CI 0.97 to 3.22) (<LINK REF="CMP-006.01" TYPE="ANALYSIS">Analysis 6.1</LINK>).</P>
<P>In addition, a subgroup analysis was performed in order to compare the results for overall survival of RFA versus PEI and RFA versus PAI. RFA versus PAI was only investigated in one three-armed trial (<LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>), as compared to the six trials that investigated RFA versus PEI (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). In a test of subgroup differences, we found no significant difference between the effect of RFA versus PEI or PAI (P value = 0.75) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>). The body of evidence was not changed if the comparison of RFA versus PAI was excluded (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>; <LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>; <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="5">Trial sequential analysis on overall mortality</HEADING>
<P>Heterogeneity was not detected (I<SUP>2</SUP> = 0%, P value = 0.70). The DARIS was calculated based upon a proportion of deaths of 30% in the PEI group; an RRR of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. Trial sequential analysis with data from six trials that compared RFA with PEI found that only 986 patients of the DARIS of 2455 were accrued (40.2%) in order to obtain a risk reduction of 20%. As can be seen, the cumulative Z-score did not cross the trial sequential monitoring boundaries for benefit, harm, or futility (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Subgroup analysis</HEADING>
<P>A subgroup analysis including low-risk of bias trials only, was performed for all comparisons, but it did not change the body of evidence (<LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>; <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>; <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>; <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>; <LINK REF="CMP-005.04" TYPE="ANALYSIS">Analysis 5.4</LINK>).</P>
<P>A separate post-hoc analysis of the three trials conducted in Italy compared to the three trials conducted in Asia that compared RFA with PEI was performed. In Italian patients, there was no difference between treatment groups (HR 1.24; 95%; CI 0.84 to 1.83), while in Asian patients, the RFA seemed superior to PEI (HR 1.95; 95% CI 1.38 to 2.75). We found no statistically significant difference between the two subgroups (P value = 0.09) (<LINK REF="CMP-006.03" TYPE="ANALYSIS">Analysis 6.3</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>All studies reported on minor complications. In six trials (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI-hd)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>), serious adverse events occurred. One trial reported a procedure-related death within the PEI group (<LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>). The proportion of patients with a serious adverse event did not differ significantly between the compared intervention groups (PEI/PAI versus RFA; OR 0.70; 95% CI 0.33 to 1.48) (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcomes</HEADING>
<P>Duration of hospital stay was documented in three trials including five comparisons (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI-hd)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>).<I> </I>However, the settings of the trials differed due to regional habits. While <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK> treated all patients as inpatients until treatment success was documented by computed tomography, PEI/PAI patients in the Lin trials were routinely treated as outpatients in the cases when there was no severe adverse effect during the first PEI/PAI session (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>). <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK> reported a shorter hospitalisation time within the RFA group. These patients showed a shorter mean duration of hospital stay for the few complications that occurred. Due to the heterogeneous settings - also demonstrated by high Chi<SUP>2</SUP> values and the small number of trials with available data, no valid conclusions can be deduced to date with regards to length of hospital stay (standardised mean difference -1.50; 95% CI -3.69 to 0.68). <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK> reported the cost of interventions and found PEI to be 100 times less expensive than RFA (EUR1359 versus EUR171,000, P value &lt; 0.0001). The study authors included the costs of the radiofrequency generator into this calculation.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Radiofrequency ablation versus percutaneous microwave coagulation</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for efficacy outcomes</HEADING>
<P>Only one trial examined the effects of RFA versus percutaneous microwave coagulation. Shibata et al randomised 72 patients with 94 hepatic tumour nodules to RFA versus percutaneous microwave coagulation (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>). Data on overall survival, two-year survival, and event-free survival could not be extracted as the data presentation was based on tumour nodules and were not done patient-wise. There was no significant difference between RFA and percutaneous microwave coagulation regarding local progression (HR 2.14; 95% CI 0.67 to 6.80) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>No death or other serious adverse events were observed during the trial in the RFA or percutaneous microwave coagulation group. In the RFA group, one patient had a segmental hepatic infarction. In the percutaneous microwave coagulation group, one patient each developed liver abscess, cholangitis, subcutaneous abscess, and skin burn. The OR of major complications was 4.38 (95% CI 0.46 to 41.22).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcomes</HEADING>
<P>There were no data for economic outcomes. Data on the duration of hospital stay were not presented.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Radiofrequency ablation versus percutaneous laser ablation</HEADING>
<P>One trial randomised 40 patients to RFA versus 41 patients to laser ablation (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>). There were no significant differences between RFA and percutaneous laser ablation with regards to overall survival (HR 1.62; 95% CI 0.62 to 4.22) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>), event-free survival (HR 1.20; 95% CI 0.50 to 2.89) (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>), and local progression (HR 1.12; 95% CI 0.40 to 3.09) (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>)..</P>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for safety outcomes</HEADING>
<P>There were no data reported on safety outcomes.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparison for economic outcomes</HEADING>
<P>There were no data reported on economic outcomes.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Quality of life</HEADING>
<P>None of the identified trials reported on quality of life.<BR/>
</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatocellular carcinoma represents a major health problem worldwide. Various therapeutic approaches such as percutaneous, transarterial, and surgical interventions are available. Prognosis and therapeutic options of patients with hepatocellular carcinoma depend on tumour extension and liver function, which is often reduced by underlying liver cirrhosis. Though sophisticated prognostic classifications such as the Barcelona Clinic Liver Cancer (BCLC), a more pragmatic approach based on number and size of tumour lesions is widely used to stratify patients (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). The Milan criteria define "early hepatocellular carcinomas" as a single tumour of 5 cm or less or up to three tumours of 3 cm or less (<LINK REF="REF-Mazzaferro-1996" TYPE="REFERENCE">Mazzaferro 1996</LINK>). The Milan criteria are also used to evaluate patients for orthotopic liver transplantation. Advanced stages of disease include extensive liver involvement and extrahepatic disease. Intermediate stages are ill-defined to date and belong to none of the former two groups. Furthermore, all treatments for hepatocellular carcinoma (excluding orthotopic liver transplantation) are reserved for patients with mild and moderate functional impairment of the liver. In our review, we aimed to determine the role of RFA as compared with any other intervention in patients with 'early hepatocellular carcinoma'. The primary outcome of our analyses was overall survival, which is the most relevant outcome for patients.</P>
<SUMMARY_OF_RESULTS MODIFIED="2013-12-17 16:30:58 +0100" MODIFIED_BY="[Empty name]">
<P>In contrast to two former versions of this systematic review (<LINK REF="REF-Galandi-2002" TYPE="REFERENCE">Galandi 2002</LINK>; <LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>), new data on RFA for hepatocellular carcinoma has accumulated so that 11 randomised clinical trials have assessed RFA: three trials compared RFA versus resection (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>); six trials RFA versus PEI (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>); one trial RFA versus PAI (<LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>; one trial RFA versus microwave ablation (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>); and one trial RFA versus laser ablation (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>). This represents an expansion of nine new trials with 1643 new participants.</P>
<SUBSECTION>
<HEADING LEVEL="2">Radiofrequency ablation versus hepatic resection</HEADING>
<P>Our Cochrane systematic review included three randomised clinical trials comparing RFA versus surgical resection. Two of the identified trials had a low risk of bias (<LINK REF="STD-Huang-2010" TYPE="STUDY">Huang 2010</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>), while the third trial had a high risk of bias (<LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>).</P>
<P>Analysing all three trials, there was no significant difference in the HR and the RR for overall survival (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>) and the HR for two-year survival (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>) between the treatment groups, but we found the outcome to be in favour of the surgically treated patients regarding event-free survival (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>) and local progression (<LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>). In the analysis of the two trials with a low risk of bias, hepatic resection resulted in an increased overall survival (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) and increased two-year survival (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>) when compared with RFA using traditional and naive statistical boundaries. We conclude that there is moderate-quality evidence from randomised clinical trials that hepatic resection yields better results regarding benefits. However, the rate of complications is remarkably higher and the hospital stay is longer in the surgical resection group (<LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>). In order to become certain about the balance between benefits and harms, it would be necessary to conduct larger well-designed randomised clinical trials (<LINK TAG="IMPLICATIONS_RESEARCH" TYPE="SECTION">Implications for research</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Radiofrequency ablation versus local ablative interventions</HEADING>
<P>In summary, our meta-analysis adduces moderate-quality evidence compiled from six randomised clinical trials that RFA seems superior to PEI/PAI regarding overall survival, two-year survival, event-free survival, and local recurrence, with a similar frequency of major complications (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>) (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). In the comparison of RFA versus PEI, the low technical and instrumental requirements for PEI should also be taken into consideration (<LINK REF="REF-Schoppmeyer-2009" TYPE="REFERENCE">Schoppmeyer 2009</LINK>). PEI may possibly also be a treatment option for very early hepatocellular carcinoma (single lesion 3 cm or less) (<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). There is evidence from single comparisons suggesting that RFA seems better than PAI and high-dose PEI (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI-hd)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PAI)</LINK>). RFA was only compared with laser ablation and microwave coagulation in one randomised clinical trial (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>; <LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>). The trial comparing RFA versus laser ablation found no difference between treatment modalities regarding the outcomes event-free survival and local progression (<LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>). No survival data were available for microwave coagulation. In conclusion, among the available local ablative therapies, RFA seemed to be the most efficient and safe technique of all the assessed local ablative therapies.</P>
<SUBSECTION>
<HEADING LEVEL="3">Italian versus East Asian trials</HEADING>
<P>The trials comparing RFA versus PEI/PAI were performed either in Italy (<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>), or in East-Asia (<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>; <LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>; <LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>). Interestingly, there was no evidence for prolonged overall survival in European patients when treated with RFA compared with PEI (HR 1.24; 95% CI 0.84 to 1.83) (<LINK REF="SOF-03" TYPE="SOF">Summary of results table 3</LINK>), while East-Asian studies suggested that overall survival was superior after RFA (HR 1.95; 95% CI 1.38 to 2.75). In one post-hoc analysis, we compared both subgroups and found no significant difference between the groups (P value = 0.09). Therefore, undefined technical differences in tumour ablation, reporting bias, or chance might account for the difference between the European and Asian trials. However, this could be addressed in further trials.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Ongoing trials</HEADING>
<P>In addition to the included trial publications, we found three additional ongoing trials. One randomised clinical trial seeks information on RFA versus resection for hepatocellular carcinoma adjacent to large vessels (<LINK REF="STD-NCT00814242" TYPE="STUDY">NCT00814242</LINK>). Randomised trials comparing (chemo-)embolisation versus supportive care suggest that (chemo-)embolisation may increase survival<I> </I>(<LINK REF="REF-Llovet-2003" TYPE="REFERENCE">Llovet 2003</LINK>; <LINK REF="REF-Llovet-2003b" TYPE="REFERENCE">Llovet 2003b</LINK>); however, one Cochrane systematic review found no convincing evidence that transarterial (chemo)embolisation was superior compared with no intervention for unresectable hepatocellular carcinoma (<LINK REF="REF-Oliveri-2011" TYPE="REFERENCE">Oliveri 2011)</LINK>. We plan to include the information from these trials in the next update of our meta-analysis.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy outcomes were properly addressed in most trials. However, this was not the case for the pre-specified outcomes in this review, quality of life and health economics. None of the trials assessed effects of RFA on quality of life and only one trial reported on health economics. Giorgio et al. found RFA to be 100 times more expensive than PEI (<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>). The study authors included the cost of the PEI needles and the cost of a radiofrequency generator. However, in contrast to the needles used for PEI, the generator can be used multiple times, and as such, this comparison has to be interpreted very cautiously. For the comparison between RFA and hepatic resection, only retrospective data with inherent high risk of bias are available. One Japanese working group compared medical costs in 213 patients who received either RFA or hepatic resection (<LINK REF="REF-Ikeda-2005" TYPE="REFERENCE">Ikeda 2005</LINK>). Resection yielded lower recurrence rates as compared with RFA while increasing hospital stay. As a consequence, RFA had to be repeated in a higher number of patients. The study authors stated that repeated RFA was cheaper than resection (1,086,000 Japanese yen (JPY) versus 1,745,100 JPY; conversion rate 100 JPY = EUR0.71, at December 2013).</P>
<P>The relevance of other alternative interventional therapies such as laser and microwave ablation remains undetermined. No randomised clinical trial compared RFA versus no treatment, with best supportive care, or with cryoablation. Given the large differences in survival between treatment and no treatment groups in cohort studies, randomised trials with an untreated arm are neither likely to be performed nor ethically justifiable. One unresolved problem of local percutaneous ablation techniques and hepatic resection is the appearance of disease at disseminated areas of the body, and the fact that new tumours often emerge in the remaining cirrhotic liver tissue. Orthotopic liver transplantation is the only treatment that also removes underlying cirrhosis. Randomised clinical trials comparing the effectiveness of RFA versus orthotopic liver transplantation or versus RFA as a bridging therapy to liver transplantation have not been performed.</P>
<P>The current guidelines by the EASL and EORTC state that RFA is the interventional treatment of choice in patients that are not suitable for hepatic resection. If RFA is not feasible, PEI is recommended (<LINK REF="REF-EASL_x002d_EORTC-2012" TYPE="REFERENCE">EASL-EORTC 2012</LINK>). In our meta-analysis, we found moderate evidence to support this recommendation, but too few patients were included in order to draw firm conclusion on the pre-specified survival outcomes. To the best of our knowledge, this meta-analysis is the first that includes the trials by <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK> and <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK> and thus it provides the best evidence available to date.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-12-17 18:42:44 +0100" MODIFIED_BY="[Empty name]">
<P>The Cochrane Collaboration stresses the importance of good-quality trials. It is recognised to date that methodological quality of trials influences estimates of intervention effects<I> (</I>
<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Moher-1998" TYPE="REFERENCE">Moher 1998</LINK>; <LINK REF="REF-Kjaergard-2001" TYPE="REFERENCE">Kjaergard 2001</LINK>; <LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>; <LINK REF="REF-Lundh-2012" TYPE="REFERENCE">Lundh 2012</LINK>; <LINK REF="REF-Savovic-2012" TYPE="REFERENCE">Savovic 2012</LINK>; <LINK REF="REF-Savovic-2012a" TYPE="REFERENCE">Savovic 2012a</LINK>). Considering possible sources of bias, we found five trials with low risk of bias. Six trials had methodological weaknesses that qualified them as trials with high risk of bias but were still eligible for inclusion (<LINK REF="STD-Shibata-2002" TYPE="STUDY">Shibata 2002</LINK>; <LINK REF="STD-Chen-2006" TYPE="STUDY">Chen 2006</LINK>; <LINK REF="STD-Ferrari-2007" TYPE="STUDY">Ferrari 2007</LINK>; <LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>; <LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>; <LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>). In summary, we found moderate-quality evidence derived from six trials with 1088 participants that RFA is superior to PEI regarding efficacy outcomes, while at the same time, the risk of adverse events does not seem to differ between the two treatment modalities (<LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>). As for the comparison between RFA and hepatic resection, there is moderate-quality evidence from two low risk of bias trials that randomised 398 patients that hepatic resection is more effective than RFA regarding overall survival and two-year survival. However, if a third trial with an additional 168 patients and a high risk of bias is included, the evidence becomes weak. With regards to the outcomes event-free survival and local progression, hepatic resection was found to yield better results than RFA regardless of the inclusion of the third trial with high risk of bias. In order to strengthen the body of evidence, more trials with low risk of bias are needed. There is high-quality evidence that complication rates were consistently higher in patients treated with hepatic resection (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>). Due to their high risk of bias, no firm conclusions regarding the pre-specified outcomes can be drawn for other interventional therapies.</P>
<P>Trial sequential analysis revealed that less than half of the required number of patients was recruited into the eligible trials in order to judge an RRR of 20% (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>). In addition, the calculation of the RR for the comparison RFA versus PEI did not reach statistical significance (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). Therefore, we conclude that there is only moderate-quality evidence to support RFA versus PEI or hepatic resection (<LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-12-17 16:04:12 +0100" MODIFIED_BY="[Empty name]">
<P>We excluded two trials from the analysis as it was unclear whether they were randomised clinical trials. We tried to contact the study authors but did not receive any replies (<LINK REF="STD-Gan-2004" TYPE="STUDY">Gan 2004</LINK>; <LINK REF="STD-Chen-2005" TYPE="STUDY">Chen 2005</LINK>). If these trials had been eligible for inclusion, we might have obtained information about the efficacy of RFA compared with chemotherapy and TACE. In addition, the two studies awaiting classification might have added important data to the meta-analysis (<LINK REF="STD-Di-Costanzo-2011" TYPE="STUDY">Di Costanzo 2011</LINK>; <LINK REF="STD-Kuansheng-2011" TYPE="STUDY">Kuansheng 2011</LINK>).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Radiofrequency ablation compared with hepatic resection</HEADING>
<P>Some non-randomised studies (<LINK REF="REF-Abu_x002d_Hilal-2008" TYPE="REFERENCE">Abu-Hilal 2008</LINK>; <LINK REF="STD-Ueno-2009" TYPE="STUDY">Ueno 2009</LINK>; <LINK REF="STD-Cho-2010" TYPE="STUDY">Cho 2010</LINK>), one Markov model analysis (<LINK REF="REF-Molinari-2009" TYPE="REFERENCE">Molinari 2009</LINK>), and one prior meta-analysis (<LINK REF="REF-Zhou-2010" TYPE="REFERENCE">Zhou 2010</LINK>) reported superiority of hepatic resection as compared with RFA with regards to survival and recurrence. Although the post-interventional morbidity was less in RFA-treated patients, this did not significantly influence mortality. These results are in agreement with our review results.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Radiofrequency ablation compared with percutaneous ethanol injection or percutaneous acetic acid injection</HEADING>
<P>In addition to the above mentioned meta-analysis (<LINK REF="REF-Zhou-2010" TYPE="REFERENCE">Zhou 2010</LINK>), three meta-analyses on the effects of RFA on hepatocellular carcinoma have been published (<LINK REF="REF-Cho-2009" TYPE="REFERENCE">Cho 2009</LINK>; <LINK REF="REF-Bouza-2009" TYPE="REFERENCE">Bouza 2009</LINK>; <LINK REF="REF-Lau-2009" TYPE="REFERENCE">Lau 2009</LINK>). Cho et al investigated the three-year survival in randomised clinical trials comparing RFA versus PEI for small hepatocellular carcinoma (<LINK REF="REF-Cho-2009" TYPE="REFERENCE">Cho 2009</LINK>). The four identified trials were also included in our review. The Lencioni trial included in our analyses was not considered for missing three-year survival rates. In accordance with our analyses, the study authors found evidence that RFA treatment was superior to PEI (OR 0.48; 95% CI 0.34 to 0.67, P value &lt; 0.001). Another meta-analysis identified six studies that compared RFA versus PEI (<LINK REF="REF-Bouza-2009" TYPE="REFERENCE">Bouza 2009</LINK>). An important difference to our analysis was that the previous authors included a quasi-randomised trial (<LINK REF="STD-Livraghi-1999" TYPE="STUDY">Livraghi 1999</LINK>). The RR for one-, two-, three-, and four-year survival, the local recurrence rates as well as the complications were assessed. There was strong (overall survival, one-year disease-free survival, disease free-survival, complete tumour response, major complications) or very strong (one-, two-, three-year survival, total complications) evidence in favour of RFA versus PEI. Lau and Lai referred to four categories in their trial publication: RFA versus other ablative techniques, RFA for unresectable hepatocellular carcinoma, RFA as a bridging therapy for liver transplantation, and RFA for recurrent hepatocellular carcinoma after hepatectomy (<LINK REF="REF-Lau-2009" TYPE="REFERENCE">Lau 2009</LINK>). We acknowledge this holistic and thorough approach. However, there are some major differences to our work. First, existing data were included regardless of the quality of trials. For instance, the trial of <LINK REF="STD-L_x00fc_-2006" TYPE="STUDY">Lü 2006</LINK> was excluded from our analysis since effects of RFA were not extractable (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table). Second, quantitative meta-analyses of the data were not performed. Thus, the conclusions presented there should be considered with caution.<BR/>
</P>
</SUBSECTION>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-12-17 16:04:17 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-12-17 16:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>In this update of the previous Cochrane review from 2004 (<LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>), we identified 11 trials comparing radiofrequency ablation (RFA) versus other interventions that fulfilled the inclusion criteria. There is moderate-quality evidence from two trials with low risk of bias that hepatic resection seems to yield better results than RFA in patients with early hepatocellular carcinoma. This is counterbalanced by an increased rate of adverse events and by a longer hospital stay in surgically treated patients requiring a cautious choice of the appropriate therapy for any individual patient. There is moderate-quality evidence that RFA seems to be to be more effective than percutaneous ethanol injection (PEI) or percutaneous acetic acid injection (PAI) in early hepatocellular carcinoma. However, trial sequential analyses showed that only 40% of the required number of patients were recruited in order to judge a relative risk reduction of 20%, therefore, more trials with low risk of bias are needed to confirm our results. A small number of studies have been conducted to compare RFA versus other interventions such as microwave and laser ablation. Due to a high risk of bias in these trials, these interventions cannot yet be recommended for clinical practice.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-12-17 16:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>The is a need for well-designed, sufficiently powered, multicentre trials with low risk of bias comparing RFA versus hepatic resection, PEI, or PAI in patients with hepatocellular carcinoma. Although there is evidence from two low risk of bias trials that hepatic resection yields better survival rates, more data are needed in order to confirm these results. There is a lack of evidence whether RFA can be used as a bridging therapy for patients that are listed for liver transplantation.</P>
<P>In general, trial outcomes should comprise overall survival, event-free survival, adverse events, and quality of life. With regards to increasing financial restrictions in public healthcare systems, the economic costs should also be investigated. In addition, a sufficiently extended follow-up period should be ensured in every trial. To obtain a higher level of external validity, trials involving RFA should be conducted as multicentre trials because surgical as well as percutaneous interventions are strongly affected by the individual experience of the physician(s)/investigator(s).</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-12-17 16:04:17 +0100" MODIFIED_BY="[Empty name]">
<P>We thank Dr. Galandi for handing over this meta-analysis to us. We also thank Dimitrinka Nikolova, Sarah Klingenberg, and Christian Gluud from the Cochrane Hepato-Biliary Group for their patience and ongoing support. We are grateful to Dr. Hannelore Tenckhoff from HepNet for database assistance and Ping La from the Children's Hospital of Philadelphia for the translation of the Chinese publications. We also want to express our thanks to Christian Gluud from the Cochrane Hepato-Biliary Group for the help with the trial sequence analysis.</P>
<P>Peer reviewers: Ronald L. Koretz, USA.<BR/>Contact editor: Christian Gluud, Denmark.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2011-01-20 16:44:40 +0100" MODIFIED_BY="[Empty name]">
<P>None.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2013-12-17 16:04:39 +0100" MODIFIED_BY="[Empty name]">
<P>Konrad Schoppmeyer and Sebastian Weis searched the literature, extracted the data, and drafted the manuscript.<BR/>Annegret Franke extracted the data and performed the statistical evaluation. Annegret Franke also took part in the quality assessment of the trials.<BR/>Joachim Mössner critically reviewed the manuscript.<BR/>Janus Jakobsen performed the analysis for the summary of finding tables and critically reviewed the manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-12-17 16:04:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>To date the term radiofrequency thermal ablation (RFTA) is not routinely used. It was replaced with the more common term radiofrequency ablation (RFA).</LI>
<LI>The authoring team changed.</LI>
<LI>Random-effects models were applied.</LI>
<LI>CancerLit evolved into MEDLINE in 2003. The database was not searched again. Current Contents is represented by ISI Web of Science and was not searched again.</LI>
<LI>Trial sequential analysis (TSA) and report of dichotomous outcomes for the outcome overall survival was included following the requirements of The Cochrane Hepato-Biliary Group.</LI>
</OL>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-12-17 19:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>This is the second update of a review published in 2002 (<LINK REF="REF-Galandi-2002" TYPE="REFERENCE">Galandi 2002</LINK>), and first updated in 2004 by <LINK REF="REF-Galandi-2004" TYPE="REFERENCE">Galandi 2004</LINK>.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-12-17 19:50:20 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-12-17 16:38:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Brunello-2008" MODIFIED="2013-12-17 16:15:22 +0100" MODIFIED_BY="[Empty name]" NAME="Brunello 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-12-17 16:15:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al</AU>
<TI>Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial</TI>
<SO>Scandinavian Journal of Gastroenterology</SO>
<YR>2008</YR>
<VL>43</VL>
<PG>727-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2006" MODIFIED="2012-11-23 16:41:31 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-11-23 16:41:31 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen MS, Li JQ, Zheng Y, Go RP, Liang HH, Zhang YQ, et al</AU>
<TI>A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma</TI>
<SO>Annals of Surgery</SO>
<YR>2006</YR>
<VL>243</VL>
<NO>3</NO>
<PG>321-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Feng-2012" MODIFIED="2013-12-17 16:28:56 +0100" MODIFIED_BY="[Empty name]" NAME="Feng 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-17 16:28:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Feng K, Yan J, Li X, Ma K, Wang S, Bie P, et al</AU>
<TI>A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>57</VL>
<NO>4</NO>
<PG>794-802</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ferrari-2007" MODIFIED="2013-12-17 16:38:17 +0100" MODIFIED_BY="[Empty name]" NAME="Ferrari 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-17 16:38:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ferrari FS, Mgliola A, Scorzelli A, Stella A, Vigni F, Drudi FM, et al</AU>
<TI>Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results</TI>
<SO>La Radiologia Medica</SO>
<YR>2007</YR>
<VL>112</VL>
<NO>3</NO>
<PG>377-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giorgio-2011" MODIFIED="2013-12-17 16:34:12 +0100" MODIFIED_BY="[Empty name]" NAME="Giorgio 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-17 16:34:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giorgio A, Di Sarno A, De Stefano G, Scognamiglio U, Farella N, Mariniello A, et al</AU>
<TI>Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial</TI>
<SO>Anticancer Research</SO>
<YR>2011</YR>
<VL>31</VL>
<NO>6</NO>
<PG>2291-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2010" MODIFIED="2012-11-23 16:41:41 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-11-23 16:41:41 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang J, Yan L, Cheng Z, Wu H, Du L, Wang J, et al</AU>
<TI>A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria</TI>
<SO>Annals of Surgery</SO>
<YR>2010</YR>
<VL>252</VL>
<NO>6</NO>
<PG>903-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lencioni-2003" NAME="Lencioni 2003" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni R, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al</AU>
<TI>Small hepatocellular carcinoma: randomized comparison of radio-frequency thermal ablation and percutaneous ethanol injection</TI>
<SO>Radiology</SO>
<YR>2003</YR>
<VL>228</VL>
<PG>235-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" MODIFIED="2013-12-16 21:08:43 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2004 (RFA vs. PEI)" YEAR="2004">
<REFERENCE MODIFIED="2013-06-22 00:35:12 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YG</AU>
<TI>Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>1714-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-12-14 20:59:30 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" MODIFIED="2013-12-16 21:08:55 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2004 (RFA vs. PEI-hd)" YEAR="">
<REFERENCE MODIFIED="2013-06-22 00:34:38 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YG</AU>
<TI>Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma of 4 or less than 4 cm</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>1714-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" MODIFIED="2013-12-16 21:09:19 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2005 (RFA vs. PAI)" YEAR="">
<REFERENCE MODIFIED="2012-11-23 15:34:30 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC</AU>
<TI>Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>8</NO>
<PG>1151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" MODIFIED="2013-12-16 21:09:31 +0100" MODIFIED_BY="[Empty name]" NAME="Lin 2005 (RFA vs. PEI)" YEAR="2005">
<REFERENCE MODIFIED="2012-11-23 15:34:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lin SM, Lin CJ, Lin CC, Hsu CW, Chen YC</AU>
<TI>Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less</TI>
<SO>Gut</SO>
<YR>2005</YR>
<VL>54</VL>
<NO>8</NO>
<PG>1151-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shibata-2002" MODIFIED="2012-11-23 15:35:23 +0100" MODIFIED_BY="[Empty name]" NAME="Shibata 2002" YEAR="2002">
<REFERENCE MODIFIED="2012-11-23 15:35:23 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al</AU>
<TI>Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy</TI>
<SO>Radiology</SO>
<YR>2002</YR>
<VL>223</VL>
<PG>331-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shiina-2005" MODIFIED="2012-11-23 15:35:40 +0100" MODIFIED_BY="[Empty name]" NAME="Shiina 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-23 15:35:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shiina S, Teratani T, Obi S, Sato S, Tateishi R, Fujishima T, et al</AU>
<TI>A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma</TI>
<SO>Gastroenterology</SO>
<YR>2005</YR>
<VL>129</VL>
<NO>1</NO>
<PG>122-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-12-17 19:50:20 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akamatsu-2004" MODIFIED="2012-11-23 15:38:37 +0100" MODIFIED_BY="[Empty name]" NAME="Akamatsu 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-11-23 15:38:37 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akamatsu M, Yoshida H, Obi S, Sato S, Koike Y, Fujishima T, et al</AU>
<TI>Evaluation of transcatheter arterial embolization prior to percutaneous tumor ablation in patients with hepatocellular carcinoma: a randomized controlled trial</TI>
<SO>Liver International</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>6</NO>
<PG>625-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amarnath-2006" MODIFIED="2013-12-17 19:48:53 +0100" MODIFIED_BY="[Empty name]" NAME="Amarnath 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-12-17 19:48:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amarnath S, Griffith KA, Higgins E, Lawrence TS, Rubin J, Pan CC</AU>
<TI>Comparison of patients with hepatocellular carcinoma (HCC) treated with external beam radiotherapy (EBRT) or radiofrequency ablation (RFA)</TI>
<SO>International Journal of Radiation Oncology, Biology, Physics</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3 Suppl</NO>
<PG>1071</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Buscarini-1996" NAME="Buscarini 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buscarini L, Di Stasi M, Buscarini E, Fornari F, Squassante L, Rossi S, et al</AU>
<TI>Clinical presentation, diagnostic work-up and therapeutic choices in two consecutive series of patients with hepatocellular carcinoma</TI>
<SO>Oncology</SO>
<YR>1996</YR>
<VL>53</VL>
<NO>3</NO>
<PG>204-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2012-11-23 15:40:15 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-11-23 15:40:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen MS, Zhang YJ, Li JQ, Liang HH, Zhang YQ, Zheng Y</AU>
<TI>Randomized clinical trial of percutaneous radiofrequency ablation plus absolute ethanol injection compared with radiofrequency alone for small hepatocellular carcinoma</TI>
<SO>Chinese Journal of Oncology</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>10</NO>
<PG>623-5</PG>
<IDENTIFIERS MODIFIED="2010-12-14 22:00:06 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cheng-2008" MODIFIED="2012-11-23 15:40:29 +0100" MODIFIED_BY="[Empty name]" NAME="Cheng 2008" YEAR="2008">
<REFERENCE MODIFIED="2012-11-23 15:40:29 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL, et al</AU>
<TI>Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial</TI>
<SO>Journal of the American Medical Association</SO>
<YR>2008</YR>
<VL>299</VL>
<NO>14</NO>
<PG>1669-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cho-2010" MODIFIED="2013-06-12 14:13:13 +0200" MODIFIED_BY="[Empty name]" NAME="Cho 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-12 14:13:13 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cho YK, Kim JK, Kim WT, Chung JW</AU>
<TI>Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis</TI>
<SO>Hepatology</SO>
<YR>2010</YR>
<VL>51</VL>
<NO>4</NO>
<PG>1116-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cuschieri-1999" NAME="Cuschieri 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cuschieri A, Bracken J, Boni L</AU>
<TI>Initial experience with laparoscopic ultrasound-guided radiofrequency thermal ablation of hepatic tumours</TI>
<SO>Endoscopy</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>4</NO>
<PG>318-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gan-2004" MODIFIED="2012-11-23 15:40:45 +0100" MODIFIED_BY="[Empty name]" NAME="Gan 2004" YEAR="2004">
<REFERENCE MODIFIED="2012-11-23 15:40:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gan YH, Yie SH, Ren ZG, Xia JL, Zhang BH, Wang YH, et al</AU>
<TI>Prospective randomized trial of RFA and chemotherapy for unresectable small hepatocellular carcinoma</TI>
<SO>Chinese Journal of Oncology</SO>
<YR>2004</YR>
<VL>26</VL>
<NO>8</NO>
<PG>496-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giorgio-2011a" MODIFIED="2012-11-23 15:46:14 +0100" MODIFIED_BY="[Empty name]" NAME="Giorgio 2011a" YEAR="2011">
<REFERENCE MODIFIED="2012-11-23 15:46:14 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giorgio A, Farella N, Di Sarno A, Scognamiglio U, De Stefano G, De Rogatis A, et al</AU>
<TI>Western trial comparing percutaneous radiofrequency of both hepatocellular carcinoma and the portal venous tumor thrombus plus sorafenib with sorafenib alone</TI>
<SO>Journal of Hepatology</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>Suppl 1</NO>
<PG>S542</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goldberg-1998" NAME="Goldberg 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SN, Hahn PF, Tanabe KK, Mueller PR, Schima W, Athanasoulis CA, et al</AU>
<TI>Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis?</TI>
<SO>Journal of Vascular &amp; Interventional Radiology</SO>
<YR>1998</YR>
<VL>9</VL>
<NO>1</NO>
<PG>101-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gory-2012" MODIFIED="2013-12-17 19:50:20 +0100" MODIFIED_BY="[Empty name]" NAME="Gory 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-17 19:50:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gory I, Fink M, Bell S, Gow P, Nicoll A, Knight V, et al</AU>
<TI>Radiofrequency ablation versus surgical resection for the treatment of early stage hepatocellular carcinoma (HCC) - a large multicentre study</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>Suppl 2</NO>
<PG>S392-S393</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jiao-1999" NAME="Jiao 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jiao LR, Hansen PD, Havlik R, Mitry RR, Pignatelli M, Habib N</AU>
<TI>Clinical short-term results of radiofrequency ablation in primary and secondary liver tumors</TI>
<SO>American Journal of Surgery</SO>
<YR>1999</YR>
<VL>177</VL>
<NO>4</NO>
<PG>303-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Khan-2007" MODIFIED="2013-12-17 19:49:34 +0100" MODIFIED_BY="[Empty name]" NAME="Khan 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-12-17 19:49:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Khan MR, Poon RTP, Ng KK, Chan ACC, Yuen J, Tung H, et al</AU>
<TI>Comparison of percutaneous and surgical approaches for radiofrequency ablation of small and medium hepatocellular carcinoma</TI>
<SO>Archives of Surgery</SO>
<YR>2007</YR>
<VL>142</VL>
<NO>12</NO>
<PG>1136-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kobayashi-2007" MODIFIED="2013-09-12 18:08:57 +0200" MODIFIED_BY="[Empty name]" NAME="Kobayashi 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-12 18:08:56 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kobayashi M, Ikeda K, Kawamura Y, Hosaka T, Sezaki H, Yatsuji H, et al</AU>
<TI>Randomized controlled trial for the efficacy of hepatic arterial occlusion during radiofrequency ablation for small hepatocellular carcinoma-direct ablative effects and a long-term outcome</TI>
<SO>Liver International</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>3</NO>
<PG>353-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurokohchi-2005" MODIFIED="2013-12-17 19:50:03 +0100" MODIFIED_BY="[Empty name]" NAME="Kurokohchi 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-17 19:50:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kurokohchi K, Watanabe S, Masaki T, Hosomi N, Himoto T, Kimura Y, et al</AU>
<TI>Comparison between combination therapy of percutaneous ethanol injection and radiofrequency ablation and radiofrequency ablation alone for patients with hepatocellular carcinoma</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>10</NO>
<PG>1426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Livraghi-1999" NAME="Livraghi 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS</AU>
<TI>Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection</TI>
<SO>Radiology</SO>
<YR>1999</YR>
<VL>210</VL>
<NO>3</NO>
<PG>655-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00fc_-2006" MODIFIED="2012-11-23 15:49:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lü 2006" YEAR="2006">
<REFERENCE MODIFIED="2012-11-23 15:49:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lü MD, Kuang M, Liang LJ, Xie XY, Peng BG, Liu GJ, et al</AU>
<TI>Surgical resection versus percutaneous thermal ablation for early-stage hepatocellular carcinoma: a randomized clinical trial</TI>
<SO>National Medical Journal of China</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>12</NO>
<PG>801-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morimoto-2010" MODIFIED="2013-12-17 19:10:37 +0100" MODIFIED_BY="[Empty name]" NAME="Morimoto 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-09-12 18:05:33 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K</AU>
<TI>Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization</TI>
<SO>Cancer</SO>
<YR>2010</YR>
<VL>116</VL>
<NO>23</NO>
<PG>5452-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morimoto-2011" MODIFIED="2013-12-17 19:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Morimoto 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-17 16:38:33 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morimoto M, Numata K, Kondo M, Nozaki A, Moriya S, Takizawa K, et al</AU>
<TI>Long-term outcome in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial to determine the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization</TI>
<SO>Hepatology</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>Suppl S1</NO>
<PG>1366A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ohmoto-2009" MODIFIED="2013-12-17 19:07:48 +0100" MODIFIED_BY="[Empty name]" NAME="Ohmoto 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-12-17 19:07:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ohmoto K, Yoshioka N, Tomiyama Y, Shibata N, Kawase T, Yoshida K, et al</AU>
<TI>Comparison of therapeutic effects between radiofrequency ablation and percutaneous microwave coagulation therapy for small hepatocellular carcinomas</TI>
<SO>Journal of Gastroenterology and Hepatology</SO>
<YR>2009</YR>
<VL>24</VL>
<PG>223-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Opocher-2010" MODIFIED="2013-06-12 14:14:26 +0200" MODIFIED_BY="[Empty name]" NAME="Opocher 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-06-12 14:14:26 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Opocher E, Barabino M, Costa M, Zuin M, Carnevali P, Santambrogio R</AU>
<TI>The impact of radiofrequency ablation and liver resection on patients with cirrhosis and early and very early hepatocellular carcinoma</TI>
<SO>HPB</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>Suppl S1</NO>
<PG>69</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Peng-2012" MODIFIED="2013-12-17 16:38:08 +0100" MODIFIED_BY="[Empty name]" NAME="Peng 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-12-17 16:38:08 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Peng ZW, Zhang YJ, Liang HH, Lin XJ, Guo RP, Chen M</AU>
<TI>Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial</TI>
<SO>Radiology</SO>
<YR>2012</YR>
<VL>262</VL>
<NO>2</NO>
<PG>689-700</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santambrogio-2012" MODIFIED="2012-11-23 16:03:28 +0100" MODIFIED_BY="[Empty name]" NAME="Santambrogio 2012" YEAR="2012">
<REFERENCE MODIFIED="2012-11-23 16:03:28 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santambrogio R, Kluger M, Costa M, Belli A, Laurent A, Zuin M, et al</AU>
<TI>Hepatic resection versus laparoscopic radiofrequency ablation for "very early" hepatocellular carcinoma</TI>
<SO>Digestive and Liver Disease</SO>
<YR>2012</YR>
<VL>44</VL>
<NO>Suppl 1</NO>
<PG>S9-S10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sreenivasan-2010" MODIFIED="2013-04-23 17:04:28 +0200" MODIFIED_BY="[Empty name]" NAME="Sreenivasan 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-04-23 17:04:28 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sreenivasan K, Roy S, Subramaniam M</AU>
<TI>Comparison of radiofrequency ablation versus resection for the treatment of hepatocellular carcinoma</TI>
<SO>HPB</SO>
<YR>2010</YR>
<VL>12</VL>
<NO>Suppl S1</NO>
<PG>164</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ueno-2009" MODIFIED="2012-11-23 16:05:02 +0100" MODIFIED_BY="[Empty name]" NAME="Ueno 2009" YEAR="2009">
<REFERENCE MODIFIED="2012-11-23 16:05:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ueno S, Sakoda M, Kubo F, Hiwatashi K, Tateno T, Baba Y, et al</AU>
<TI>Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria</TI>
<SO>Journal of Hepato-Biliary-Pancreatic Surgery</SO>
<YR>2009</YR>
<VL>16</VL>
<PG>359-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2013-12-17 16:38:44 +0100" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-12-17 16:38:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang FJ, Wu PH, Zhao M, Gu YK, Zhang L, Tan ZB</AU>
<TI>Evaluation of combined percutaneous radio-frequency ablation and percutaneous ethanol injection after transcatheter arterial chemoembolization for hepatocellular carcinoma</TI>
<SO>Zhonghua Zhong Liu Za Zhi</SO>
<YR>2005</YR>
<VL>27</VL>
<NO>4</NO>
<PG>248-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2007" MODIFIED="2013-09-12 18:07:46 +0200" MODIFIED_BY="[Empty name]" NAME="Zhang 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-09-12 18:07:44 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang YJ, Liang HH, Chen MS, Guo RP, Li JQ, Zheng Y, et al</AU>
<TI>Hepatocellular carcinoma treated with radiofrequency ablation with or without ethanol injection: a prospective randomized trial</TI>
<SO>Radiology</SO>
<YR>2007</YR>
<VL>244</VL>
<NO>2</NO>
<PG>599-607</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-12-17 16:39:18 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Di-Costanzo-2011" MODIFIED="2013-12-17 16:39:18 +0100" MODIFIED_BY="[Empty name]" NAME="Di Costanzo 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-12-17 16:39:18 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Di Costanzo GG, Tortora R, D'Adamo G, Galeota Lanza A, Carannante N, Lampasi F, et al</AU>
<TI>Radiofrequency ablation versus laser ablation for the treatment of small hepatocellular carcinoma: a randomized controlled trial</TI>
<SO>Journal of Hepatology</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>Suppl 1</NO>
<PG>S254-S255</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuansheng-2011" MODIFIED="2012-08-25 18:20:50 +0200" MODIFIED_BY="[Empty name]" NAME="Kuansheng 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-08-25 18:20:49 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuansheng M, Feng K, Yan J, Wang S, Bie P</AU>
<TI>A randomized controlled study of radiofrequency ablation and surgical resection for early-stage hepatocellular carcinomas less than 4 cm in diameter</TI>
<SO>Hepatology</SO>
<YR>2011</YR>
<VL>54</VL>
<NO>S1</NO>
<PG>418A</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2013-12-17 16:37:57 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00814242" MODIFIED="2013-12-17 16:37:57 +0100" MODIFIED_BY="[Empty name]" NAME="NCT00814242" YEAR="">
<REFERENCE MODIFIED="2013-12-17 16:37:57 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00814242</AU>
<TI>Hepatectomy versus radiofrequency ablation for hepatocellular carcinoma adjacent to major blood vessels</TI>
<SO>clinicaltrials.gov/ct2/show/NCT00814242</SO>
<YR>(accessed 16 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Abu_x002d_Hilal-2008" MODIFIED="2012-11-23 16:08:26 +0100" MODIFIED_BY="[Empty name]" NAME="Abu-Hilal 2008" TYPE="JOURNAL_ARTICLE">
<AU>Abu-Hilal M, Primrose JN, Casaril A, McPhail MJ, Pearce NW, Nicoli N</AU>
<TI>Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma</TI>
<SO>Journal of Gastrointestinal Surgery</SO>
<YR>2008</YR>
<VL>12</VL>
<NO>9</NO>
<PG>1521-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allgaier-1999" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Allgaier 1999" TYPE="JOURNAL_ARTICLE">
<AU>Allgaier HP, Deibert P, Zuber I, Olschewski M, Blum HE</AU>
<TI>Percutaneous radiofrequency interstitial thermal ablation of small hepatocellular carcinoma</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>353</VL>
<NO>9165</NO>
<PG>1676-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arii-2000" MODIFIED="2012-11-23 16:08:53 +0100" MODIFIED_BY="[Empty name]" NAME="Arii 2000" TYPE="JOURNAL_ARTICLE">
<AU>Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al</AU>
<TI>Results of surgical and nonsurgical treatment for hepatocellular carcinomas: a retrospective and nationwide survey in Japan</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>1224-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bismuth-2000" MODIFIED="2012-11-23 16:09:07 +0100" MODIFIED_BY="[Empty name]" NAME="Bismuth 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bismuth H, Majno PE</AU>
<TI>Hepatobiliary surgery</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>32</VL>
<PG>208-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bosch-2004" MODIFIED="2010-01-18 18:11:50 +0100" MODIFIED_BY="[Empty name]" NAME="Bosch 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bosch FX, Ribes J, Díaz M, Cléries R</AU>
<TI>Primary liver cancer: worldwide incidence and trends</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>127</VL>
<PG>S5-S16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouza-2009" MODIFIED="2012-11-23 16:09:23 +0100" MODIFIED_BY="[Empty name]" NAME="Bouza 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bouza C, López-Cuadrado T, Alcázar R, Saz-Parkinson Z, Amate JM</AU>
<TI>Meta-analysis of percutaneous radiofrequency ablation versus ethanol injection in hepatocellular carcinoma</TI>
<SO>BMC Gastroenterology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2008" MODIFIED="2013-04-23 16:20:39 +0200" MODIFIED_BY="[Empty name]" NAME="Brok 2008" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Gluud C, Wetterslev J</AU>
<TI>Trial sequential analysis reveals insufficient information size and potentially false positive results in many meta-analyses</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>763-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brok-2009" MODIFIED="2013-12-17 16:40:44 +0100" MODIFIED_BY="[Empty name]" NAME="Brok 2009" TYPE="JOURNAL_ARTICLE">
<AU>Brok J, Thorlund K, Wetterslev J, Gluud C</AU>
<TI>Apparently conclusive meta-analyses may be inconclusive - trial sequential analysis adjustment of random error risk due to repetitive testing of accumulating data in apparently conclusive neonatal meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>287-98</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruix-2001" MODIFIED="2012-11-23 16:09:48 +0100" MODIFIED_BY="[Empty name]" NAME="Bruix 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al</AU>
<TI>Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference</TI>
<SO>Journal of Hepatology</SO>
<YR>2001</YR>
<VL>35</VL>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bruix-2005" MODIFIED="2012-11-23 16:09:58 +0100" MODIFIED_BY="[Empty name]" NAME="Bruix 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bruix J, Sherman M</AU>
<TI>Management of hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>2005</YR>
<VL>42</VL>
<PG>1208-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Calle-2003" MODIFIED="2012-11-23 16:10:06 +0100" MODIFIED_BY="[Empty name]" NAME="Calle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ</AU>
<TI>Overweight, obesity, and mortality of cancer in a prospectively studied cohort of U.S. adults</TI>
<SO>New England Journal of Medicine</SO>
<YR>2003</YR>
<VL>348</VL>
<PG>1625-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cho-2009" MODIFIED="2013-12-17 19:12:54 +0100" MODIFIED_BY="[Empty name]" NAME="Cho 2009" TYPE="JOURNAL_ARTICLE">
<AU>Cho YK, Kim JK, Kim MY, Rhim H, Han JK</AU>
<TI>Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies</TI>
<SO>Hepatology</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>2</NO>
<PG>453-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-CTU-2011" MODIFIED="2013-12-17 16:40:14 +0100" MODIFIED_BY="[Empty name]" NAME="CTU 2011" TYPE="OTHER">
<AU>Copenhagen Trial Unit</AU>
<TI>TSA - trial sequential analysis, 2011</TI>
<SO>ctu.dk/tsa/</SO>
<YR>(accessed 16 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curley-1999" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Curley 1999" TYPE="JOURNAL_ARTICLE">
<AU>Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, et al</AU>
<TI>Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients</TI>
<SO>Annals of Surgery</SO>
<YR>1999</YR>
<VL>230</VL>
<NO>1</NO>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2012-11-23 16:10:35 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird N</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<NO>3</NO>
<PG>177-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dubay-2011" MODIFIED="2013-04-23 17:08:49 +0200" MODIFIED_BY="[Empty name]" NAME="Dubay 2011" TYPE="JOURNAL_ARTICLE">
<AU>Dubay DA, Sandroussi C, Kachura JR, Ho CS, Beecroft JR, Vollmer CM, et al</AU>
<TI>Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation</TI>
<SO>HPB</SO>
<YR>2011</YR>
<VL>13</VL>
<NO>1</NO>
<PG>24-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EASL_x002d_EORTC-2012" MODIFIED="2013-10-02 14:06:42 +0200" MODIFIED_BY="[Empty name]" NAME="EASL-EORTC 2012" TYPE="JOURNAL_ARTICLE">
<AU>European Association for the Study of the Liver; European Organisation for Research and Treatment Of Cancer</AU>
<TI>EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma</TI>
<SO>Journal of Hepatology</SO>
<YR>2012</YR>
<VL>56</VL>
<NO>4</NO>
<PG>908-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-1999" MODIFIED="2010-08-16 19:53:32 +0200" MODIFIED_BY="[Empty name]" NAME="El Serag 1999" TYPE="JOURNAL_ARTICLE">
<AU>El Serag HB, Mason AC</AU>
<TI>Rising incidence of hepatocellular carcinoma in the United States</TI>
<SO>New England Journal of Medicine</SO>
<YR>1999</YR>
<VL>340</VL>
<PG>745-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-2004" MODIFIED="2010-08-16 20:03:17 +0200" MODIFIED_BY="[Empty name]" NAME="El Serag 2004" TYPE="JOURNAL_ARTICLE">
<AU>El Serag HB, Tran T, Everhart JE</AU>
<TI>Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma</TI>
<SO>Gastroenterology</SO>
<YR>2004</YR>
<VL>126</VL>
<PG>460-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-El-Serag-2007" MODIFIED="2012-11-23 16:11:20 +0100" MODIFIED_BY="[Empty name]" NAME="El Serag 2007" TYPE="JOURNAL_ARTICLE">
<AU>El-Serag HB, Rudolph KL</AU>
<TI>Hepatocellular carcinoma: epidemiology and molecular carcinogenesis</TI>
<SO>Gastroenterology</SO>
<YR>2007</YR>
<VL>132</VL>
<NO>7</NO>
<PG>2557-76</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Francia-1999" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Francia 1999" TYPE="JOURNAL_ARTICLE">
<AU>Francia G, Marone G</AU>
<TI>Ultrasound guided percutaneous treatment of hepatocellular carcinoma by radiofrequency hyperthermia with 'cooled-tip needle'. A preliminary clinical experience</TI>
<SO>European Journal of Ultrasound</SO>
<YR>1999</YR>
<VL>9</VL>
<PG>145-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gluud-2013" MODIFIED="2013-04-23 17:09:48 +0200" MODIFIED_BY="[Empty name]" NAME="Gluud 2013" TYPE="OTHER">
<AU>Gluud C, Nikolova D, Klingenberg SL, Alexakis N, Als-Nielsen B, Colli A, et al</AU>
<TI>Cochrane Hepato-Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs))</TI>
<SO>2013, Issue 3. Art. No.: LIVER</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goldberg-2000" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Goldberg 2000" TYPE="JOURNAL_ARTICLE">
<AU>Goldberg SN, Gazelle GS, Mueller PR</AU>
<TI>Thermal ablation therapy for focal malignancy: a unified approach to underlying principles, techniques, and diagnostic imaging guidance</TI>
<SO>American Journal of Roentgenology</SO>
<YR>2000</YR>
<VL>174</VL>
<NO>2</NO>
<PG>323-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grasso-2000" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Grasso 2000" TYPE="JOURNAL_ARTICLE">
<AU>Grasso A, Watkinson AF, Tibballs JM, Burroughs AK</AU>
<TI>Radiofrequency ablation in the treatment of hepatocellular carcinoma - a clinical viewpoint</TI>
<SO>Journal of Hepatology</SO>
<YR>2000</YR>
<VL>33</VL>
<PG>667-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2012-11-23 16:14:34 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]</TI>
<SO>The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICH_x002d_GCP-1997" MODIFIED="2012-11-23 16:15:06 +0100" MODIFIED_BY="[Empty name]" NAME="ICH-GCP 1997" TYPE="BOOK">
<AU>International Conference on Harmonisation Expert Working Group</AU>
<SO>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline. Guideline for good clinical practice CFR &amp; ICH Guidelines</SO>
<YR>1997</YR>
<VL>1</VL>
<PB>Barnett International/PAREXEL</PB>
<CY>PA 19063-2043, USA</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ikeda-2005" MODIFIED="2013-10-02 14:07:38 +0200" MODIFIED_BY="[Empty name]" NAME="Ikeda 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ikeda K, Kobayashi M, Saitoh S, Someya T, Hosaka T, Sezaki H, et al</AU>
<TI>Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3 cm or less in diameter</TI>
<SO>Hepatology Research</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>3</NO>
<PG>241-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jepsen-2007" MODIFIED="2012-11-23 16:15:31 +0100" MODIFIED_BY="[Empty name]" NAME="Jepsen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Jepsen P, Vilstrup H, Tarone RE, Friis S, Sørensen HT</AU>
<TI>Incidence rates of hepatocellular carcinoma in the U.S. and Denmark: recent trends</TI>
<SO>International Journal of Cancer</SO>
<YR>2007</YR>
<VL>121</VL>
<NO>7</NO>
<PG>1624-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kjaergard-2001" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Kjaergard 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kjaergard LL, Villumsen J, Gluud C</AU>
<TI>Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2001</YR>
<VL>135</VL>
<NO>11</NO>
<PG>982-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lau-2009" MODIFIED="2012-11-23 16:15:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lau 2009" TYPE="JOURNAL_ARTICLE">
<AU>Lau WY, Lai EC</AU>
<TI>The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review</TI>
<SO>Annals of Surgery</SO>
<YR>2009</YR>
<VL>249</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lencioni-1997" MODIFIED="2011-05-09 22:33:53 +0200" MODIFIED_BY="[Empty name]" NAME="Lencioni 1997" TYPE="JOURNAL_ARTICLE">
<AU>Lencioni R, Pinto F, Bassi AM, Moretti M, Di Giulio M, Marchi S, et al</AU>
<TI>Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: an European experience</TI>
<SO>European Radiology</SO>
<YR>1997</YR>
<VL>7</VL>
<PG>514-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livraghi-1995" MODIFIED="2012-11-23 16:17:05 +0100" MODIFIED_BY="[Empty name]" NAME="Livraghi 1995" TYPE="JOURNAL_ARTICLE">
<AU>Livraghi T, Giorgio A, Marin G, Salmi A, de Sio I, Bolodi L, et al</AU>
<TI>Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection</TI>
<SO>Radiology</SO>
<YR>1995</YR>
<VL>197</VL>
<NO>1</NO>
<PG>101-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Livraghi-2000" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Livraghi 2000" TYPE="JOURNAL_ARTICLE">
<AU>Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Ierace T, Solbiati L, et al</AU>
<TI>Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions</TI>
<SO>Radiology</SO>
<YR>2000</YR>
<VL>214</VL>
<NO>3</NO>
<PG>761-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2000" MODIFIED="2013-12-16 23:04:51 +0100" MODIFIED_BY="[Empty name]" NAME="Llovet 2000" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Sala M, Castells L, Suarez Y, Vilana R, Bianchi L, et al</AU>
<TI>Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>2000</YR>
<VL>31</VL>
<PG>54-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2003" MODIFIED="2012-11-23 16:17:21 +0100" MODIFIED_BY="[Empty name]" NAME="Llovet 2003" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Bruix J, the Barcelona-Clínic Liver Cancer Group</AU>
<TI>Systematic review of randomised trials for unresectable hepatocellular carcinoma: chemoembolization improves survival</TI>
<SO>Hepatology</SO>
<YR>2003</YR>
<VL>37</VL>
<PG>429-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2003b" MODIFIED="2012-11-23 16:18:19 +0100" MODIFIED_BY="[Empty name]" NAME="Llovet 2003b" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Burroughs A, Bruix J</AU>
<TI>Hepatocellular carcinoma</TI>
<SO>Lancet</SO>
<YR>2003</YR>
<VL>362</VL>
<PG>1907-17</PG>
<IDENTIFIERS MODIFIED="2012-08-23 22:31:36 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Llovet-2008" MODIFIED="2013-04-23 17:13:53 +0200" MODIFIED_BY="[Empty name]" NAME="Llovet 2008" TYPE="JOURNAL_ARTICLE">
<AU>Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al</AU>
<TI>Sorafenib in advanced hepatocellular carcinoma</TI>
<SO>New England Journal of Medicine</SO>
<YR>2008</YR>
<VL>359</VL>
<NO>4</NO>
<PG>378-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lundh-2012" MODIFIED="2013-04-23 16:17:22 +0200" MODIFIED_BY="[Empty name]" NAME="Lundh 2012" TYPE="COCHRANE_REVIEW">
<AU>Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L</AU>
<TI>Industry sponsorship and research outcome</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2012</YR>
<NO>12</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.MR000033.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Machin-1997" MODIFIED="2011-05-09 22:33:05 +0200" MODIFIED_BY="[Empty name]" NAME="Machin 1997" TYPE="JOURNAL_ARTICLE">
<AU>Machin D, Stenning SP, Parmar MK, Fayers PM, Girling DJ, Stephens RJ, et al</AU>
<TI>Thirty years of Medical Research Council randomized trials in solid tumours</TI>
<SO>Clinical Oncology</SO>
<YR>1997</YR>
<VL>9</VL>
<PG>100-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mazzaferro-1996" MODIFIED="2012-11-23 16:17:54 +0100" MODIFIED_BY="[Empty name]" NAME="Mazzaferro 1996" TYPE="JOURNAL_ARTICLE">
<AU>Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al</AU>
<TI>Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis</TI>
<SO>New England Journal of Medicine</SO>
<YR>1996</YR>
<VL>334</VL>
<PG>693-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Minami-2010" MODIFIED="2013-12-17 16:42:12 +0100" MODIFIED_BY="[Empty name]" NAME="Minami 2010" TYPE="JOURNAL_ARTICLE">
<AU>Minami Y, Kudo M</AU>
<TI>Radiofrequency ablation of hepatocellular carcinoma: current status</TI>
<SO>World Journal of Gastroenterology</SO>
<YR>2010</YR>
<VL>2</VL>
<NO>11</NO>
<PG>417-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-1998" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Moher 1998" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, et al</AU>
<TI>Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?</TI>
<SO>Lancet</SO>
<YR>1998</YR>
<VL>352</VL>
<NO>9128</NO>
<PG>609-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Molinari-2009" MODIFIED="2013-12-17 19:50:38 +0100" MODIFIED_BY="[Empty name]" NAME="Molinari 2009" TYPE="JOURNAL_ARTICLE">
<AU>Molinari M, Helton S</AU>
<TI>Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis</TI>
<SO>American Journal of Surgery</SO>
<YR>2009</YR>
<VL>198</VL>
<NO>3</NO>
<PG>396-406</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicoli-2000" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Nicoli 2000" TYPE="JOURNAL_ARTICLE">
<AU>Nicoli N, Casaril A, Marchiori L, Mangiante G, Marini G, Colombardi R</AU>
<TI>Intraoperative and percutaneous radiofrequency thermal ablation in the treatment of hepatocellular carcinoma</TI>
<SO>Chirurgia Italiana</SO>
<YR>2000</YR>
<VL>52</VL>
<PG>29-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohnishi-1998" MODIFIED="2012-11-23 16:19:23 +0100" MODIFIED_BY="[Empty name]" NAME="Ohnishi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Ohnishi K, Yoshioka H, Ito S, Fujiwara K</AU>
<TI>Prospective randomized controlled trial comparing percutaneous acetic acid injection and percutaneous ethanol injection for small hepatocellular carcinoma</TI>
<SO>Hepatology</SO>
<YR>1998</YR>
<VL>27</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oliveri-2011" MODIFIED="2013-10-02 14:11:16 +0200" MODIFIED_BY="[Empty name]" NAME="Oliveri 2011" TYPE="COCHRANE_REVIEW">
<AU>Oliveri RS, Wetterslev J, Gluud C</AU>
<TI>Transarterial (chemo)embolisation for unresectable hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-10-02 14:11:16 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2013-10-02 14:11:16 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004787.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Parmer-1998" MODIFIED="2012-11-23 16:19:29 +0100" MODIFIED_BY="[Empty name]" NAME="Parmer 1998" TYPE="JOURNAL_ARTICLE">
<AU>Parmar MK, Torri V, Stewart L</AU>
<TI>Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>1998</YR>
<VL>17</VL>
<NO>24</NO>
<PG>2815-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-04-23 16:24:26 +0200" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-1996" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Rossi 1996" TYPE="JOURNAL_ARTICLE">
<AU>Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al</AU>
<TI>Percutaneous RF interstitial thermal ablation in the treatment of hepatic cancer</TI>
<SO>American Journal of Roentgenology</SO>
<YR>1996</YR>
<VL>167</VL>
<NO>3</NO>
<PG>759-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rossi-1998" MODIFIED="2008-11-10 01:35:17 +0100" MODIFIED_BY="[Empty name]" NAME="Rossi 1998" TYPE="JOURNAL_ARTICLE">
<AU>Rossi S, Buscarini E, Garbagnati F, Di Stasi M, Quaretti P, Rago M, et al</AU>
<TI>Percutaneous treatment of small hepatic tumors by an expandable RF needle electrode</TI>
<SO>American Journal of Roentgenology</SO>
<YR>1998</YR>
<VL>170</VL>
<NO>4</NO>
<PG>1015-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Royle-2003" MODIFIED="2013-04-23 16:14:08 +0200" MODIFIED_BY="[Empty name]" NAME="Royle 2003" TYPE="JOURNAL_ARTICLE">
<AU>Royle P, Milne R</AU>
<TI>Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches</TI>
<SO>International Journal of Technology Assessment in Health Care</SO>
<YR>2003</YR>
<VL>19</VL>
<NO>4</NO>
<PG>591-603</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012" MODIFIED="2013-04-23 16:17:22 +0200" MODIFIED_BY="[Empty name]" NAME="Savovic 2012" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Health Technology Assessment</SO>
<YR>2012</YR>
<VL>16</VL>
<NO>35</NO>
<PG>1-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Savovic-2012a" MODIFIED="2013-04-23 16:17:22 +0200" MODIFIED_BY="[Empty name]" NAME="Savovic 2012a" TYPE="JOURNAL_ARTICLE">
<AU>Savovic J, Jones HE, Altman DG, Harris RJ, Jüni P, Pildal J, et al</AU>
<TI>Influence of reported study design characteristics on intervention effect estimates from randomized, controlled trials</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2012</YR>
<VL>157</VL>
<NO>6</NO>
<PG>429-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoppmeyer-2009" MODIFIED="2013-12-17 16:41:19 +0100" MODIFIED_BY="[Empty name]" NAME="Schoppmeyer 2009" TYPE="COCHRANE_REVIEW">
<AU>Schoppmeyer K, Weis S, Mössner J, Fleig WE</AU>
<TI>Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2013-04-23 17:22:42 +0200" MODIFIED_BY="Sarah L Klingenberg">
<IDENTIFIER MODIFIED="2013-04-23 17:22:42 +0200" MODIFIED_BY="Sarah L Klingenberg" TYPE="DOI" VALUE="10.1002/14651858.CD006745.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2011-06-05 07:15:16 +0200" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF, Chalmers I, Hayes RJ, Altman DG</AU>
<TI>Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials</TI>
<SO>Journal of the American Medical Association</SO>
<YR>1995</YR>
<VL>273</VL>
<NO>5</NO>
<PG>408-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-S_x00f8_rensen-2003" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NAME="Sørensen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sørensen HT, Mellemkjær L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al</AU>
<TI>Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2003</YR>
<VL>36</VL>
<PG>356-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Takamori-2000" MODIFIED="2011-06-05 07:15:45 +0200" MODIFIED_BY="[Empty name]" NAME="Takamori 2000" TYPE="JOURNAL_ARTICLE">
<AU>Takamori R, Wong LL, Dang C, Wong L</AU>
<TI>Needle-tract implantation from hepatocellular cancer: is needle biopsy of the liver always necessary?</TI>
<SO>Liver Transplantation</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>67-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2009" MODIFIED="2013-04-23 16:20:09 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2009" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Devereaux PJ, Wetterslev J, Guyatt G, Ioannidis JP, Thabane L, et al</AU>
<TI>Can trial sequential monitoring boundaries reduce spurious inferences from meta-analyses</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2009</YR>
<VL>38</VL>
<NO>1</NO>
<PG>276-86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2010" MODIFIED="2013-04-23 16:20:09 +0200" MODIFIED_BY="[Empty name]" NAME="Thorlund 2010" TYPE="JOURNAL_ARTICLE">
<AU>Thorlund K, Anema A, Mills E</AU>
<TI>Interpreting meta-analysis according to the adequacy of sample size. An example using isoniazid chemoprophylaxis for tuberculosis in purified protein derivative negative HIV-infected individuals</TI>
<SO>Clinical Epidemiology</SO>
<YR>2010</YR>
<VL>2</VL>
<PG>57-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thorlund-2011" MODIFIED="2013-12-17 16:41:04 +0100" MODIFIED_BY="[Empty name]" NAME="Thorlund 2011" TYPE="OTHER">
<AU>Thorlund K, Engstrøm J, Wetterslev J, Brok J, Imberger G, Gluud C</AU>
<TI>User manual for trial sequential analysis (TSA), 2011</TI>
<SO>ctu.dk/tsa/files/tsa_manual.pdf</SO>
<YR>(accessed 16 December 2013)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Weis-2013" MODIFIED="2013-12-17 16:41:32 +0100" MODIFIED_BY="[Empty name]" NAME="Weis 2013" TYPE="OTHER">
<AU>Weis S, Franke A, Berg T, Mössner J, Fleig WE, Schoppmeyer K</AU>
<TI>Percutaneous ethanol injection or percutaneous acetic acid injection for early hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2013</YR>
<VL>in press</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2008" MODIFIED="2013-01-09 17:58:43 +0100" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Trial sequential analysis may establish when firm evidence is reached in cumulative meta-analysis</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2008</YR>
<VL>61</VL>
<PG>64-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wetterslev-2009" MODIFIED="2013-04-23 17:17:05 +0200" MODIFIED_BY="[Empty name]" NAME="Wetterslev 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wetterslev J, Thorlund K, Brok J, Gluud C</AU>
<TI>Estimating required information size by quantifying diversity in random-effects model meta-analyses</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2009</YR>
<VL>9</VL>
<PG>86</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2012-11-23 13:57:42 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman GD, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ (Clinical Research Ed.)</SO>
<YR>2008</YR>
<VL>336</VL>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-W_x00f6_rns-2009" MODIFIED="2012-11-23 16:22:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wörns 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wörns MA, Weinmann A, Pfingst K, Schulte-Sasse C, Messow CM, Schulze-Bergkamen H, et al</AU>
<TI>Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver disease</TI>
<SO>Journal of Clinical Gastroenterology</SO>
<YR>2009</YR>
<VL>43</VL>
<NO>5</NO>
<PG>389-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zhou-2010" MODIFIED="2012-11-23 16:23:43 +0100" MODIFIED_BY="[Empty name]" NAME="Zhou 2010" TYPE="JOURNAL_ARTICLE">
<AU>Zhou Y, Zhao Y, Li B, Xu D, Yin Z, Xie F, et al</AU>
<TI>Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma</TI>
<SO>BMC Gastroenterology</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>78</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-11-23 16:32:35 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Galandi-2001" MODIFIED="2012-11-23 16:31:54 +0100" MODIFIED_BY="Sarah L Klingenberg" NAME="Galandi 2001" TYPE="OTHER">
<AU>Galandi D, Antes G</AU>
<TI>Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Protocol]</TI>
<SO>The Cochrane Library (Update Software, Oxford)</SO>
<YR>2001, Issue 2</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galandi-2002" MODIFIED="2012-11-23 16:32:35 +0100" MODIFIED_BY="[Empty name]" NAME="Galandi 2002" TYPE="OTHER">
<AU>Galandi D, Antes G</AU>
<TI>Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma [Review]</TI>
<SO>The Cochrane Library (Update Software, Oxford)</SO>
<YR>2002, Issue 3</YR>
<IDENTIFIERS MODIFIED="2012-11-23 16:32:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-11-23 16:32:00 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Galandi-2004" MODIFIED="2012-11-23 16:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="Galandi 2004" TYPE="COCHRANE_REVIEW">
<AU>Galandi D, Antes G</AU>
<TI>Radiofrequency thermal ablation versus other interventions for hepatocellular carcinoma</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-11-23 16:28:45 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-11-23 16:28:45 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD003046"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Inclusion Criteria" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Exclusion Criteria" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Follow-up">
<INCLUDED_CHAR MODIFIED="2013-12-17 16:06:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brunello-2008">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:05:12 +0100" MODIFIED_BY="[Empty name]">
<P>139 patients: RFA = 70; PEI = 69.</P>
<P>Recruitment: January 2001 to September 2004.</P>
<P>Country: Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-21 23:59:27 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:04:57 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>complete response at 1 year.</P>
<P>Secondary outcome: early complete response (at 30-50 days after treatment), complications, survival, costs.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:05:04 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child-Pugh cirrhosis A and B.</LI>
<LI>1 to 3 nodules, each &#8804; 30 mm.</LI>
<LI>HCC confirmed by radiology or histology.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-12-17 16:06:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>no liver cirrhosis.</LI>
<LI>Child-Pugh cirrhosis C.</LI>
<LI>platelet count &lt; 40,000 mm<SUP>3</SUP>.</LI>
<LI>INR &gt; 1.75.</LI>
<LI>prothrombin time &gt; 40 seconds.</LI>
<LI>hypovascular HCC.</LI>
<LI>lesions not detectable by ultrasound.</LI>
<LI>lesions close to gallbladder, hilum, colon, stomach (&lt; 1 cm).</LI>
<LI>venous invasion.</LI>
<LI>metastasis.</LI>
<LI>tumour &gt; 30 mm.</LI>
<LI>patients suitable for liver transplantation or resection.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-12-14 21:16:51 +0100" MODIFIED_BY="[Empty name]">
<P>26 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:05:17 +0100" MODIFIED_BY="[Empty name]">
<P>Patients suitable for resection were excluded.</P>
<P>Patients with incomplete response (2 cycles) were further treated with PEI, RFA, or TACE.</P>
<P>Intention-to-treat analysis for complete response and survival was performed.</P>
<P>Trial stopped early after conclusive interim analysis indicating effects that exceeded the expectations.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:05:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2006">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:05:30 +0100" MODIFIED_BY="[Empty name]">
<P>180 patients: partial hepatectomy = 90; percutaneous local ablative therapy = 90.</P>
<P>Recruitment: November 1999 to June 2004.</P>
<P>Country: China.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:00:31 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus hepatic resection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:05:30 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>tumour recurrence rate at 2 years.</P>
<P>Secondary outcomes: overall survival, tumour-free survival, pain, length of hospital stay.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:05:36 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>HCC confirmed histologically or by 2 imaging procedures + AFP &gt; 400 ng/mL.</LI>
<LI>1 HCC nodule &#8804; 5 cm.</LI>
<LI>aged 18 to 75 years.</LI>
<LI>no extrahepatic metastasis.</LI>
<LI>no radiological evidence of invasion into major portal/hepatic vein branches.</LI>
<LI>Child-Pugh cirrhosis A with no history of encephalopathy, ascites refractory to diuretics, or variceal bleeding.</LI>
<LI>indocyanine green retention at 15 minutes &lt; 30%.</LI>
<LI>platelet count &gt; 40,000 mm<SUP>3</SUP>.</LI>
<LI>suitable for surgical or percutaneous local ablative therapy treatment.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-01-20 16:38:19 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>none quoted.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:05:45 +0100" MODIFIED_BY="[Empty name]">
<P>RFA 27.9 ± 10.6 months, resection 29.2 ± 11.9 months</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:05:45 +0100" MODIFIED_BY="[Empty name]">
<P>19 patients who were randomised to RFA withdrew their consent and received resection. Survival analysis according to the intention-to-treat principle.</P>
<P>When residual tumour was present, RFA or PEI and TACE were performed. Only 62% of patients were treated with RFA once.</P>
<P>2 patients randomised to surgery were treated with PEI because of disseminated disease.</P>
<P>Focal nodular hyperplasia was found in 1 patient instead of HCC.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Feng-2012">
<CHAR_METHODS MODIFIED="2013-12-17 16:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>168 patients: RFA = 84; surgical resection = 84.</P>
<P>Recruitment: January 2005 to March 2008.</P>
<P>Country: China.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:00:48 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus hepatic resection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:06:49 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: 3-year survival.</P>
<P>Secondary outcomes: 1- and 2- year survival, tumour recurrence, complications.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:06:55 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>diagnosis of HCC confirmed at study authors' hospital.</LI>
<LI>no more than 2 nodules.</LI>
<LI>tumour diameter &lt; 4 cm.</LI>
<LI>Child&#8211;Pugh cirrhosis A or B.</LI>
<LI>no intrahepatic and extrahepatic metastases.</LI>
<LI>no invasion of the portal vein.</LI>
<LI>no invasion of the hepatic vein trunk or secondary branches.</LI>
<LI>indocyanine green retention at 15 minutes &lt; 30%.</LI>
<LI>platelet count &gt; 50,000 mm<SUP>3</SUP>.</LI>
<LI>prolonged prothrombin time of &lt; 5 seconds.</LI>
<LI>no other previous anti-tumour therapy.</LI>
<LI>suitable candidates for both hepatic resection and RFA.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2012-11-22 16:57:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>patients met the inclusion criteria but declined to participate.</LI>
<LI>severe portal hypertension.</LI>
<LI>history of oesophageal variceal haemorrhage.</LI>
<LI>severe hypersplenism syndrome.</LI>
<LI>refractory ascites.</LI>
<LI>patients whose permanent pathology after treatment suggested metastatic</LI>
<LI>liver cancer or primary liver cancer of another tissue type.</LI>
<LI>patients who were willing to receive a liver transplantation</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2012-08-02 20:27:15 +0200" MODIFIED_BY="[Empty name]">
<P>36 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<P>The absolute number of deaths that occurred in the resection group were 18 including 1 patient died of a cerebral vascular accident. 24 patients died in the RFA group including one patient who died in a motor vehicle accident.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:07:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ferrari-2007">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:28 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>81 patients: RFA = 40; laser ablation = 41.</P>
<P>Recruitment: January 2003 to December 2005.</P>
<P>Country: Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus laser ablation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>Survival, complications, complete tumour ablation, disease recurrence.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:07:25 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>histologically confirmed HCC.</LI>
<LI>single nodule &#8804; 40 mm or no more than 3 nodules &#8804; 30 mm each.</LI>
<LI>no previous HCC treatment.</LI>
<LI>performance status ECOG 0-2.</LI>
<LI>cardiac and pulmonary function WHO 0-2.</LI>
<LI>aged 19 to 82 years.</LI>
<LI>underlying liver cirrhosis.</LI>
<LI>delayed inclusion.</LI>
<LI>prothrombin activity &lt; 40%.</LI>
<LI>INR &gt; 1.99.</LI>
<LI>platelet count &gt; 40,000 mm<SUP>3</SUP>.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>tumour invasion into vessels or main bile duct.</LI>
<LI>extrahepatic metastases.</LI>
<LI>Child-Pugh C cirrhosis.</LI>
<LI>severely decompensated cirrhosis.</LI>
<LI>major oesophageal varices.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>Not stated.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:07:21 +0100" MODIFIED_BY="[Empty name]">
<P>No primary and secondary endpoints were defined.</P>
<P>The study authors stated that there were no complications at all.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:39:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giorgio-2011">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>285 patients: RFA = 142; PEI = 143.</P>
<P>Recruitment: January 2005 to January 2010.</P>
<P>Country: Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:01:20 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: 5-year survival, rate of recurrence.</P>
<P>Secondary survival: feasibility of both procedures considering segmental location.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:07:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>single nodule &#8804; 3 cm.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
<LI>no ascites.</LI>
<LI>no portal vein or segmental portal thrombosis.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-12-17 16:07:33 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>&gt; 1 nodule.</LI>
<LI>&gt; 3 cm in diameter.</LI>
<LI>Child-Pugh C cirrhosis.</LI>
<LI>patients eligible for resection or liver transplantation.</LI>
<LI>patients with extrahepatic diseases.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:39:34 +0100" MODIFIED_BY="[Empty name]">
<P>8 to 68 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:07:33 +0100" MODIFIED_BY="[Empty name]">
<P>Additional information from study authors was obtained: HR of overall survival.</P>
<P>14 patients randomised to RFA could not be treated by RFA and were not included in the survival analysis.</P>
<P>Patients and field staff were blinded to treatment assignment.</P>
<P>In addition, the total number of deaths were obtained from the study authors and were: HCC &lt; 3 cm treated with PEI 45; HCC &lt; 3 treated with RFA 30; HCC &lt; 2 cm treated with PEI 14; HCC &lt; 2 cm treated with RFA 11.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:08:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2010">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:31 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>230 patients: RFA 115; surgical resection 115.</P>
<P>Recruitment: March 2003 to January 2005.</P>
<P>Country: China.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:01:42 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus hepatic resection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:07:52 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>overall survival.</P>
<P>Secondary outcome:<B> </B>recurrence-free survival, overall recurrence, adverse events, length of hospital stay.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:07:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>diagnosis of HCC confirmed in the study hospital.</LI>
<LI>tumour within the Milan criteria.</LI>
<LI>no extrahepatic metastasis or obvious vascular invasion.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
<LI>no previous or simultaneous malignancies.</LI>
<LI>indocyanine green retention at 15 minutes &lt; 20%.</LI>
<LI>platelet count &gt; 50,000 mm<SUP>3</SUP> or correctable by transfusion.</LI>
<LI>prothrombin time &lt; 5 seconds.</LI>
<LI>HBV-DNA quantification in HBV-infected patients &lt; 10,000 copies/mL.</LI>
<LI>no previous HCC treatment.</LI>
<LI>suitable to be treated by resection or RFA.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2013-12-17 16:07:57 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>severe portal hypertension with history of oesophageal variceal haemorrhage, with large oesophageal varices, refractory ascites.</LI>
<LI>willing to receive liver transplantation.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:08:32 +0100" MODIFIED_BY="[Empty name]">
<P>1 to 60 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:08:41 +0100" MODIFIED_BY="[Empty name]">
<P>Study authors reported limitations of the trial. Patients that were willing to receive liver transplantation were excluded.</P>
<P>Subgroup analysis regarding solitary HCC &lt; 3 cm, solitary HCC 3 to 5 cm and multifocal HCC.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lencioni-2003">
<CHAR_METHODS MODIFIED="2011-06-04 18:21:53 +0200" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>102 patients: RFA = 52; PEI = 50.</P>
<P>Recruitment: unclear.</P>
<P>Country: Italy, Germany.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:01:57 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>overall survival.<BR/>Secondary outcome: local recurrence free and event free (metastasis, new HCC) survival, adverse events.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>adults with cirrhosis and (a) single HCC &#8804; 5 cm in diameter or (b) 3 HCCs each &#8804; 3 cm in diameter.</LI>
<LI>HCCs all located at least 1 cm from the hepatic hilum or the gall bladder.</LI>
<LI>absence of vascular invasion or extrahepatic metastases.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
<LI>prothrombin activity &gt; 50%.</LI>
<LI>platelet count &gt; 50,000 mm<SUP>3</SUP>
</LI>
<LI>no previous treatment for HCC.</LI>
<LI>ineligibility for surgical resection or transplantation.</LI>
<LI>written informed consent.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:06:43 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>none given.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>RFA mean 22.9 months, PEI mean 22.4 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:08:53 +0100" MODIFIED_BY="[Empty name]">
<P>2 patients randomised to RFA were excluded due to violation of the inclusion criteria (1 with a large carcinoma &gt; 5 cm and 1 with extrahepatic tumour).</P>
<P>Histological confirmation of HCC was only obtained in 45/102 patients.</P>
<P>Based on contact with the statistician of the trial we have been informed that the risk ratios are indeed HRs.</P>
<P>No sample size calculation reported.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:16:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>157 patients: RFA 52; high-dose PEI 53; PEI 52.</P>
<P>Recruitment: April 2000 to April 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 15:25:07 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus high-dose PEI versus PEI.</P>
<P>Comparison 1: RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: local tumour progression.</P>
<P>Secondary outcome:<B> c</B>omplete tumour necrosis, overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:09:17 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>histologically or cytologically confirmed HCC.</LI>
<LI>1 to 3 nodules up to 4 cm.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:09:40 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child-Pugh cirrhosis C.</LI>
<LI>previous HCC treatment.</LI>
<LI>tumour within 5 mm of liver hila or common bile duct.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:16:09 +0100" MODIFIED_BY="[Empty name]">
<P>4 to 43 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>6 patients with PEI, 3 patients with high-dose PEI, and 2 patients with RFA did not receive a complete treatment course or did not achieve complete necrosis and underwent TACE.</P>
<P>Patients of both PEI arms treated as outpatients as long as no adverse event occurred.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:09:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>157 patients: RFA = 52; high-dose PEI = 53; PEI = 52.</P>
<P>Recruitment: April 2000 to April 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 15:01:58 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus high-dose PEI versus PEI.</P>
<P>Comparison 2: RFA versus high-dose PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-14 15:43:47 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome: local tumour progression.</P>
<P>Secondary outcome: complete tumour necrosis, overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:09:49 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>histologically or cytologically confirmed HCC.</LI>
<LI>1 to 3 nodules up to 4 cm.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:11:51 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child-Pugh cirrhosis C.</LI>
<LI>previous HCC treatment.</LI>
<LI>tumour within 5 mm of liver hila or common bile duct.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:09:55 +0100" MODIFIED_BY="[Empty name]">
<P>4 to 43 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:09:40 +0100" MODIFIED_BY="[Empty name]">
<P>6 patients with PEI, 3 patients with high-dose PEI, and 2 patients with RFA did not receive a complete treatment course or did not achieve complete necrosis and received TACE.</P>
<P>Patients of both PEI arms treated as outpatients as long as no adverse event occurred.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:10:29 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:10:05 +0100" MODIFIED_BY="[Empty name]">
<P>187 patients: RFA = 62; PEI = 62; PAI = 63.</P>
<P>Recruitment: April 2000 to June 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-03 15:24:56 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI versus PAI.</P>
<P>Comparison 1: RFA versus PAI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-30 21:19:25 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>local recurrence.</P>
<P>Secondary outcome: overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:10:15 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>1 to 3 HCC nodules each &#8804; 3 cm.</LI>
<LI>&gt; 1 cm distance to hepatic hilum.</LI>
<LI>absence of extrahepatic 3 cm metastasis or vascular invasion.</LI>
<LI>liver cirrhosis Child A or B.</LI>
<LI>prothrombin time 3 seconds less than control values</LI>
<LI>platelet count &gt; 50,000/mm<SUP>3</SUP>.</LI>
<LI>no previous treatment.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:14:08 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child-Pugh cirrhosis C.</LI>
<LI>previous HCC treatment.</LI>
<LI>tumour located within 1 cm of the liver hilum or common bile duct.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:10:25 +0100" MODIFIED_BY="[Empty name]">
<P>41 to 44 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:10:29 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>4.8% major complications in RFA, 0% in the PAI and PEI groups.</LI>
<LI>11 patients had a treatment failure and were treated with additional therapies.</LI>
<LI>Planned early stopping if there was a survival benefit for 1 of the treatments as evaluated every 3 months.</LI>
<LI>patients of PEI/PAI arms treated as outpatients as long as no adverse events occurred.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:10:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<CHAR_METHODS MODIFIED="2013-12-17 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Prospective randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>187 patients: RFA = 62; PEI = 62; PAI = 63.</P>
<P>Recruitment: April 2000 to June 2002.</P>
<P>Country: Taiwan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-17 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI versus PAI.</P>
<P>Comparison 1: RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:10:45 +0100" MODIFIED_BY="[Empty name]">
<P>Primary outcome: local recurrence.</P>
<P>Secondary outcome: overall survival, cancer-free survival.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:10:47 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>1 to 3 HCC nodules each &#8804; 3 cm.</LI>
<LI>&gt; 1 cm distance to hepatic hilum.</LI>
<LI>absence of extrahepatic metastasis or vascular invasion.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
<LI>prothrombin time 3 seconds less than control values.</LI>
<LI>platelet count &gt; 50,000/mm<SUP>3</SUP>.</LI>
<LI>no previous treatment.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:13:30 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>Child-Pugh cirrhosis C.</LI>
<LI>previous HCC treatment.</LI>
<LI>tumour located within 1 cm of the liver hilum or common bile duct.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:10:59 +0100" MODIFIED_BY="[Empty name]">
<P>4 to 44 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:10:56 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>4.8% major complications in RFA, 0% in the PAI and PEI groups.</LI>
<LI>7 patients had a treatment failure and were treated with additional therapies.</LI>
<LI>Planned early stopping if there was a survival benefit for 1 of the treatments as evaluated every 3 months.</LI>
<LI>patients of PEI/PAI arms treated as outpatients as long as no adverse events occurred.</LI>
</UL>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:11:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shibata-2002">
<CHAR_METHODS MODIFIED="2013-12-16 20:33:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:11:23 +0100" MODIFIED_BY="[Empty name]">
<P>72 patients: RFA = 36; percutaneous microwave ablation = 36.</P>
<P>Recruitment: March 1999 to October 2000.</P>
<P>Country: Japan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-10-02 14:24:34 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus percutaneous microwave coagulation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-30 21:19:35 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>tumour recurrence.<BR/>Secondary outcome:<B> </B>pain, complications, duration of the procedure.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:11:23 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>HCC diagnosis confirmed by ultrasound-guided needle biopsy.</LI>
<LI>a solitary HCC nodule &#8804; 4 cm in diameter or 2 or 3 HCC nodules &#8804; 3 cm in diameter.</LI>
<LI>informed consent.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-06-04 17:15:17 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>none given.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:11:27 +0100" MODIFIED_BY="[Empty name]">
<P>6 to 27 months.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2011-06-04 17:15:13 +0200" MODIFIED_BY="[Empty name]">
<P>No data on survival were reported.</P>
<P>Detailed description of complications was included.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-12-17 16:12:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Shiina-2005">
<CHAR_METHODS MODIFIED="2013-11-30 21:54:35 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>232 patients: RFA = 118; PEI = 114.</P>
<P>Recruitment: April 1999 to January 2001.</P>
<P>Country: Japan.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:04:30 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus PEI.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-03 08:27:50 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome: overall survival.</P>
<P>Secondary outcome: overall recurrence, local tumour progression.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2013-12-17 16:12:09 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>histopathologically or radiologically confirmed HCC.</LI>
<LI>lesions were unresectable or the patient had refused surgery.</LI>
<LI>1 to 3 HCC nodules each &#8804; 3 cm.</LI>
<LI>Child-Pugh cirrhosis A or B.</LI>
<LI>no extrahepatic metastasis or vascular invasion; no previous or simultaneous malignancies.</LI>
</UL>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2011-09-10 12:36:53 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>refractory ascites.</LI>
<LI>platelet count &lt; 50,000/mm<SUP>3</SUP>
</LI>
<LI>prothrombin activity below &lt; 50%.</LI>
</UL>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2013-12-17 16:12:03 +0100" MODIFIED_BY="[Empty name]">
<P>0.6 to 4.3 years (median 3.1 years).</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2013-12-17 16:11:57 +0100" MODIFIED_BY="[Empty name]">
<P>No patients were excluded for lesion location.</P>
<P>Detection of fourth lesion in 3 RFA patients and 4 PEI patients.</P>
<P>Intention-to-treat analysis performed.</P>
<P>More experienced physician performed the difficult lesions.</P>
<P>Adverse events reported.</P>
<P>All patients were treated as inpatients until computed tomography stated treatment success.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AFP: alpha-fetoprotein; DNA: deoxyribonucleic acid; ECOG: Eastern Cooperative Oncology Group; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HR: hazard ratio; INR: international normalised ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation; TACE: transarterial chemoembolisation; WHO: World Health Organization.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2013-12-17 16:12:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akamatsu-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 16:12:37 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised trial (using sealed envelopes) that was not included due to the following reasons: patients were switched from PEI to RFA as soon as this technique was available. Randomisation of 6 versus 10 patients. Therefore, the study design was considered insufficient to evaluate RFA effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-29 14:56:01 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amarnath-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-29 14:56:01 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Buscarini-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-17 16:12:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 16:12:40 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation not clear. Study authors did not reply to our contact approaches via email.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-10-17 21:58:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cheng-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-10-17 21:58:01 +0200" MODIFIED_BY="[Empty name]">
<P>Publication retracted in May 2009.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-05 09:12:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cho-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-05 09:12:33 +0200" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial. Markov model analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 09:05:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cuschieri-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 09:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-17 16:12:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gan-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 16:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomisation not clear. Study authors did not reply.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-23 20:03:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Giorgio-2011a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-23 20:03:33 +0200" MODIFIED_BY="[Empty name]">
<P>RFA also used to treat portal vein thrombosis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-05 09:12:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goldberg-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-05 09:12:22 +0200" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gory-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective multicentre analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-25 09:05:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jiao-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-25 09:05:36 +0100" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-23 16:39:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Khan-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-23 16:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-27 15:36:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kobayashi-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-27 15:36:36 +0100" MODIFIED_BY="[Empty name]">
<P>RFA compared with combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-11-23 16:39:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kurokohchi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-11-23 16:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>Not a randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-17 16:12:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Livraghi-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 16:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>Controlled trial without randomisation.<BR/>Different diagnostic follow-up schedules in the 2 treatment groups.<BR/>No data concerning overall survival.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-12-17 16:12:50 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x00fc_-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-12-17 16:12:50 +0100" MODIFIED_BY="[Empty name]">
<P>Radiofrequency or microwave ablation therapy applied in 1 group compared with surgical resection in the other group. Therefore, RFA effects were not extractable.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-27 15:36:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morimoto-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-27 15:36:40 +0100" MODIFIED_BY="[Empty name]">
<P>RFA compared with combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-27 15:36:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morimoto-2011">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-27 15:36:41 +0100" MODIFIED_BY="[Empty name]">
<P>RFA compared with combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-09-30 17:37:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ohmoto-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-09-30 17:37:19 +0200" MODIFIED_BY="[Empty name]">
<P>Not a controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-03 20:47:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Opocher-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-03 20:47:38 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-24 23:26:43 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Peng-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-24 23:26:43 +0200" MODIFIED_BY="[Empty name]">
<P>Only recurrent HCC treated.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-08-24 23:24:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santambrogio-2012">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-08-24 23:24:14 +0200" MODIFIED_BY="[Empty name]">
<P>Not a percutaneous intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-01-03 20:47:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sreenivasan-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-01-03 20:47:34 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-29 14:56:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ueno-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-29 14:56:14 +0100" MODIFIED_BY="[Empty name]">
<P>Retrospective cohort study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-05-22 20:51:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-05-22 20:51:33 +0200" MODIFIED_BY="[Empty name]">
<P>Quasi-randomised trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2013-10-27 15:36:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2013-10-27 15:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>RFA compared with combination treatment.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>HCC: hepatocellular carcinoma; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-12-17 16:13:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-12-17 16:13:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Di-Costanzo-2011">
<CHAR_METHODS MODIFIED="2013-10-27 15:36:43 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>80 patients: RFA = 40; laser ablation = 40.</P>
<P>Recruitment: January 2009 to October 2010.</P>
<P>Country: Italy.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-17 16:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus laser ablation.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-06-22 00:07:18 +0200" MODIFIED_BY="[Empty name]">
<P>Primary outcome:<B> </B>complete tumour ablation, time to recurrence.</P>
<P>Secondary outcome: overall survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-17 16:13:09 +0100" MODIFIED_BY="[Empty name]">
<P>From the meeting abstract. Insufficient information to judge bias, randomisation process, etc. Author contact failed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-12-17 16:13:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kuansheng-2011">
<CHAR_METHODS MODIFIED="2013-10-27 15:36:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised clinical trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>168 patients: RFA = 84; surgical resection = 84.</P>
<P>Recruitment: December 2004 to October 2007</P>
<P>Country: most likely China.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-06-22 00:07:09 +0200" MODIFIED_BY="[Empty name]">
<P>RFA versus surgical resection.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>1-, 2- and 3-year survival.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-12-17 16:13:05 +0100" MODIFIED_BY="[Empty name]">
<P>From the meeting abstract. Insufficient information to judge bias, randomisation process, etc. Probably data published in the trial by Feng et al (<LINK REF="STD-Feng-2012" TYPE="STUDY">Feng 2012</LINK>).</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES>
<P>RFA: radiofrequency ablation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2013-12-17 16:13:38 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2013-12-17 16:13:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00814242">
<CHAR_STUDY_NAME MODIFIED="2010-01-13 19:16:13 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatectomy Versus Radiofrequency Ablation for Hepatocellular Carcinoma Adjacent to Major Blood Vessels.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2013-05-22 20:51:37 +0200" MODIFIED_BY="[Empty name]">
<P>Randomisation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-12-17 16:13:22 +0100" MODIFIED_BY="[Empty name]">
<UL>
<LI>approximately 120 participants.</LI>
</UL>
<P>Inclusion:</P>
<UL>
<LI>HCC at complex site (see below).</LI>
<LI>Child-Pugh cirrhosis.</LI>
<LI>no dysfunction in major organs; blood routine, kidney function, cardiac function, and lung function are basically normal.</LI>
<LI>aged 18 to 70 years.</LI>
</UL>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-12-17 16:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>RFA versus surgery.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-12-17 16:13:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Primary:</B>
</P>
<UL>
<LI>tumour recurrence rate after 1 and 2 years.</LI>
<LI>disease-free survival.</LI>
<LI>overall survival.</LI>
</UL>
<P>
<B>Secondary:</B>
</P>
<UL>
<LI>overall survival rate in 1, 2, 3, or 5 years.</LI>
<LI>disease-free survival in 1, 2, 3, or 5 years.</LI>
<LI>hepatic function of patients after surgery.</LI>
<LI>complications and the decline level of serum AFP concentration.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2013-12-17 16:13:30 +0100" MODIFIED_BY="[Empty name]">
<P>December 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2013-12-17 16:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Feng Shen, MD, Study Chair.<BR/>
<BR/>Lehua Shi, MD, telephone: 0086-21-25070784.<BR/>Email: shilh@ehbh.cn.<BR/>
<BR/>Yong Xia, MD, telephone: 0086-21-25074943.<BR/>Email: xiay99@hotmail.com.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2013-12-17 16:13:27 +0100" MODIFIED_BY="[Empty name]">
<P>Hepatoma at a complex site (8 segment of liver, caudate lobe, the substantial depth of liver below hepatic integument adjacent to the trunk of inferior vena cava, hepatic vein, and portal vein).</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>AFP: alpha-fetoprotein; HCC: hepatocellular carcinoma; RFA: radiofrequency ablation.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-12-17 19:48:42 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-08 21:35:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-03 07:25:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-02 20:46:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 22:34:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 11:41:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>Random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-22 00:01:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 12:00:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-04 17:10:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-25 11:15:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 14:53:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 10:46:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>Random number generator.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-12-17 16:11:47 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-08 21:35:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 14:54:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Computer at a central registry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-02 21:07:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-02 12:22:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>Computer randomisation.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 11:41:21 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>Coded list.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 14:57:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>Sealed envelopes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 12:00:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>Central registry.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-10 12:28:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Locked computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-22 00:03:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Locked computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:11:47 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>Sealed envelope.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-08-28 10:46:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>Computer.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="STUDY" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Blinding of survival outcomes</NAME>
<DESCRIPTION/>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:49:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:49:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:50:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 16:04:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>Patients and field staff blinded to treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:08:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influenced by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:51:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:51:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:09:59 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:51:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:51:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-12 15:51:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>Survival outcomes may not be significantly influences by a lack of blinding.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2013-09-12 15:48:04 +0200" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-12-17 19:48:42 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-08 21:35:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>Number and reasons for drop-outs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-18 11:04:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>Drop-outs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-08-02 20:56:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Drop-outs reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-09-18 11:53:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>Not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:07:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>Drop-outs reported, but 14 patients randomised to RFA were treated with PEI and not included in the survival analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:08:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>Drop-outs and protocol violations were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:09:09 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>Reasons for drop-out/withdrawal stated.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:09:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Drop-outs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 19:48:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION>
<P>Drop-outs were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-22 00:03:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Drop-outs did not occur.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>Drop-outs not reported. No intention-to-treat analysis. Apparently all patients received the assigned treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-12-17 16:12:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>No patient was lost to follow-up. An intention-to-treat analysis was performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-10-30 16:01:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>All outcomes were appropriately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 22:34:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>All outcomes were appropriately reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:07:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Power calculation performed. Intention-to-treat analysis performed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 11:58:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-10 10:16:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>All relevant outcomes were reported. HR was given only for overall survival.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-14 21:02:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 12:30:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-04 17:10:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>All relevant outcomes were reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-13 22:40:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>All outcomes were addressed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-25 11:48:45 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>Survival was not a defined outcome and not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:34:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>All outcomes reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-10-11 13:25:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>An interim analysis was carried out after 3 years leading to the interruption of the study, because the difference in 1-year complete response rate (the primary endpoint) was larger than expected. It remains unclear, whether this was a preplanned analysis. In addition, the impact on survival (a secondary endpoint) remains speculative.</P>
<P>More patients received a second treatment cycle in the PEI group.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:06:43 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>A high percentage of patients randomised to the percutaneous local ablative therapy arm withdrew their consent and received surgical resection. They were analysed in an intention-to-treat analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:07:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>Zelen method used for stratification. Written informed consent signed after agreement with randomisation.</P>
<P>Patients who died of causes unrelated to HCC were judged as lost to follow-up.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-11-04 00:37:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>Outcomes not defined.</P>
<P>Unclear whether normalisation of coagulation did improve Child-Pugh status.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-02 21:09:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>There was no other source of bias detected.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-17 15:36:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>No other source of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 14:53:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>No other source of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-09-10 10:51:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>No source of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-05 17:26:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Local recurrence was primary outcome, not survival, thus sample size calculation was based on local recurrence.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-12-29 14:53:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>No other source of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-23 21:34:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>There was no other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2013-09-12 15:48:04 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Baseline imbalance</NAME>
<DESCRIPTION>
<P>Were there any imbalance in the baseline of the treatment groups?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="STUDY" MODIFIED="2013-09-12 15:48:04 +0200" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Early stopping?</NAME>
<DESCRIPTION>
<P>Was the trial stopped early due to formal stopping rules?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-09" LEVEL="STUDY" MODIFIED="2013-12-17 19:48:39 +0100" MODIFIED_BY="[Empty name]" NO="9">
<NAME>Vested interest bias?</NAME>
<DESCRIPTION>
<P>Was there any vested interest bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:05:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or other funding bias was ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:06:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or other funding bias was ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:07:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or other funding bias was ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-30 21:54:29 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or funding bias could not be ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 19:48:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>Vested interest bias such as academic bias or industry funding, etc. was not present.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:08:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or other funding bias was ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-30 21:54:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>No previous randomised controlled trials but retrospective studies published. Industry or other funding bias was excluded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:09:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>The same research group performed another randomised clinical trial at the same time. Patients were assigned to 1 of the parallel trials depending on hospital admission during alternative weeks.</P>
<P>Previous retrospective trial on PEI for HCC.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:11:16 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>The same trial group performed another randomised clinical trial at the same time. Patients were assigned to 1 of the parallel trials depending on hospital admission during alternative weeks.</P>
<P>Previous retrospective trial on PEI for HCC.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-30 21:54:34 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or funding bias could not be ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-11-30 21:54:36 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>No previous RFA trial was performed by this group. Industry or other funding bias was ruled out.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-10" LEVEL="GROUP" MODIFIED="2013-09-12 15:47:14 +0200" MODIFIED_BY="[Empty name]" NO="10">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-11" LEVEL="STUDY" MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" NO="11">
<NAME>Overall risk of bias assessment</NAME>
<DESCRIPTION>
<P>What ist the overall risk assessment of the trial?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-01 22:07:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brunello-2008">
<DESCRIPTION>
<P>High risk of bias (other bias unclear: number of second treatment cycles; baseline imbalance unclear; interim analysis not mentioned as preplanned).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-01 22:06:48 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chen-2006">
<DESCRIPTION>
<P>High risk of bias (other bias: &gt; 20% withdrawals in the percutaneous local ablative therapy arm; baseline imbalance; source of funding).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:47:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Feng-2012">
<DESCRIPTION>
<P>High risk of bias due to unclear other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-18 11:57:06 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ferrari-2007">
<DESCRIPTION>
<P>High risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-01 22:04:59 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Giorgio-2011">
<DESCRIPTION>
<P>High risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:11:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2010">
<DESCRIPTION>
<P>Low risk of bias regarding efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:12:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lencioni-2003">
<DESCRIPTION>
<P>Low risk of bias regarding efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:12:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Low risk of bias regarding efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-12-17 16:10:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:12:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_">
<DESCRIPTION>
<P>Low risk of bias regarding efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-09-25 11:56:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Shibata-2002">
<DESCRIPTION>
<P>High risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-09-11 19:13:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Shiina-2005">
<DESCRIPTION>
<P>Low risk of bias regarding efficacy outcomes.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2013-09-12 15:47:14 +0200" MODIFIED_BY="[Empty name]" NO="12">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2013-12-17 16:26:30 +0100" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2013-12-17 16:26:30 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-12-17 16:26:30 +0100" MODIFIED_BY="[Empty name]">Hepatic resection compared with radiofrequency ablation</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TD COLSPAN="5">
<P>
<B>Hepatic resection compared with radiofrequency ablation for early hepatocellular carcinoma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Patient or population: 578 patients with early HCC</B>
</P>
<P>
<B>Intervention: hepatic resection</B>
</P>
<P>
<B>Comparison: RFA</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Hazard ratio (95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Overall survival</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.71 (0.44 to 1.15)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(3)<BR/>
</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2-year survival-</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.51 (0.24 to 1.08)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Event-free survival</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.70 (0.54 to 0.91)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>+++O<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Local progression</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.48 (0.28 to 0.82)</P>
</TD>
<TD VALIGN="TOP">
<P>168</P>
<P>(1)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Only 1 trial reported on local progression.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Rate of complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>8.24 (2.12 to 31.95)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Statistical method is: odds ratio (M-H, random, 95% CI)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Length of hospital stay (days)</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2.18 (1.97 to 2.39)</P>
</TD>
<TD VALIGN="TOP">
<P>578</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>++++<BR/>
<B>high</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Statistical method is: standard. mean difference (IV, random, 95% CI)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2013-12-17 16:14:51 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2013-12-17 16:14:27 +0100" MODIFIED_BY="[Empty name]">Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</TITLE>
<TABLE COLS="5" ROWS="10">
<TR>
<TD COLSPAN="5">
<P>
<B>Percutaneous ethanol injection compared with radiofrequency ablation for early hepatocellular carcinoma</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>
<B>Patient or population: 1088 patients with early HCC</B>
</P>
<P>
<B>Intervention: PEI/PAI</B>
</P>
<P>
<B>Comparison: RFA</B>
</P>
</TD>
</TR>
<TR>
<TH VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH VALIGN="TOP">
<P>Hazard ratio (95% CI)</P>
</TH>
<TH VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Overall survival</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1.64 (1.31 to 2.07)</P>
</TD>
<TD VALIGN="TOP">
<P>1088</P>
<P>(6)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>As there were 2 three-armed trials, we report 6 trials with 8 comparisons.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>2-year survival</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1.82 (1.34 to 2.47)</P>
</TD>
<TD VALIGN="TOP">
<P>715</P>
<P>(4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Event-free survival</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>1.55 (1.31 to 1.85)</P>
</TD>
<TD VALIGN="TOP">
<P>949</P>
<P>(5)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Local progression</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>2.44 (1.71 to 3.49)</P>
</TD>
<TD VALIGN="TOP">
<P>678</P>
<P>(4)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Rate of complications</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>0.70 (0.33 to 1.48)</P>
</TD>
<TD VALIGN="TOP">
<P>1088</P>
<P>(6)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Statistical method is: odds ratio (M-H, random, 95% CI).</P>
<P>As there were 2 three-armed trials, it is 5 studies with 7 comparisons.</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Length of hospital stay</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>-1.50 (-3.69 to 0.68)</P>
</TD>
<TD VALIGN="TOP">
<P>576</P>
<P>(3)</P>
</TD>
<TD VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Statistical method is: standard. Mean difference (IV, random, 95% CI).</P>
<P>As there were 2 three-armed trials, it is 3 studies with 5 comparisons.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="5">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval; HCC: hepatocellular carcinoma; HR: hazard ratio; PAI: percutaneous acetic acid injection; PEI: percutaneous ethanol injection; RFA: radiofrequency ablation.</P>
</FOOTNOTES>
</SOF_TABLE>
<SOF_TABLE ID="SOF-03" MODIFIED="2013-12-17 16:15:13 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2013-12-17 16:15:00 +0100" MODIFIED_BY="[Empty name]">Clinical characteristics of patients treated with radiofrequency ablation or percutaneous ethanol injection</TITLE>
<TABLE COLS="13" ROWS="12">
<TR>
<TH>
<P/>
</TH>
<TH ALIGN="CENTER" COLSPAN="2">
<P>
<B>Child-Pugh </B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="5">
<P>
<B>Aetiology</B>
</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="4">
<P>Tumour</P>
</TH>
<TH>
<P>
<B>Overall survival</B>
</P>
</TH>
</TR>
<TR>
<TH>
<P>
<B>
<U>Italian Trials</U>
</B>
</P>
</TH>
<TH ALIGN="CENTER">
<P>A</P>
</TH>
<TH ALIGN="CENTER">
<P>B</P>
</TH>
<TH ALIGN="CENTER">
<P>HBV</P>
</TH>
<TH ALIGN="CENTER">
<P>HCV</P>
</TH>
<TH ALIGN="CENTER">
<P>HBC+HCV</P>
</TH>
<TH ALIGN="CENTER">
<P>Alcohol</P>
</TH>
<TH ALIGN="CENTER">
<P>Others</P>
</TH>
<TH>
<P>Mean number of nodules</P>
</TH>
<TH ALIGN="CENTER">
<P>1 tumour</P>
</TH>
<TH ALIGN="CENTER">
<P>Mean size</P>
</TH>
<TH ALIGN="CENTER">
<P>Size &lt; 2 cm</P>
</TH>
<TH>
<P>HR (95% CI)</P>
</TH>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Brunello-2008" TYPE="STUDY">Brunello 2008</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.78</P>
</TD>
<TD ALIGN="CENTER">
<P>0.22</P>
</TD>
<TD ALIGN="CENTER">
<P>0.04</P>
</TD>
<TD ALIGN="CENTER">
<P>0.65</P>
</TD>
<TD ALIGN="CENTER">
<P>0.04</P>
</TD>
<TD ALIGN="CENTER">
<P>0.14</P>
</TD>
<TD ALIGN="CENTER">
<P>0.12</P>
</TD>
<TD ALIGN="CENTER">
<P>1.27</P>
</TD>
<TD ALIGN="CENTER">
<P>0.78</P>
</TD>
<TD ALIGN="CENTER">
<P>2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>0.39</P>
</TD>
<TD ALIGN="CENTER">
<P>1.14 (0.65 to 2.01)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Giorgio-2011" TYPE="STUDY">Giorgio 2011</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.51</P>
</TD>
<TD ALIGN="CENTER">
<P>0.49</P>
</TD>
<TD ALIGN="CENTER">
<P>0.41</P>
</TD>
<TD ALIGN="CENTER">
<P>0.59</P>
</TD>
<TD ALIGN="CENTER">
<P>0.00</P>
</TD>
<TD ALIGN="CENTER">
<P>0.00</P>
</TD>
<TD ALIGN="CENTER">
<P>0.00</P>
</TD>
<TD ALIGN="CENTER">
<P>1.00</P>
</TD>
<TD ALIGN="CENTER">
<P>1</P>
</TD>
<TD ALIGN="CENTER">
<P>2.3</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>1.23 (0.71 to 2.14)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lencioni-2003" TYPE="STUDY">Lencioni 2003</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.78</P>
</TD>
<TD ALIGN="CENTER">
<P>0.22</P>
</TD>
<TD ALIGN="CENTER">
<P>0.15</P>
</TD>
<TD ALIGN="CENTER">
<P>0.43</P>
</TD>
<TD ALIGN="CENTER">
<P>0.25</P>
</TD>
<TD ALIGN="CENTER">
<P>0.15</P>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
<TD ALIGN="CENTER">
<P>1.39</P>
</TD>
<TD ALIGN="CENTER">
<P>0.7</P>
</TD>
<TD ALIGN="CENTER">
<P>2.2</P>
</TD>
<TD ALIGN="CENTER">
<P>0.25</P>
</TD>
<TD ALIGN="CENTER">
<P>5.00 (0.55 to 45.82)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Mean</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.69</P>
</TD>
<TD ALIGN="CENTER">
<P>0.31</P>
</TD>
<TD ALIGN="CENTER">
<P>0.20</P>
</TD>
<TD ALIGN="CENTER">
<P>0.56</P>
</TD>
<TD ALIGN="CENTER">
<P>0.10</P>
</TD>
<TD ALIGN="CENTER">
<P>0.09</P>
</TD>
<TD ALIGN="CENTER">
<P>0.05</P>
</TD>
<TD ALIGN="CENTER">
<P>1.22</P>
</TD>
<TD ALIGN="CENTER">
<P>0.83</P>
</TD>
<TD ALIGN="CENTER">
<P>2.27</P>
</TD>
<TD ALIGN="CENTER">
<P>0.32</P>
</TD>
<TD ALIGN="CENTER">
<P>1.24 (0.84 to 1.83)</P>
</TD>
</TR>
<TR>
<TH>
<P>
<B>
<U>East-Asian Trials</U>
</B>
</P>
</TH>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P> </P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2004 (RFA vs. PEI)</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.77</P>
</TD>
<TD ALIGN="CENTER">
<P>0.22</P>
</TD>
<TD ALIGN="CENTER">
<P>0.69</P>
</TD>
<TD ALIGN="CENTER">
<P>0.29</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0.02</P>
</TD>
<TD ALIGN="CENTER">
<P>1.31</P>
</TD>
<TD ALIGN="CENTER">
<P>0.75</P>
</TD>
<TD ALIGN="CENTER">
<P>2.9</P>
</TD>
<TD ALIGN="CENTER">
<P>0.29</P>
</TD>
<TD ALIGN="CENTER">
<P>2.08 (1.02 to 4.20)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TYPE="STUDY">Lin 2005 (RFA vs. PEI)</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.75</P>
</TD>
<TD ALIGN="CENTER">
<P>0.25</P>
</TD>
<TD ALIGN="CENTER">
<P>0.67</P>
</TD>
<TD ALIGN="CENTER">
<P>0.31</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0.02</P>
</TD>
<TD ALIGN="CENTER">
<P>1.26</P>
</TD>
<TD ALIGN="CENTER">
<P>0.8</P>
</TD>
<TD ALIGN="CENTER">
<P>2.4</P>
</TD>
<TD ALIGN="CENTER">
<P>0.6</P>
</TD>
<TD ALIGN="CENTER">
<P>2.01 (1.03 to 3.92)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<LINK REF="STD-Shiina-2005" TYPE="STUDY">Shiina 2005</LINK>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.73</P>
</TD>
<TD ALIGN="CENTER">
<P>0.27</P>
</TD>
<TD ALIGN="CENTER">
<P>0.13</P>
</TD>
<TD ALIGN="CENTER">
<P>0.81</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0.06</P>
</TD>
<TD ALIGN="CENTER">
<P>1.63</P>
</TD>
<TD ALIGN="CENTER">
<P>0.57</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0.44</P>
</TD>
<TD ALIGN="CENTER">
<P>1.86 (0.33 to 0.88)</P>
</TD>
</TR>
<TR>
<TD>
<P>
<I>Mean</I>
</P>
</TD>
<TD ALIGN="CENTER">
<P>0.75</P>
</TD>
<TD ALIGN="CENTER">
<P>0.25</P>
</TD>
<TD ALIGN="CENTER">
<P>0.5</P>
</TD>
<TD ALIGN="CENTER">
<P>0.47</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>0.03</P>
</TD>
<TD ALIGN="CENTER">
<P>1.40</P>
</TD>
<TD ALIGN="CENTER">
<P>0.69</P>
</TD>
<TD ALIGN="CENTER">
<P>2.65</P>
</TD>
<TD ALIGN="CENTER">
<P>0.52</P>
</TD>
<TD ALIGN="CENTER">
<P>1.95 (1.38 to 2.75)</P>
</TD>
</TR>
<TR>
<TD>
<P>Student's t-test</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>-</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P>n.s.</P>
</TD>
<TD ALIGN="CENTER">
<P> -</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>CI: confidence interval; HBV: hepatitis B virus; HCV: hepatitis C virus; HR: hazard ratio; n.s.: not significant (P value &gt; 0.05); PEI: percutaneous ethanol injection; RFA: radiofrequency ablation.<BR/>
</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2013-01-24 12:53:17 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Overall survival</NAME>
<IV_OUTCOME CHI2="33.03108113737498" CI_END="1.7328590140044366" CI_START="1.1562521288217567" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_SIZE="1.4154935266155761" ESTIMABLE="YES" I2="66.69803221320117" I2_Q="79.09284221904545" ID="CMP-001.01" LOG_CI_END="0.23876322980528733" LOG_CI_START="0.06305254534465941" LOG_DATA="YES" LOG_EFFECT_SIZE="0.15090788757497345" MODIFIED="2013-12-17 16:32:35 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.200968018977958E-4" P_Q="0.00837046178606804" P_Z="7.610026414804976E-4" Q="9.566101815244862" RANDOM="YES" SCALE="341.74" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1903208379659177" TOTALS="SUB" TOTAL_1="936" TOTAL_2="811" WEIGHT="300.0" Z="3.3666026119913326">
<NAME>Overall survival: control interventions versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.9922859216714635" CI_END="1.1527681785173558" CI_START="0.4432384577726569" DF="2" EFFECT_SIZE="0.7148084985612774" ESTIMABLE="YES" I2="66.62375550594341" ID="CMP-001.01.01" LOG_CI_END="0.06174197952950888" LOG_CI_START="-0.3533625648999962" LOG_EFFECT_SIZE="-0.14581029268524362" MODIFIED="2013-10-27 15:58:16 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04997959184116507" P_Z="0.1685369121250038" STUDIES="3" TAU2="0.11809149732620325" TOTAL_1="289" TOTAL_2="289" WEIGHT="100.00000000000001" Z="1.376920229245308">
<NAME>Resection versus RFA</NAME>
<IV_DATA CI_END="1.7002779138635007" CI_START="0.6901876813333825" EFFECT_SIZE="1.0832870676749586" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.23051991349167703" LOG_CI_START="-0.16103279638715676" LOG_EFFECT_SIZE="0.034743558552260176" MODIFIED="2012-08-28 10:52:20 +0200" MODIFIED_BY="[Empty name]" ORDER="17" SE="0.23" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="90" WEIGHT="34.77087858793254"/>
<IV_DATA CI_END="1.2068204760208079" CI_START="0.37232461086405555" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.08164267020315598" LOG_CI_START="-0.4290782557257575" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2012-08-28 10:52:22 +0200" MODIFIED_BY="[Empty name]" ORDER="65" SE="0.3" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="28.57168442484716"/>
<IV_DATA CI_END="0.7645960963242013" CI_START="0.33568151627696435" EFFECT_SIZE="0.5066169923655895" ESTIMABLE="YES" ESTIMATE="-0.68" LOG_CI_END="-0.11656792361909156" LOG_CI_START="-0.4740725717693311" LOG_EFFECT_SIZE="-0.2953202476942113" MODIFIED="2012-08-28 10:52:25 +0200" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.21" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="36.65743698722031"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="4.699205081209182" CI_END="2.069159726036467" CI_START="1.3073356710564352" DF="7" EFFECT_SIZE="1.6447146618671684" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="0.3157940167453839" LOG_CI_START="0.11638711120006989" LOG_EFFECT_SIZE="0.21609056397272688" MODIFIED="2013-11-30 21:57:59 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.6966157757453565" P_Z="2.1578921317696578E-5" STUDIES="8" TAU2="0.0" TOTAL_1="606" TOTAL_2="482" WEIGHT="100.00000000000001" Z="4.247894240445438">
<NAME>PEI or PAI versus RFA</NAME>
<IV_DATA CI_END="2.010512280496049" CI_START="0.6450744415974338" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.30330673017973103" LOG_CI_START="-0.1903901648848855" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2013-10-27 15:58:18 +0100" MODIFIED_BY="[Empty name]" ORDER="8" SE="0.29" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" WEIGHT="16.31396763217256"/>
<IV_DATA CI_END="2.1779619528630585" CI_START="0.6988008002701454" EFFECT_SIZE="1.2336780599567432" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.3380502887319911" LOG_CI_START="-0.15564660633262534" LOG_EFFECT_SIZE="0.09120184119968286" MODIFIED="2013-10-27 15:58:19 +0100" MODIFIED_BY="[Empty name]" ORDER="61" SE="0.29" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" WEIGHT="16.31396763217256"/>
<IV_DATA CI_END="45.82176985481562" CI_START="0.5462058811922451" EFFECT_SIZE="5.002811227833588" ESTIMABLE="YES" ESTIMATE="1.61" LOG_CI_END="1.6610718596970229" LOG_CI_START="-0.26264362796855173" LOG_EFFECT_SIZE="0.6992141158642354" MODIFIED="2013-10-27 15:58:19 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SE="1.13" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="1.074480913043866"/>
<IV_DATA CI_END="4.202111068780668" CI_START="1.0247134018746136" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.623467527346722" LOG_CI_START="0.010602416232025747" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2013-10-27 15:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="10" SE="0.36" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="10.58645584772926"/>
<IV_DATA CI_END="3.6516775848029814" CI_START="0.856255321718074" EFFECT_SIZE="1.768267051433735" ESTIMABLE="YES" ESTIMATE="0.57" LOG_CI_END="0.5624924256743503" LOG_CI_START="-0.06739671630464317" LOG_EFFECT_SIZE="0.24754785468485352" MODIFIED="2013-10-27 15:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="49" SE="0.37" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="10.021947975644354"/>
<IV_DATA CI_END="3.54801309319538" CI_START="0.9357679454746356" EFFECT_SIZE="1.8221188003905089" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.5499852138350022" LOG_CI_START="-0.028831835551099985" LOG_EFFECT_SIZE="0.2605766891419511" MODIFIED="2013-10-30 14:31:27 +0100" MODIFIED_BY="[Empty name]" ORDER="50" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="11.86855257669301"/>
<IV_DATA CI_END="3.921160887551156" CI_START="1.0341835194059656" EFFECT_SIZE="2.0137527074704766" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.5934146620253273" LOG_CI_START="0.01459761263922522" LOG_EFFECT_SIZE="0.3040061373322763" MODIFIED="2013-10-27 15:58:21 +0100" MODIFIED_BY="[Empty name]" ORDER="12" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="11.86855257669301"/>
<IV_DATA CI_END="3.0343310736053684" CI_START="1.1388386372277903" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.4820629645837301" LOG_CI_START="0.05646219297630215" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2013-10-27 15:58:21 +0100" MODIFIED_BY="[Empty name]" ORDER="19" SE="0.25" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="21.952074845851392"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="4.222309918834004" CI_START="0.6185468437012177" DF="0" EFFECT_SIZE="1.6160744021928934" ESTIMABLE="YES" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="0.6255501074888402" LOG_CI_START="-0.2086274048617185" LOG_EFFECT_SIZE="0.2084613513135609" MODIFIED="2013-10-27 15:58:23 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.32728764875134464" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.9795918367346939">
<NAME>Laser ablation versus RFA</NAME>
<IV_DATA CI_END="4.222309918834004" CI_START="0.6185468437012177" EFFECT_SIZE="1.6160744021928934" ESTIMABLE="YES" ESTIMATE="0.48" LOG_CI_END="0.6255501074888402" LOG_CI_START="-0.2086274048617185" LOG_EFFECT_SIZE="0.2084613513135609" MODIFIED="2013-10-27 15:58:23 +0100" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.49" STUDY_ID="STD-Ferrari-2007" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="6.714961461245661" CI_END="0.9976373519500688" CI_START="0.5813581112977164" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_SIZE="0.7615671780544033" ESTIMABLE="YES" I2="70.21576353724912" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.0010272990622674102" LOG_CI_START="-0.23555626373799735" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.11829178140013233" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.034822981823591004" P_Q="1.0" P_Z="0.048026450610015564" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="YEAR" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="289" TOTAL_2="289" WEIGHT="100.0" Z="1.9771343086079562">
<NAME>Fixed-effect model</NAME>
<GROUP_LABEL_1>Resection</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.7002779138635007" CI_START="0.6901876813333825" EFFECT_SIZE="1.0832870676749586" ESTIMABLE="YES" ESTIMATE="0.08" LOG_CI_END="0.23051991349167703" LOG_CI_START="-0.16103279638715676" LOG_EFFECT_SIZE="0.034743558552260176" MODIFIED="2013-10-11 12:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="77" SE="0.23" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="90" WEIGHT="35.876701295954305"/>
<IV_DATA CI_END="1.7297712863743357" CI_START="0.5336638165161832" EFFECT_SIZE="0.9607894391523232" ESTIMABLE="YES" ESTIMATE="-0.04" LOG_CI_END="0.23798868368832665" LOG_CI_START="-0.27273224224058684" LOG_EFFECT_SIZE="-0.017371779276130088" MODIFIED="2013-10-11 12:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.3" STUDY_ID="STD-Huang-2010" TOTAL_1="84" TOTAL_2="84" WEIGHT="21.087527761733142"/>
<IV_DATA CI_END="0.7645960963242013" CI_START="0.33568151627696435" EFFECT_SIZE="0.5066169923655895" ESTIMABLE="YES" ESTIMATE="-0.68" LOG_CI_END="-0.11656792361909156" LOG_CI_START="-0.4740725717693311" LOG_EFFECT_SIZE="-0.2953202476942113" MODIFIED="2013-10-11 12:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="78" SE="0.21" STUDY_ID="STD-Feng-2012" TOTAL_1="115" TOTAL_2="115" WEIGHT="43.035770942312546"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.5846383296047726" CI_END="0.7782326210977932" CI_START="0.39648814973868396" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.5554817836845329" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="-0.1088905688730122" LOG_CI_START="-0.40176978837161675" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.25533017862231455" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.4445001053057209" P_Q="1.0" P_Z="6.322987788886695E-4" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="199" WEIGHT="99.99999999999999" Z="3.4173674398794263">
<NAME>Trials with low risk of bias</NAME>
<GROUP_LABEL_1>Resection</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.2068204760208079" CI_START="0.37232461086405555" EFFECT_SIZE="0.6703200460356393" ESTIMABLE="YES" ESTIMATE="-0.4" LOG_CI_END="0.08164267020315598" LOG_CI_START="-0.4290782557257575" LOG_EFFECT_SIZE="-0.17371779276130073" MODIFIED="2013-10-11 12:00:50 +0200" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.3" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="32.88590604026845"/>
<IV_DATA CI_END="0.7645960963242013" CI_START="0.33568151627696435" EFFECT_SIZE="0.5066169923655895" ESTIMABLE="YES" ESTIMATE="-0.68" LOG_CI_END="-0.11656792361909156" LOG_CI_START="-0.4740725717693311" LOG_EFFECT_SIZE="-0.2953202476942113" MODIFIED="2013-10-11 12:00:50 +0200" MODIFIED_BY="[Empty name]" ORDER="81" SE="0.21" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="67.11409395973153"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.9903966395347334" CI_END="0.8203971408371007" CI_START="0.44227075393677634" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6023600767029637" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="76" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.08597586185905136" LOG_CI_START="-0.35431177829672994" LOG_EFFECT_SIZE="-0.2201438200778906" METHOD="MH" MODIFIED="2013-10-11 13:06:28 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.31964568850578867" P_Q="1.0" P_Z="0.0013002525494402247" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="199" TOTAL_2="199" WEIGHT="100.0" Z="3.215924014196898">
<NAME>Resection versus RFA, dichotomous outcome</NAME>
<GROUP_LABEL_1>Favours resection</GROUP_LABEL_1>
<GROUP_LABEL_2>Favours RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.275535147593668" CI_START="0.4409913760990214" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="24" LOG_CI_END="0.10569243017095473" LOG_CI_START="-0.3555699033875546" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2013-10-11 12:01:07 +0200" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.27094777801764386" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" VAR="0.0734126984126984" WEIGHT="33.84243699991628"/>
<DICH_DATA CI_END="0.7872401730651526" CI_START="0.3683003463523337" EFFECT_SIZE="0.5384615384615384" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="52" LOG_CI_END="-0.10389275185396535" LOG_CI_START="-0.4337978727311946" LOG_EFFECT_SIZE="-0.26884531229257996" MODIFIED="2013-10-11 12:01:07 +0200" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="0.19378790105997035" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" VAR="0.03755375059722886" WEIGHT="66.15756300008371"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="4.699205081209182" CI_END="2.069159726036467" CI_START="1.3073356710564352" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_SIZE="1.6447146618671684" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.3157940167453839" LOG_CI_START="0.11638711120006989" LOG_DATA="YES" LOG_EFFECT_SIZE="0.21609056397272688" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6966157757453565" P_Q="0.7482715412875456" P_Z="2.1578921317696578E-5" Q="0.10298922722878279" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="606" TOTAL_2="482" WEIGHT="100.00000000000001" Z="4.247894240445438">
<NAME>PEI or PAI versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="4.5962158539804" CI_END="2.0715938824439903" CI_START="1.2702661513335638" DF="6" EFFECT_SIZE="1.622182353552856" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.01" LOG_CI_END="0.3163046198469471" LOG_CI_START="0.10389472563739957" LOG_EFFECT_SIZE="0.2100996727421733" MODIFIED="2013-10-27 15:55:50 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5965407920715435" P_Z="1.0562474410658285E-4" STUDIES="7" TAU2="0.0" TOTAL_1="543" TOTAL_2="451" WEIGHT="88.13144742330701" Z="3.8772938828553136">
<NAME>PEI versus RFA</NAME>
<IV_DATA CI_END="2.010512280496049" CI_START="0.6450744415974338" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.30330673017973103" LOG_CI_START="-0.1903901648848855" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2013-10-27 15:54:49 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SE="0.29" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" WEIGHT="16.31396763217256"/>
<IV_DATA CI_END="2.1779619528630585" CI_START="0.6988008002701454" EFFECT_SIZE="1.2336780599567432" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.3380502887319911" LOG_CI_START="-0.15564660633262534" LOG_EFFECT_SIZE="0.09120184119968286" MODIFIED="2013-10-27 15:54:55 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SE="0.29" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" WEIGHT="16.31396763217256"/>
<IV_DATA CI_END="45.82176985481562" CI_START="0.5462058811922451" EFFECT_SIZE="5.002811227833588" ESTIMABLE="YES" ESTIMATE="1.61" LOG_CI_END="1.6610718596970229" LOG_CI_START="-0.26264362796855173" LOG_EFFECT_SIZE="0.6992141158642354" MODIFIED="2013-10-27 15:55:03 +0100" MODIFIED_BY="[Empty name]" ORDER="109" SE="1.13" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="1.074480913043866"/>
<IV_DATA CI_END="4.202111068780668" CI_START="1.0247134018746136" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.623467527346722" LOG_CI_START="0.010602416232025747" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2013-10-27 15:55:25 +0100" MODIFIED_BY="[Empty name]" ORDER="111" SE="0.36" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="10.58645584772926"/>
<IV_DATA CI_END="3.6516775848029814" CI_START="0.856255321718074" EFFECT_SIZE="1.768267051433735" ESTIMABLE="YES" ESTIMATE="0.57" LOG_CI_END="0.5624924256743503" LOG_CI_START="-0.06739671630464317" LOG_EFFECT_SIZE="0.24754785468485352" MODIFIED="2013-10-27 15:55:12 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SE="0.37" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="10.021947975644354"/>
<IV_DATA CI_END="3.921160887551156" CI_START="1.0341835194059656" EFFECT_SIZE="2.0137527074704766" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.5934146620253273" LOG_CI_START="0.01459761263922522" LOG_EFFECT_SIZE="0.3040061373322763" MODIFIED="2013-10-27 15:55:40 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="11.86855257669301"/>
<IV_DATA CI_END="3.0343310736053684" CI_START="1.1388386372277903" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.4820629645837301" LOG_CI_START="0.05646219297630215" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2013-10-27 15:55:50 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SE="0.25" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="21.952074845851392"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.54801309319538" CI_START="0.9357679454746356" DF="0" EFFECT_SIZE="1.8221188003905089" ESTIMABLE="YES" I2="0.0" ID="CMP-001.05.02" LOG_CI_END="0.5499852138350022" LOG_CI_START="-0.028831835551099985" LOG_EFFECT_SIZE="0.2605766891419511" MODIFIED="2013-10-27 15:52:52 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.07761320945816541" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="31" WEIGHT="11.86855257669301" Z="1.764705882352941">
<NAME>PAI versus RFA</NAME>
<IV_DATA CI_END="3.54801309319538" CI_START="0.9357679454746356" EFFECT_SIZE="1.8221188003905089" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.5499852138350022" LOG_CI_START="-0.028831835551099985" LOG_EFFECT_SIZE="0.2605766891419511" MODIFIED="2013-10-27 15:52:52 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="11.86855257669301"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Two-year survival</NAME>
<IV_OUTCOME CHI2="35.52619068222647" CI_END="2.01351838782157" CI_START="1.143903679287335" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="1.5176531527795791" ESTIMABLE="YES" I2="77.48140218139866" I2_Q="89.5391293294872" ID="CMP-002.01" LOG_CI_END="0.30395560001893007" LOG_CI_START="0.05838945687384458" LOG_DATA="YES" LOG_EFFECT_SIZE="0.1811725284463873" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.143707037216558E-5" P_Q="0.0019892626784858702" P_Z="0.00382768299648132" Q="9.559433736417454" RANDOM="YES" SCALE="10.84" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.47073125173302005" TOTALS="SUB" TOTAL_1="702" TOTAL_2="591" WEIGHT="200.0" Z="2.892024333608418">
<NAME>Control interventions versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="7.019207241401981" CI_END="1.0779446322545982" CI_START="0.24308632083037002" DF="2" EFFECT_SIZE="0.5118921709829293" ESTIMABLE="YES" I2="71.50675380827579" ID="CMP-002.01.01" LOG_CI_END="0.032596454242332144" LOG_CI_START="-0.6142394794743806" LOG_EFFECT_SIZE="-0.29082151261602424" MODIFIED="2013-10-11 12:53:05 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.029908804605691786" P_Z="0.07799763243130854" STUDIES="3" TAU2="0.30855259347024755" TOTAL_1="289" TOTAL_2="289" WEIGHT="100.0" Z="1.762424321053582">
<NAME>Resection versus RFA</NAME>
<IV_DATA CI_END="1.7098194065686008" CI_START="0.45095498556246527" EFFECT_SIZE="0.8780954309205613" ESTIMABLE="YES" ESTIMATE="-0.13" LOG_CI_END="0.23295024204562834" LOG_CI_START="-0.3458668073404738" LOG_EFFECT_SIZE="-0.056458282647422746" MODIFIED="2012-11-08 23:16:34 +0100" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.34" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="90" WEIGHT="34.03622247996473"/>
<IV_DATA CI_END="1.3412274922684206" CI_START="0.26885442048552355" EFFECT_SIZE="0.6004955788122659" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="0.12750244694743246" LOG_CI_START="-0.5704828184887494" LOG_EFFECT_SIZE="-0.22149018577065846" MODIFIED="2012-08-28 10:57:50 +0200" MODIFIED_BY="[Empty name]" ORDER="67" SE="0.41" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="30.287367014417605"/>
<IV_DATA CI_END="0.49046019027341514" CI_START="0.14549859697400624" EFFECT_SIZE="0.26713530196585034" ESTIMABLE="YES" ESTIMATE="-1.32" LOG_CI_END="-0.3093962377156871" LOG_CI_START="-0.8371411945088978" LOG_EFFECT_SIZE="-0.5732687161122925" MODIFIED="2012-11-08 23:16:35 +0100" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.31" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="35.676410505617675"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="1.582289150352558" CI_END="2.4738607007099196" CI_START="1.342569023839764" DF="5" EFFECT_SIZE="1.8224513014255475" ESTIMABLE="YES" I2="0.0" ID="CMP-002.01.02" LOG_CI_END="0.39337524152744824" LOG_CI_START="0.12793662279031895" LOG_EFFECT_SIZE="0.2606559321588836" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9033828180943796" P_Z="1.1845657932096727E-4" STUDIES="6" TAU2="0.0" TOTAL_1="413" TOTAL_2="302" WEIGHT="100.0" Z="3.849298506891806">
<NAME>PEI/PAI versus RFA</NAME>
<IV_DATA CI_END="2.5743241520295235" CI_START="0.627766476462891" EFFECT_SIZE="1.2712491503214047" ESTIMABLE="YES" ESTIMATE="0.24" LOG_CI_END="0.41066323121412857" LOG_CI_START="-0.20220187990056765" LOG_EFFECT_SIZE="0.10423067565678046" MODIFIED="2013-01-07 00:27:37 +0100" MODIFIED_BY="[Empty name]" ORDER="15" SE="0.36" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" WEIGHT="18.758513492479256"/>
<IV_DATA CI_END="4.921361567899832" CI_START="0.9865066291622347" EFFECT_SIZE="2.203396426255937" ESTIMABLE="YES" ESTIMATE="0.79" LOG_CI_END="0.6920852734216599" LOG_CI_START="-0.005899992014521949" LOG_EFFECT_SIZE="0.343092640703569" MODIFIED="2012-08-28 10:57:17 +0200" MODIFIED_BY="[Empty name]" ORDER="16" SE="0.41" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="14.462244786587222"/>
<IV_DATA CI_END="4.406958960651297" CI_START="0.8494341360300822" EFFECT_SIZE="1.9347923344020317" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.6441390062063858" LOG_CI_START="-0.07087029009409326" LOG_EFFECT_SIZE="0.28663435805614623" MODIFIED="2012-08-28 10:57:26 +0200" MODIFIED_BY="[Empty name]" ORDER="51" SE="0.42" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="13.78176501488272"/>
<IV_DATA CI_END="3.6487547827278375" CI_START="0.791056445593772" EFFECT_SIZE="1.6989323086185508" ESTIMABLE="YES" ESTIMATE="0.53" LOG_CI_END="0.5621446772625174" LOG_CI_START="-0.10179252644507031" LOG_EFFECT_SIZE="0.2301760754087235" MODIFIED="2012-08-28 10:57:35 +0200" MODIFIED_BY="[Empty name]" ORDER="52" SE="0.39" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="15.983585461047412"/>
<IV_DATA CI_END="3.9923736508071914" CI_START="0.8655536197279551" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.60123118063381" LOG_CI_START="-0.06270602307377768" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2012-08-28 10:57:31 +0200" MODIFIED_BY="[Empty name]" ORDER="17" SE="0.39" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="15.983585461047412"/>
<IV_DATA CI_END="4.290433405429173" CI_START="1.131577011565756" EFFECT_SIZE="2.203396426255937" ESTIMABLE="YES" ESTIMATE="0.79" LOG_CI_END="0.6325011653966199" LOG_CI_START="0.05368411601051788" LOG_EFFECT_SIZE="0.343092640703569" MODIFIED="2012-08-28 10:57:40 +0200" MODIFIED_BY="[Empty name]" ORDER="44" SE="0.34" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="21.030305783955978"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.4833459500378505" CI_END="0.8432825716690927" CI_START="0.1740459891114463" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.3831056633444504" ESTIMABLE="YES" I2="59.731748209114464" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="-0.07402687525235467" LOG_CI_START="-0.7593359805775518" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.4166814279149532" MODIFIED="2013-12-16 21:49:40 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.1150575151150196" P_Q="1.0" P_Z="0.01715385282932643" Q="0.0" RANDOM="YES" SCALE="10.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.19595" TOTALS="YES" TOTAL_1="199" TOTAL_2="199" WEIGHT="100.0" Z="2.383393377948757">
<NAME>Resection versus RFA, low risk of bias trials</NAME>
<GROUP_LABEL_1>Resection</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours resection</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="1.3412274922684206" CI_START="0.26885442048552355" EFFECT_SIZE="0.6004955788122659" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="0.12750244694743246" LOG_CI_START="-0.5704828184887494" LOG_EFFECT_SIZE="-0.22149018577065846" MODIFIED="2012-09-03 16:30:54 +0200" MODIFIED_BY="[Empty name]" ORDER="79" SE="0.41" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="44.51303155006859"/>
<IV_DATA CI_END="0.49046019027341514" CI_START="0.14549859697400624" EFFECT_SIZE="0.26713530196585034" ESTIMABLE="YES" ESTIMATE="-1.32" LOG_CI_END="-0.3093962377156871" LOG_CI_START="-0.8371411945088978" LOG_EFFECT_SIZE="-0.5732687161122925" MODIFIED="2012-09-03 16:31:04 +0200" MODIFIED_BY="[Empty name]" ORDER="80" SE="0.31" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="55.4869684499314"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.3501428816877831" CI_END="2.7798464769363926" CI_START="1.4110021477454386" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="1.9804972480061267" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.4440208117236698" LOG_CI_START="0.14952767481266296" LOG_DATA="YES" LOG_EFFECT_SIZE="0.29677424326816637" MODIFIED="2013-12-16 21:49:48 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.9863515034792261" P_Q="1.0" P_Z="7.805615681841349E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="344" TOTAL_2="232" WEIGHT="100.0" Z="3.9502912322232424">
<NAME>PEI or PAI versus RFA, low risk of bias trials</NAME>
<GROUP_LABEL_1>PEI/PAI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI/PAI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="4.921361567899832" CI_START="0.9865066291622347" EFFECT_SIZE="2.203396426255937" ESTIMABLE="YES" ESTIMATE="0.79" LOG_CI_END="0.6920852734216599" LOG_CI_START="-0.005899992014521949" LOG_EFFECT_SIZE="0.343092640703569" MODIFIED="2013-08-02 00:00:42 +0200" MODIFIED_BY="[Empty name]" ORDER="371" SE="0.41" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="17.80155116345442"/>
<IV_DATA CI_END="4.406958960651297" CI_START="0.8494341360300822" EFFECT_SIZE="1.9347923344020317" ESTIMABLE="YES" ESTIMATE="0.66" LOG_CI_END="0.6441390062063858" LOG_CI_START="-0.07087029009409326" LOG_EFFECT_SIZE="0.28663435805614623" MODIFIED="2013-08-02 00:00:42 +0200" MODIFIED_BY="[Empty name]" ORDER="370" SE="0.42" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="16.963949833201177"/>
<IV_DATA CI_END="3.6487547827278375" CI_START="0.791056445593772" EFFECT_SIZE="1.6989323086185508" ESTIMABLE="YES" ESTIMATE="0.53" LOG_CI_END="0.5621446772625174" LOG_CI_START="-0.10179252644507031" LOG_EFFECT_SIZE="0.2301760754087235" MODIFIED="2013-08-02 00:00:42 +0200" MODIFIED_BY="[Empty name]" ORDER="372" SE="0.39" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="19.674166670458167"/>
<IV_DATA CI_END="3.9923736508071914" CI_START="0.8655536197279551" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.60123118063381" LOG_CI_START="-0.06270602307377768" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2013-08-02 00:00:42 +0200" MODIFIED_BY="[Empty name]" ORDER="373" SE="0.39" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="19.674166670458167"/>
<IV_DATA CI_END="4.290433405429173" CI_START="1.131577011565756" EFFECT_SIZE="2.203396426255937" ESTIMABLE="YES" ESTIMATE="0.79" LOG_CI_END="0.6325011653966199" LOG_CI_START="0.05368411601051788" LOG_EFFECT_SIZE="0.343092640703569" MODIFIED="2013-08-02 00:00:42 +0200" MODIFIED_BY="[Empty name]" ORDER="374" SE="0.34" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="25.886165662428084"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Event-free survival</NAME>
<IV_OUTCOME CHI2="37.24667834281253" CI_END="1.4173077447604827" CI_START="1.0641433017786632" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_SIZE="1.2280954943105569" ESTIMABLE="YES" I2="73.15196832329158" I2_Q="91.69189827824768" ID="CMP-003.01" LOG_CI_END="0.15146416029694926" LOG_CI_START="0.027000115723234363" LOG_DATA="YES" LOG_EFFECT_SIZE="0.08923213801009182" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.12934085179495E-5" P_Q="5.924374022581169E-6" P_Z="0.004949256128653325" Q="24.072887730341442" RANDOM="YES" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="11" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.1415696992637583" TOTALS="SUB" TOTAL_1="867" TOTAL_2="741" WEIGHT="300.0" Z="2.810318069966084">
<NAME>Event-free survival: control interventions versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.8722791417964912" CI_END="1.8467596383077756" CI_START="1.3070982406632152" DF="6" EFFECT_SIZE="1.5536718682398574" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.26641037429811903" LOG_CI_START="0.11630823010123408" LOG_EFFECT_SIZE="0.1913593021996765" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.931062162089092" P_Z="5.812004445894524E-7" STUDIES="7" TAU2="0.0" TOTAL_1="537" TOTAL_2="412" WEIGHT="100.0" Z="4.99736152904158">
<NAME>PEI/PAI versus RFA</NAME>
<IV_DATA CI_END="2.1519787220848547" CI_START="0.5675719493066663" EFFECT_SIZE="1.1051709180756477" ESTIMABLE="YES" ESTIMATE="0.1" LOG_CI_END="0.33283797288337624" LOG_CI_START="-0.24597907650272588" LOG_EFFECT_SIZE="0.043429448190325216" MODIFIED="2013-01-07 00:27:51 +0100" MODIFIED_BY="[Empty name]" ORDER="72" SE="0.34" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" WEIGHT="6.724982557374443"/>
<IV_DATA CI_END="3.8852544417727692" CI_START="1.1082825057862817" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.5894194656181277" LOG_CI_START="0.04465047796061994" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2012-08-28 11:47:46 +0200" MODIFIED_BY="[Empty name]" ORDER="14" SE="0.32" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="7.591874840160994"/>
<IV_DATA CI_END="2.536516584755547" CI_START="1.0296390290209028" EFFECT_SIZE="1.6160744021928934" ESTIMABLE="YES" ESTIMATE="0.48" LOG_CI_END="0.4042377062529778" LOG_CI_START="0.012684996374143975" LOG_EFFECT_SIZE="0.2084613513135609" MODIFIED="2012-08-28 11:47:49 +0200" MODIFIED_BY="[Empty name]" ORDER="18" SE="0.23" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="14.695803093241697"/>
<IV_DATA CI_END="2.4128092111535353" CI_START="0.9794229410190274" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.38252298215781516" LOG_CI_START="-0.009029727721018581" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2012-08-28 11:47:55 +0200" MODIFIED_BY="[Empty name]" ORDER="54" SE="0.23" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="14.695803093241697"/>
<IV_DATA CI_END="2.365032387715014" CI_START="0.960029067393051" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.3738370925197501" LOG_CI_START="-0.017715617359083637" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2012-08-28 11:48:01 +0200" MODIFIED_BY="[Empty name]" ORDER="53" SE="0.23" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="14.695803093241697"/>
<IV_DATA CI_END="2.4615511904477363" CI_START="0.999208596880558" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.3912088717958802" LOG_CI_START="-3.4383808295354134E-4" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2012-08-28 11:47:57 +0200" MODIFIED_BY="[Empty name]" ORDER="19" SE="0.23" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="14.695803093241697"/>
<IV_DATA CI_END="2.166675309816949" CI_START="1.1127185026264477" EFFECT_SIZE="1.552707218511336" ESTIMABLE="YES" ESTIMATE="0.44" LOG_CI_END="0.3357938343839564" LOG_CI_START="0.04638530969090532" LOG_EFFECT_SIZE="0.1910895720374308" MODIFIED="2012-08-28 11:48:05 +0200" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.17" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="26.899930229497773"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="3.0479341368107713" CI_END="0.9143740488777894" CI_START="0.5350631259824447" DF="2" EFFECT_SIZE="0.6994625343145797" ESTIMABLE="YES" I2="34.38178417816091" ID="CMP-003.01.02" LOG_CI_END="-0.03887610827890378" LOG_CI_START="-0.2715949775141549" LOG_EFFECT_SIZE="-0.15523554289652935" MODIFIED="2013-10-11 13:03:48 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.21784604141588682" P_Z="0.008928101184500553" STUDIES="3" TAU2="0.019356701940035255" TOTAL_1="289" TOTAL_2="289" WEIGHT="100.0" Z="2.6147950460360256">
<NAME>Resection versus RFA</NAME>
<IV_DATA CI_END="1.3263000617318925" CI_START="0.6297746908950377" EFFECT_SIZE="0.9139311852712282" ESTIMABLE="YES" ESTIMATE="-0.09" LOG_CI_END="0.12264178983953" LOG_CI_START="-0.20081479658211535" LOG_EFFECT_SIZE="-0.039086503371292665" MODIFIED="2012-08-28 11:46:49 +0200" MODIFIED_BY="[Empty name]" ORDER="22" SE="0.19" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="90" WEIGHT="33.696466498519044"/>
<IV_DATA CI_END="0.9619354566937568" CI_START="0.4060852863259016" EFFECT_SIZE="0.6250022682827008" ESTIMABLE="YES" ESTIMATE="-0.47" LOG_CI_END="-0.016854066987260052" LOG_CI_START="-0.3913827460017966" LOG_EFFECT_SIZE="-0.20411840649452836" MODIFIED="2012-08-28 11:46:51 +0200" MODIFIED_BY="[Empty name]" ORDER="68" SE="0.22" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="27.579484324584616"/>
<IV_DATA CI_END="0.8379422268122053" CI_START="0.4303338925225124" EFFECT_SIZE="0.6004955788122659" ESTIMABLE="YES" ESTIMATE="-0.51" LOG_CI_END="-0.07678592342413292" LOG_CI_START="-0.36619444811718393" LOG_EFFECT_SIZE="-0.22149018577065846" MODIFIED="2012-08-28 11:46:53 +0200" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.17" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="38.72404917689634"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="2.8921026352760837" CI_START="0.49560115781420494" DF="0" EFFECT_SIZE="1.1972173631218102" ESTIMABLE="YES" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="0.4612137011892705" LOG_CI_START="-0.30486768770409983" LOG_EFFECT_SIZE="0.07817300674258533" MODIFIED="2013-10-11 13:04:00 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6891565177502668" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.39999999999999997">
<NAME>Laser ablation versus RFA</NAME>
<IV_DATA CI_END="2.8921026352760837" CI_START="0.49560115781420494" EFFECT_SIZE="1.1972173631218102" ESTIMABLE="YES" ESTIMATE="0.18" LOG_CI_END="0.4612137011892705" LOG_CI_START="-0.30486768770409983" LOG_EFFECT_SIZE="0.07817300674258533" MODIFIED="2012-08-28 11:48:09 +0200" MODIFIED_BY="[Empty name]" ORDER="23" SE="0.45" STUDY_ID="STD-Ferrari-2007" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.7962603359047656" CI_END="1.9042954670908685" CI_START="1.3314206607704517" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="1.5922996982654678" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.2797343336344341" LOG_CI_START="0.12431529197946374" LOG_DATA="YES" LOG_EFFECT_SIZE="0.2020248128069489" MODIFIED="2013-11-30 21:55:34 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9772712601619707" P_Q="1.0" P_Z="3.4799942415437156E-7" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="394" TOTAL_2="284" WEIGHT="99.99999999999999" Z="5.095403405769273">
<NAME>PEI or PAI versus RFA, low risk of bias trials</NAME>
<GROUP_LABEL_1>PEI/PAI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI/PAI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="3.8852544417727692" CI_START="1.1082825057862817" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.5894194656181277" LOG_CI_START="0.04465047796061994" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="375" SE="0.32" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="8.139237116552495"/>
<IV_DATA CI_END="2.536516584755547" CI_START="1.0296390290209028" EFFECT_SIZE="1.6160744021928934" ESTIMABLE="YES" ESTIMATE="0.48" LOG_CI_END="0.4042377062529778" LOG_CI_START="0.012684996374143975" LOG_EFFECT_SIZE="0.2084613513135609" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="377" SE="0.23" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="15.7553474619088"/>
<IV_DATA CI_END="2.4128092111535353" CI_START="0.9794229410190274" EFFECT_SIZE="1.5372575235482815" ESTIMABLE="YES" ESTIMATE="0.43" LOG_CI_END="0.38252298215781516" LOG_CI_START="-0.009029727721018581" LOG_EFFECT_SIZE="0.1867466272183983" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="376" SE="0.23" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="15.7553474619088"/>
<IV_DATA CI_END="2.365032387715014" CI_START="0.960029067393051" EFFECT_SIZE="1.5068177851128535" ESTIMABLE="YES" ESTIMATE="0.41" LOG_CI_END="0.3738370925197501" LOG_CI_START="-0.017715617359083637" LOG_EFFECT_SIZE="0.17806073758033322" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="378" SE="0.23" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="15.7553474619088"/>
<IV_DATA CI_END="2.4615511904477363" CI_START="0.999208596880558" EFFECT_SIZE="1.5683121854901687" ESTIMABLE="YES" ESTIMATE="0.45" LOG_CI_END="0.3912088717958802" LOG_CI_START="-3.4383808295354134E-4" LOG_EFFECT_SIZE="0.1954325168564633" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="379" SE="0.23" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="15.7553474619088"/>
<IV_DATA CI_END="2.166675309816949" CI_START="1.1127185026264477" EFFECT_SIZE="1.552707218511336" ESTIMABLE="YES" ESTIMATE="0.44" LOG_CI_END="0.3357938343839564" LOG_CI_START="0.04638530969090532" LOG_EFFECT_SIZE="0.1910895720374308" MODIFIED="2013-08-02 00:04:29 +0200" MODIFIED_BY="[Empty name]" ORDER="380" SE="0.17" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="28.839373035812297"/>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Local progression/recurrences</NAME>
<IV_OUTCOME CHI2="27.618780819548846" CI_END="1.939543251381058" CI_START="1.1164811662829024" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_SIZE="1.4715513960980284" ESTIMABLE="YES" I2="71.03420294954685" I2_Q="88.2435307654782" ID="CMP-004.01" LOG_CI_END="0.28769946871395047" LOG_CI_START="0.04785140143486647" LOG_DATA="YES" LOG_EFFECT_SIZE="0.1677754350744085" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="5.52437263406147E-4" P_Q="1.2032212171053658E-5" P_Z="0.006106307068892266" Q="25.517865442039124" RANDOM="YES" SCALE="20.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.45682072260397677" TOTALS="SUB" TOTAL_1="555" TOTAL_2="444" WEIGHT="400.0" Z="2.742017594444504">
<NAME>Local progression: control intervention versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="2.100915377509722" CI_END="3.4931022790771555" CI_START="1.7094896582317034" DF="5" EFFECT_SIZE="2.4436493654425937" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="0.5432113020958523" LOG_CI_START="0.2328664778225872" LOG_EFFECT_SIZE="0.38803888995921976" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8350127111592087" P_Z="9.52179568455879E-7" STUDIES="6" TAU2="0.0" TOTAL_1="394" TOTAL_2="284" WEIGHT="100.00000000000001" Z="4.901272323145293">
<NAME>PEI/PAI versus RFA</NAME>
<IV_DATA CI_END="12.863282693373856" CI_START="1.0466797905278984" EFFECT_SIZE="3.6692966676192444" ESTIMABLE="YES" ESTIMATE="1.3" LOG_CI_END="1.1093518141317351" LOG_CI_START="0.019813838816719557" LOG_EFFECT_SIZE="0.5645828264742274" MODIFIED="2012-08-28 11:03:33 +0200" MODIFIED_BY="[Empty name]" ORDER="24" SE="0.64" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="8.11342582100251"/>
<IV_DATA CI_END="5.128362021409346" CI_START="1.1562866259900928" EFFECT_SIZE="2.4351296512898744" ESTIMABLE="YES" ESTIMATE="0.89" LOG_CI_END="0.7099786753155394" LOG_CI_START="0.06306550247224883" LOG_EFFECT_SIZE="0.3865220888938941" MODIFIED="2012-08-28 11:03:36 +0200" MODIFIED_BY="[Empty name]" ORDER="20" SE="0.38" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="23.014260500572213"/>
<IV_DATA CI_END="4.107376540357673" CI_START="0.7612568106341364" EFFECT_SIZE="1.768267051433735" ESTIMABLE="YES" ESTIMATE="0.57" LOG_CI_END="0.6135645182672416" LOG_CI_START="-0.11846880889753457" LOG_EFFECT_SIZE="0.24754785468485352" MODIFIED="2012-08-28 11:03:40 +0200" MODIFIED_BY="[Empty name]" ORDER="55" SE="0.43" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="17.973278616996367"/>
<IV_DATA CI_END="4.7740016498478255" CI_START="0.9201810144030396" EFFECT_SIZE="2.0959355144943643" ESTIMABLE="YES" ESTIMATE="0.74" LOG_CI_END="0.6788825647586458" LOG_CI_START="-0.03612673154183314" LOG_EFFECT_SIZE="0.3213779166084063" MODIFIED="2013-10-27 16:01:36 +0100" MODIFIED_BY="[Empty name]" ORDER="56" SE="0.42" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="18.839337960785876"/>
<IV_DATA CI_END="5.225681571559814" CI_START="1.047508792253731" EFFECT_SIZE="2.3396468519259908" ESTIMABLE="YES" ESTIMATE="0.85" LOG_CI_END="0.7181429423358551" LOG_CI_START="0.020157676899673096" LOG_EFFECT_SIZE="0.369150309617764" MODIFIED="2012-08-28 11:03:44 +0200" MODIFIED_BY="[Empty name]" ORDER="21" SE="0.41" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="19.769537277112605"/>
<IV_DATA CI_END="11.349586050728092" CI_START="1.4781905346286712" EFFECT_SIZE="4.095955404071176" ESTIMABLE="YES" ESTIMATE="1.41" LOG_CI_END="1.05498002195531" LOG_CI_START="0.16973041701185998" LOG_EFFECT_SIZE="0.612355219483585" MODIFIED="2012-08-28 11:03:52 +0200" MODIFIED_BY="[Empty name]" ORDER="25" SE="0.52" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="12.290159823530427"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.8180680753243713" CI_START="0.2838838010365764" DF="0" EFFECT_SIZE="0.48190899009020244" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.02" LOG_CI_END="-0.0872105551213627" LOG_CI_START="-0.5468593884573849" LOG_EFFECT_SIZE="-0.31703497178937384" MODIFIED="2013-10-11 13:11:34 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.00685714034847806" STUDIES="1" TAU2="0.0" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.0" Z="2.7037037037037033">
<NAME>Resection versus RFA</NAME>
<IV_DATA CI_END="0.8180680753243713" CI_START="0.2838838010365764" EFFECT_SIZE="0.48190899009020244" ESTIMABLE="YES" ESTIMATE="-0.73" LOG_CI_END="-0.0872105551213627" LOG_CI_START="-0.5468593884573849" LOG_EFFECT_SIZE="-0.31703497178937384" MODIFIED="2012-08-28 11:03:26 +0200" MODIFIED_BY="[Empty name]" ORDER="69" SE="0.27" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="6.796302748623792" CI_START="0.6727518423260361" DF="0" EFFECT_SIZE="2.1382762204968184" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.03" LOG_CI_END="0.8322727167432364" LOG_CI_START="-0.1721451042502936" LOG_EFFECT_SIZE="0.33006380624647136" MODIFIED="2013-10-11 13:11:49 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.1976987671993077" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="1.288135593220339">
<NAME>Microwave ablation versus RFA</NAME>
<IV_DATA CI_END="6.796302748623792" CI_START="0.6727518423260361" EFFECT_SIZE="2.1382762204968184" ESTIMABLE="YES" ESTIMATE="0.76" LOG_CI_END="0.8322727167432364" LOG_CI_START="-0.1721451042502936" LOG_EFFECT_SIZE="0.33006380624647136" MODIFIED="2012-08-28 11:03:28 +0200" MODIFIED_BY="[Empty name]" ORDER="26" SE="0.59" STUDY_ID="STD-Shibata-2002" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="3.093123036598746" CI_START="0.4028539168482575" DF="0" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" I2="0.0" ID="CMP-004.01.04" LOG_CI_END="0.49039719548108285" LOG_CI_START="-0.3948524094623674" LOG_EFFECT_SIZE="0.0477723930093577" MODIFIED="2013-10-11 13:12:10 +0200" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.8324671233547892" STUDIES="1" TAU2="0.0" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0" Z="0.21153846153846154">
<NAME>Laser ablation versus RFA</NAME>
<IV_DATA CI_END="3.093123036598746" CI_START="0.4028539168482575" EFFECT_SIZE="1.1162780704588713" ESTIMABLE="YES" ESTIMATE="0.11" LOG_CI_END="0.49039719548108285" LOG_CI_START="-0.3948524094623674" LOG_EFFECT_SIZE="0.0477723930093577" MODIFIED="2012-08-28 11:03:57 +0200" MODIFIED_BY="[Empty name]" ORDER="28" SE="0.52" STUDY_ID="STD-Ferrari-2007" TOTAL_1="41" TOTAL_2="40" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Other secondary outcomes</NAME>
<DICH_OUTCOME CHI2="38.398208047522296" CI_END="2.5809200987842473" CI_START="0.7317231283101958" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3742339424570582" ESTIMABLE="YES" EVENTS_1="118" EVENTS_2="34" I2="73.95711803107106" I2_Q="81.5932845445848" ID="CMP-005.01" LOG_CI_END="0.4117745596797728" LOG_CI_START="-0.13565321756637622" LOG_EFFECT_SIZE="0.1380606710566983" METHOD="MH" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="3.234681775288184E-5" P_Q="0.0043708587102724294" P_Z="0.3228581970428269" Q="10.865599595128234" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.7801405422436227" TOTALS="SUB" TOTAL_1="933" TOTAL_2="786" WEIGHT="300.0" Z="0.9886014345628957">
<NAME>Rate of complications: RFA versus other interventions</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="10.429014269331946" CI_END="31.952100101554297" CI_START="2.1230297438205086" DF="2" EFFECT_SIZE="8.236216297131229" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="16" I2="80.82273215522109" ID="CMP-005.01.01" LOG_CI_END="1.504499408113901" LOG_CI_START="0.3269560787098655" LOG_EFFECT_SIZE="0.9157277434118831" MODIFIED="2013-10-11 13:14:24 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.005437120973011522" P_Z="0.0023008706839693694" STUDIES="3" TAU2="1.15465866113047" TOTAL_1="289" TOTAL_2="270" WEIGHT="100.0" Z="3.0483691799940598">
<NAME>Resection versus RFA</NAME>
<DICH_DATA CI_END="101.32219008810185" CI_START="8.671253555494465" EFFECT_SIZE="29.641025641025642" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="3" LOG_CI_END="2.00570456853361" LOG_CI_START="0.9380818855824117" LOG_EFFECT_SIZE="1.471893227058011" MODIFIED="2012-08-28 11:49:56 +0200" MODIFIED_BY="[Empty name]" ORDER="38" O_E="0.0" SE="0.6271268487830473" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="71" VAR="0.39328808446455504" WEIGHT="30.908147900174356"/>
<DICH_DATA CI_END="6.345504381435475" CI_START="1.0578843719648974" EFFECT_SIZE="2.590909090909091" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.8024661483169675" LOG_CI_START="0.024438201383602892" LOG_EFFECT_SIZE="0.4134521748502851" MODIFIED="2012-08-28 11:07:31 +0200" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="0.4570174673291086" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" VAR="0.2088649654439128" WEIGHT="35.088623344682915"/>
<DICH_DATA CI_END="22.705136133367112" CI_START="3.168582529934548" EFFECT_SIZE="8.481927710843374" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="5" LOG_CI_END="1.3561241101477055" LOG_CI_START="0.5008650233843709" LOG_EFFECT_SIZE="0.9284945667660384" MODIFIED="2012-08-28 11:07:33 +0200" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="0.502383421165541" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" VAR="0.2523891018619934" WEIGHT="34.003228755142736"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="5.729010450275531" CI_END="1.4768037528060207" CI_START="0.3290904392815551" DF="6" EFFECT_SIZE="0.6971384337013578" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="0.1693227872983561" LOG_CI_START="-0.48268473462321176" LOG_EFFECT_SIZE="-0.1566809736624279" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45422076904129205" P_Z="0.3462028239000853" STUDIES="8" TAU2="0.0" TOTAL_1="608" TOTAL_2="480" WEIGHT="100.0" Z="0.9419801309530542">
<NAME>PEI/PAI versus RFA</NAME>
<DICH_DATA CI_END="9.54753068330715" CI_START="0.25016203993374253" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9798910627583242" LOG_CI_START="-0.6017785903182264" LOG_EFFECT_SIZE="0.18905623622004888" MODIFIED="2013-01-07 00:28:17 +0100" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.9290805836082194" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" VAR="0.8631907308377895" WEIGHT="16.99314049029066"/>
<DICH_DATA CI_END="26.497155722697" CI_START="0.27950824408839303" EFFECT_SIZE="2.7214285714285715" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4231992580789552" LOG_CI_START="-0.5536053780841927" LOG_EFFECT_SIZE="0.4347969399973813" MODIFIED="2013-01-07 00:28:16 +0100" MODIFIED_BY="[Empty name]" ORDER="147" O_E="0.0" SE="1.1611848286229982" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" VAR="1.3483502062242219" WEIGHT="10.878717777719523"/>
<DICH_DATA CI_END="4.059827218326165" CI_START="0.2262172078733016" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.608507550886488" LOG_CI_START="-0.6454743622745142" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2012-08-28 11:06:53 +0200" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="0.7365951831013531" STUDY_ID="STD-Lencioni-2003" TOTAL_1="52" TOTAL_2="50" VAR="0.5425724637681159" WEIGHT="27.03476924938852"/>
<DICH_DATA CI_END="4.11499029657513" CI_START="0.006370161297647439" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6143688154537941" LOG_CI_START="-2.1958495708371224" LOG_EFFECT_SIZE="-0.7907403776916642" MODIFIED="2012-08-28 11:06:55 +0200" MODIFIED_BY="[Empty name]" ORDER="40" O_E="0.0" SE="1.650736190912647" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" VAR="2.724929971988795" WEIGHT="5.383008557954803"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-08-28 11:06:56 +0200" MODIFIED_BY="[Empty name]" ORDER="57" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.996748095037774" CI_START="0.004323478403334208" EFFECT_SIZE="0.09291338582677165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.30032327877373277" LOG_CI_START="-2.3641667060733953" LOG_EFFECT_SIZE="-1.0319217136498315" MODIFIED="2013-10-30 14:06:41 +0100" MODIFIED_BY="[Empty name]" ORDER="58" O_E="0.0" SE="1.5651346065373446" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" VAR="2.4496463365808085" WEIGHT="5.987934315251858"/>
<DICH_DATA CI_END="4.111141038811602" CI_START="0.006436277470084871" EFFECT_SIZE="0.16266666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6139623761544495" LOG_CI_START="-2.1913652415883536" LOG_EFFECT_SIZE="-0.7887014327169518" MODIFIED="2012-08-28 11:06:57 +0200" MODIFIED_BY="[Empty name]" ORDER="41" O_E="0.0" SE="1.6478633292577902" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" VAR="2.715453551912568" WEIGHT="5.401794241227925"/>
<DICH_DATA CI_END="2.067553501633083" CI_START="0.12310433314750792" EFFECT_SIZE="0.5045045045045045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31545675651401045" LOG_CI_START="-0.9097266600749245" LOG_EFFECT_SIZE="-0.29713495178045707" MODIFIED="2012-08-28 11:07:01 +0200" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.7196788036600636" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" VAR="0.5179375804375804" WEIGHT="28.320635368166702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="41.22459043403359" CI_START="0.46430115614194595" DF="0" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="1.615156349625889" LOG_CI_START="-0.33320023490922485" LOG_EFFECT_SIZE="0.640978057358332" MODIFIED="2013-10-11 13:14:51 +0200" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.19719186448629902" STUDIES="1" TAU2="0.0" TOTAL_1="36" TOTAL_2="36" WEIGHT="100.0" Z="1.2895934114673746">
<NAME>Microwave ablation versus RFA</NAME>
<DICH_DATA CI_END="41.22459043403359" CI_START="0.46430115614194595" EFFECT_SIZE="4.375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.615156349625889" LOG_CI_START="-0.33320023490922485" LOG_EFFECT_SIZE="0.640978057358332" MODIFIED="2012-08-28 11:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="1.1444743022765642" STUDY_ID="STD-Shibata-2002" TOTAL_1="36" TOTAL_2="36" VAR="1.3098214285714285" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.729010450275531" CI_END="1.476803752806021" CI_START="0.3290904392815551" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6971384337013579" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="17" I2="0.0" I2_Q="43.29771545561082" ID="CMP-005.02" LOG_CI_END="0.16932278729835615" LOG_CI_START="-0.48268473462321176" LOG_EFFECT_SIZE="-0.15668097366242784" METHOD="MH" MODIFIED="2013-12-17 16:31:35 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.45422076904129205" P_Q="0.18417656436060437" P_Z="0.3462028239000855" Q="1.7635973718433755" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="608" TOTAL_2="480" WEIGHT="100.0" Z="0.9419801309530539">
<NAME>Rate of complications: PEI or PAI versus RFA</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.9552947138433607" CI_END="1.719062172667404" CI_START="0.3654604032485408" DF="5" EFFECT_SIZE="0.7926216971748515" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="15" I2="0.0" ID="CMP-005.02.01" LOG_CI_END="0.23529158393434793" LOG_CI_START="-0.4371596709146957" LOG_EFFECT_SIZE="-0.10093404349017393" MODIFIED="2013-10-30 14:21:34 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5558703192427925" P_Z="0.5562799456804308" STUDIES="7" TAU2="0.0" TOTAL_1="545" TOTAL_2="449" WEIGHT="94.01206568474814" Z="0.5883760008720631">
<NAME>PEI versus RFA</NAME>
<DICH_DATA CI_END="9.54753068330715" CI_START="0.25016203993374253" EFFECT_SIZE="1.5454545454545454" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="0.9798910627583242" LOG_CI_START="-0.6017785903182264" LOG_EFFECT_SIZE="0.18905623622004888" MODIFIED="2013-10-30 14:20:28 +0100" MODIFIED_BY="[Empty name]" ORDER="118" O_E="0.0" SE="0.9290805836082194" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" VAR="0.8631907308377895" WEIGHT="16.99314049029066"/>
<DICH_DATA CI_END="26.497155722697" CI_START="0.27950824408839303" EFFECT_SIZE="2.7214285714285715" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4231992580789552" LOG_CI_START="-0.5536053780841927" LOG_EFFECT_SIZE="0.4347969399973813" MODIFIED="2013-10-30 14:20:22 +0100" MODIFIED_BY="[Empty name]" ORDER="119" O_E="0.0" SE="1.1611848286229982" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" VAR="1.3483502062242219" WEIGHT="10.878717777719523"/>
<DICH_DATA CI_END="4.059827218326165" CI_START="0.2262172078733016" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.608507550886488" LOG_CI_START="-0.6454743622745142" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-10-30 14:20:36 +0100" MODIFIED_BY="[Empty name]" ORDER="120" O_E="0.0" SE="0.7365951831013531" STUDY_ID="STD-Lencioni-2003" TOTAL_1="52" TOTAL_2="50" VAR="0.5425724637681159" WEIGHT="27.03476924938852"/>
<DICH_DATA CI_END="4.11499029657513" CI_START="0.006370161297647439" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6143688154537941" LOG_CI_START="-2.1958495708371224" LOG_EFFECT_SIZE="-0.7907403776916642" MODIFIED="2013-10-30 14:20:57 +0100" MODIFIED_BY="[Empty name]" ORDER="115" O_E="0.0" SE="1.650736190912647" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" VAR="2.724929971988795" WEIGHT="5.383008557954803"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-10-30 14:20:48 +0100" MODIFIED_BY="[Empty name]" ORDER="114" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.111141038811602" CI_START="0.006436277470084871" EFFECT_SIZE="0.16266666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6139623761544495" LOG_CI_START="-2.1913652415883536" LOG_EFFECT_SIZE="-0.7887014327169518" MODIFIED="2013-10-30 14:21:19 +0100" MODIFIED_BY="[Empty name]" ORDER="116" O_E="0.0" SE="1.6478633292577902" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" VAR="2.715453551912568" WEIGHT="5.401794241227925"/>
<DICH_DATA CI_END="2.067553501633083" CI_START="0.12310433314750792" EFFECT_SIZE="0.5045045045045045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31545675651401045" LOG_CI_START="-0.9097266600749245" LOG_EFFECT_SIZE="-0.29713495178045707" MODIFIED="2013-10-30 14:21:34 +0100" MODIFIED_BY="[Empty name]" ORDER="117" O_E="0.0" SE="0.7196788036600636" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" VAR="0.5179375804375804" WEIGHT="28.320635368166702"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.996748095037774" CI_START="0.004323478403334208" DF="0" EFFECT_SIZE="0.09291338582677167" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" I2="0.0" ID="CMP-005.02.02" LOG_CI_END="0.30032327877373277" LOG_CI_START="-2.3641667060733953" LOG_EFFECT_SIZE="-1.0319217136498313" MODIFIED="2013-10-30 14:21:13 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.12898005880933622" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="31" WEIGHT="5.987934315251858" Z="1.5181362325402508">
<NAME>PAI versus RFA</NAME>
<DICH_DATA CI_END="1.996748095037774" CI_START="0.004323478403334208" EFFECT_SIZE="0.09291338582677165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.30032327877373277" LOG_CI_START="-2.3641667060733953" LOG_EFFECT_SIZE="-1.0319217136498315" MODIFIED="2013-10-30 14:21:13 +0100" MODIFIED_BY="[Empty name]" ORDER="121" O_E="0.0" SE="1.5651346065373446" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" VAR="2.4496463365808085" WEIGHT="5.987934315251858"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1389709299774498" CI_START="0.1944452201195979" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4706032864199828" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="0.05651263969675209" LOG_CI_START="-0.7112027282748002" LOG_EFFECT_SIZE="-0.3273450442890241" METHOD="MH" MODIFIED="2013-10-30 14:22:47 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.09464024603084371" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="NaN" TOTALS="SUB" TOTAL_1="396" TOTAL_2="282" WEIGHT="0.0" Z="1.6714124116580928">
<NAME>PEI/PAI versus RFA, low risk of bias trials</NAME>
<GROUP_LABEL_1>PEI/PAI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI/PAI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.059827218326165" CI_START="0.2262172078733016" EFFECT_SIZE="0.9583333333333334" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.608507550886488" LOG_CI_START="-0.6454743622745142" LOG_EFFECT_SIZE="-0.018483405694013126" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.7365951831013531" STUDY_ID="STD-Lencioni-2003" TOTAL_1="52" TOTAL_2="50" VAR="0.5425724637681159" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.11499029657513" CI_START="0.006370161297647439" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6143688154537941" LOG_CI_START="-2.1958495708371224" LOG_EFFECT_SIZE="-0.7907403776916642" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="1.650736190912647" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" VAR="2.724929971988795" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.0" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.996748095037774" CI_START="0.004323478403334208" EFFECT_SIZE="0.09291338582677165" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.30032327877373277" LOG_CI_START="-2.3641667060733953" LOG_EFFECT_SIZE="-1.0319217136498315" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="1.5651346065373446" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" VAR="2.4496463365808085" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.111141038811602" CI_START="0.006436277470084871" EFFECT_SIZE="0.16266666666666665" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6139623761544495" LOG_CI_START="-2.1913652415883536" LOG_EFFECT_SIZE="-0.7887014327169518" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="1.6478633292577902" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" VAR="2.715453551912568" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.067553501633083" CI_START="0.12310433314750792" EFFECT_SIZE="0.5045045045045045" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.31545675651401045" LOG_CI_START="-0.9097266600749245" LOG_EFFECT_SIZE="-0.29713495178045707" MODIFIED="2013-08-02 00:09:45 +0200" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.7196788036600636" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" VAR="0.5179375804375804" WEIGHT="0.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="661.499702835904" CI_END="2.3533404097929225" CI_START="1.9345282801417856" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="SMD" EFFECT_SIZE="2.143934344967354" ESTIMABLE="YES" I2="98.94179846642554" I2_Q="90.73980768700388" ID="CMP-005.04" MODIFIED="2013-12-18 15:24:57 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.6653345369377348E-15" P_Q="0.0010156052158997175" P_Z="0.0" Q="10.798911795779457" RANDOM="YES" SCALE="5.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="4.475305934915222" TOTALS="SUB" TOTAL_1="633" TOTAL_2="502" UNITS="" WEIGHT="200.0" Z="20.066439359598814">
<NAME>Length of hospital stay; control interventions versus RFA (days)</NAME>
<GROUP_LABEL_1>Control</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.33786333640223365" CI_END="2.3880993965841695" CI_START="1.9673520211105988" DF="2" EFFECT_SIZE="2.177725708847384" ESTIMABLE="YES" I2="0.0" ID="CMP-005.04.01" MODIFIED="2013-10-11 13:18:14 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8445666401049513" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="289" TOTAL_2="270" WEIGHT="100.0" Z="20.288962956661134">
<NAME>Resection versus RFA</NAME>
<CONT_DATA CI_END="2.6437155710788636" CI_START="1.847576763132099" EFFECT_SIZE="2.2456461671054813" ESTIMABLE="YES" MEAN_1="19.7" MEAN_2="9.18" MODIFIED="2012-08-28 11:54:34 +0200" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="5.61" SD_2="3.06" SE="0.20310036669719594" STUDY_ID="STD-Chen-2006" TOTAL_1="90" TOTAL_2="71" WEIGHT="27.929633887525632"/>
<CONT_DATA CI_END="2.4668589747934844" CI_START="1.7116969358127951" EFFECT_SIZE="2.0892779553031398" ESTIMABLE="YES" MEAN_1="14.8" MEAN_2="7.3" MODIFIED="2012-08-28 11:54:30 +0200" MODIFIED_BY="[Empty name]" ORDER="70" SD_1="4.5" SD_2="2.3" SE="0.1926469172233039" STUDY_ID="STD-Feng-2012" TOTAL_1="84" TOTAL_2="84" WEIGHT="31.042917479095422"/>
<CONT_DATA CI_END="2.5268500194466634" CI_START="1.869972861019166" EFFECT_SIZE="2.1984114402329147" ESTIMABLE="YES" MEAN_1="15.36" MEAN_2="6.92" MODIFIED="2012-08-28 11:54:32 +0200" MODIFIED_BY="[Empty name]" ORDER="57" SD_1="4.21" SD_2="3.4" SE="0.16757378288806848" STUDY_ID="STD-Huang-2010" TOTAL_1="115" TOTAL_2="115" WEIGHT="41.027448633378945"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="384.14787973092564" CI_END="0.6817518642986238" CI_START="-3.6899129492363496" DF="4" EFFECT_SIZE="-1.504080542468863" ESTIMABLE="YES" I2="98.95873432835246" ID="CMP-005.04.02" MODIFIED="2013-10-30 09:46:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="2.1094237467877974E-15" P_Z="0.1774463520695841" STUDIES="5" TAU2="6.141838109466845" TOTAL_1="344" TOTAL_2="232" WEIGHT="100.0" Z="1.3486595239229702">
<NAME>PEI/PAI versus RFA</NAME>
<CONT_DATA CI_END="-1.980996477082201" CI_START="-3.2437104725560117" EFFECT_SIZE="-2.6123534748191064" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="4.4" MODIFIED="2013-10-30 09:46:22 +0100" MODIFIED_BY="[Empty name]" ORDER="45" SD_1="0.3" SD_2="1.8" SE="0.3221268363689173" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="19.914211152700744"/>
<CONT_DATA CI_END="-2.348717552179485" CI_START="-3.6963105723692857" EFFECT_SIZE="-3.0225140622743853" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="4.4" MODIFIED="2013-10-30 09:46:21 +0100" MODIFIED_BY="[Empty name]" ORDER="59" SD_1="0.6" SD_2="1.0" SE="0.3437800466792865" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="19.868341760167098"/>
<CONT_DATA CI_END="-1.1708058700752293" CI_START="-2.158735264222871" EFFECT_SIZE="-1.6647705671490503" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="4.2" MODIFIED="2013-10-30 09:46:32 +0100" MODIFIED_BY="[Empty name]" ORDER="60" SD_1="0.6" SD_2="1.9" SE="0.25202743569277364" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="20.043374507224033"/>
<CONT_DATA CI_END="-1.6400175607103504" CI_START="-2.713448737605356" EFFECT_SIZE="-2.176733149157853" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="4.2" MODIFIED="2013-10-30 09:46:23 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="0.4" SD_2="1.9" SE="0.27383951576715027" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="20.00639381151475"/>
<CONT_DATA CI_END="2.224704669492533" CI_START="1.6015608927497509" EFFECT_SIZE="1.913132781121142" ESTIMABLE="YES" MEAN_1="26.1" MEAN_2="10.8" MODIFIED="2013-10-30 09:46:25 +0100" MODIFIED_BY="[Empty name]" ORDER="47" SD_1="9.9" SD_2="5.5" SE="0.15896817024650983" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.167678768393376"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="384.1478797309256" CI_END="0.6817518642986244" CI_START="-3.689912949236349" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="SMD" EFFECT_SIZE="-1.5040805424688624" ESTIMABLE="YES" I2="98.95873432835246" I2_Q="0.0" ID="CMP-005.05" MODIFIED="2013-12-17 16:34:53 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="-1.9984014443252818E-15" P_Q="0.8897928530553257" P_Z="0.17744635206958428" Q="0.01920062980434562" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="6.141838109466844" TOTALS="YES" TOTAL_1="344" TOTAL_2="232" UNITS="" WEIGHT="100.0" Z="1.3486595239229695">
<NAME>Length of hospital stay; PEI or PAI versus RFA (days)</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="350.85235576066844" CI_END="1.2991531683405262" CI_START="-4.23149697278425" DF="3" EFFECT_SIZE="-1.466171902221862" ESTIMABLE="YES" I2="99.14493947361538" ID="CMP-005.05.01" MODIFIED="2013-10-30 14:27:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="-6.661338147750939E-16" P_Z="0.2987254814551924" STUDIES="4" TAU2="7.882230049160634" TOTAL_1="281" TOTAL_2="201" WEIGHT="79.95662549277597" Z="1.0391704592310425">
<NAME>PEI versus RFA</NAME>
<CONT_DATA CI_END="-1.980996477082201" CI_START="-3.2437104725560117" EFFECT_SIZE="-2.6123534748191064" ESTIMABLE="YES" MEAN_1="1.6" MEAN_2="4.4" MODIFIED="2013-10-30 14:27:34 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="0.3" SD_2="1.8" SE="0.3221268363689173" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="19.914211152700744"/>
<CONT_DATA CI_END="-2.348717552179485" CI_START="-3.6963105723692857" EFFECT_SIZE="-3.0225140622743853" ESTIMABLE="YES" MEAN_1="2.1" MEAN_2="4.4" MODIFIED="2013-10-30 14:27:24 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="0.6" SD_2="1.0" SE="0.3437800466792865" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="19.868341760167095"/>
<CONT_DATA CI_END="-1.6400175607103504" CI_START="-2.713448737605356" EFFECT_SIZE="-2.176733149157853" ESTIMABLE="YES" MEAN_1="1.7" MEAN_2="4.2" MODIFIED="2013-10-30 14:27:48 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="0.4" SD_2="1.9" SE="0.27383951576715027" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="20.00639381151475"/>
<CONT_DATA CI_END="2.224704669492533" CI_START="1.6015608927497509" EFFECT_SIZE="1.913132781121142" ESTIMABLE="YES" MEAN_1="26.1" MEAN_2="10.8" MODIFIED="2013-10-30 14:27:59 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="9.9" SD_2="5.5" SE="0.15896817024650983" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="20.167678768393376"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="-1.1708058700752293" CI_START="-2.158735264222871" DF="0" EFFECT_SIZE="-1.6647705671490503" ESTIMABLE="YES" I2="0.0" ID="CMP-005.05.02" MODIFIED="2013-10-30 14:28:14 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="3.9614245883022465E-11" STUDIES="1" TAU2="0.0" TOTAL_1="63" TOTAL_2="31" WEIGHT="20.043374507224037" Z="6.605513255225269">
<NAME>PAI versus RFA</NAME>
<CONT_DATA CI_END="-1.1708058700752293" CI_START="-2.158735264222871" EFFECT_SIZE="-1.6647705671490503" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="4.2" MODIFIED="2013-10-30 14:28:14 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="0.6" SD_2="1.9" SE="0.25202743569277364" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="20.043374507224037"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2013-12-17 16:34:32 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>PEI or PAI versus RFA, overall survival, other</NAME>
<DICH_OUTCOME CHI2="29.059385584041095" CI_END="3.22256195083306" CI_START="0.9661382521101436" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RR" EFFECT_SIZE="1.7644943668072468" ESTIMABLE="YES" EVENTS_1="150" EVENTS_2="119" I2="82.7938550677895" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.5082012750235273" LOG_CI_START="-0.014960722619291059" LOG_EFFECT_SIZE="0.24662027620211813" METHOD="MH" MODIFIED="2013-10-30 09:45:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.257385038428872E-5" P_Q="1.0" P_Z="0.06462160557619867" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3905305868193786" TOTALS="YES" TOTAL_1="490" TOTAL_2="496" WEIGHT="99.99999999999999" Z="1.8478668610921707">
<NAME>PEI versus RFA, dichotomous outcome</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI/PAI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6588083464389556" CI_START="0.7195666941764514" EFFECT_SIZE="1.0925306577480491" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="26" LOG_CI_END="0.2197962118880634" LOG_CI_START="-0.14292894659125777" LOG_EFFECT_SIZE="0.038433632648402806" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="674" O_E="0.0" SE="0.2130665536092455" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" VAR="0.045397356266921485" WEIGHT="21.66371205474212"/>
<DICH_DATA CI_END="0.9539736555575933" CI_START="0.4991509734004691" EFFECT_SIZE="0.6900557070048595" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="59" LOG_CI_END="-0.020463618381798346" LOG_CI_START="-0.30176807762702973" LOG_EFFECT_SIZE="-0.16111584800441403" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="675" O_E="0.0" SE="0.16523963184017978" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="142" VAR="0.027304135930678156" WEIGHT="22.60180143354621"/>
<DICH_DATA CI_END="42.96149459029452" CI_START="0.629400821779339" EFFECT_SIZE="5.2" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6330793816539486" LOG_CI_START="-0.20107269438435035" LOG_EFFECT_SIZE="0.7160033436347992" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="676" O_E="0.0" SE="1.0773900086641006" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" VAR="1.1607692307692308" WEIGHT="6.087680362341169"/>
<DICH_DATA CI_END="20.109936143075103" CI_START="1.9945916697961985" EFFECT_SIZE="6.333333333333333" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" LOG_CI_END="1.3034106915438257" LOG_CI_START="0.29985400092250714" LOG_EFFECT_SIZE="0.8016323462331665" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.589494167756699" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="52" VAR="0.3475033738191633" WEIGHT="12.7959117592189"/>
<DICH_DATA CI_END="8.642540668893743" CI_START="1.337569638706681" EFFECT_SIZE="3.4" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="5" LOG_CI_END="0.9366414318632243" LOG_CI_START="0.1263164022212859" LOG_EFFECT_SIZE="0.5314789170422551" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="678" O_E="0.0" SE="0.4759889335852628" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="62" VAR="0.22656546489563573" WEIGHT="15.303642616723359"/>
<DICH_DATA CI_END="2.5415963360217493" CI_START="1.0791646269434034" EFFECT_SIZE="1.656140350877193" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="25" LOG_CI_END="0.4051065757384005" LOG_CI_START="0.03308770151275469" LOG_EFFECT_SIZE="0.2190971386255776" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="679" O_E="0.0" SE="0.21852572824327152" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" VAR="0.04775349390425216" WEIGHT="21.547251773428236"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.8736416009585023" CI_END="2.5495111778550186" CI_START="1.457190152674337" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="1.927465325888765" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-006.02" LOG_CI_END="0.4064569203906123" LOG_CI_START="0.16351622772658486" LOG_DATA="YES" LOG_EFFECT_SIZE="0.2849865740585986" MODIFIED="2013-10-11 13:23:17 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9721004618649501" P_Q="1.0" P_Z="4.25845875979059E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="394" TOTAL_2="284" WEIGHT="100.0" Z="4.598352092498313">
<NAME>PEI/PAI versus RFA, low risk of bias trials</NAME>
<GROUP_LABEL_1>PEI/PAI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI/PAI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_DATA CI_END="45.82176985481562" CI_START="0.5462058811922451" EFFECT_SIZE="5.002811227833588" ESTIMABLE="YES" ESTIMATE="1.61" LOG_CI_END="1.6610718596970229" LOG_CI_START="-0.26264362796855173" LOG_EFFECT_SIZE="0.6992141158642354" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="353" SE="1.13" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="1.5948463465677714"/>
<IV_DATA CI_END="4.202111068780668" CI_START="1.0247134018746136" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.623467527346722" LOG_CI_START="0.010602416232025747" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="354" SE="0.36" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="15.713420524169651"/>
<IV_DATA CI_END="3.6516775848029814" CI_START="0.856255321718074" EFFECT_SIZE="1.768267051433735" ESTIMABLE="YES" ESTIMATE="0.57" LOG_CI_END="0.5624924256743503" LOG_CI_START="-0.06739671630464317" LOG_EFFECT_SIZE="0.24754785468485352" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="356" SE="0.37" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x002d_hd_x0029_" TOTAL_1="53" TOTAL_2="26" WEIGHT="14.875524469922475"/>
<IV_DATA CI_END="3.54801309319538" CI_START="0.9357679454746356" EFFECT_SIZE="1.8221188003905089" ESTIMABLE="YES" ESTIMATE="0.6" LOG_CI_END="0.5499852138350022" LOG_CI_START="-0.028831835551099985" LOG_EFFECT_SIZE="0.2605766891419511" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="357" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PAI_x0029_" TOTAL_1="63" TOTAL_2="31" WEIGHT="17.616429930210955"/>
<IV_DATA CI_END="3.921160887551156" CI_START="1.0341835194059656" EFFECT_SIZE="2.0137527074704766" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.5934146620253273" LOG_CI_START="0.01459761263922522" LOG_EFFECT_SIZE="0.3040061373322763" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="355" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="17.616429930210955"/>
<IV_DATA CI_END="3.0343310736053684" CI_START="1.1388386372277903" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.4820629645837301" LOG_CI_START="0.05646219297630215" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2013-09-04 23:42:45 +0200" MODIFIED_BY="[Empty name]" ORDER="358" SE="0.25" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="32.58334879891819"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.534936178933269" CI_END="2.0802120307192036" CI_START="1.2373200760166496" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_SIZE="1.6043341634398471" ESTIMABLE="YES" I2="0.0" I2_Q="64.90426401541512" ID="CMP-006.03" LOG_CI_END="0.3181076037503829" LOG_CI_START="0.09248205958605853" LOG_DATA="YES" LOG_EFFECT_SIZE="0.2052948316682207" MODIFIED="2013-12-17 16:34:32 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.47522280085750745" P_Q="0.09141106111134478" P_Z="3.614907266180646E-4" Q="2.8493489933911933" RANDOM="YES" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="490" TOTAL_2="425" WEIGHT="100.0" Z="3.566710301107369">
<NAME>PEI versus RFA, Italian versus Asian trials</NAME>
<GROUP_LABEL_1>PEI</GROUP_LABEL_1>
<GROUP_LABEL_2>RFA</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours PEI</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours RFA</GRAPH_LABEL_2>
<EFFECT_MEASURE>Hazard Ratio</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="1.6102096130137034" CI_END="1.8429410563537616" CI_START="0.83565101121924" DF="2" EFFECT_SIZE="1.2409897490952435" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.01" LOG_CI_END="0.26551144519754855" LOG_CI_START="-0.07797505694587009" LOG_EFFECT_SIZE="0.09376819412583927" MODIFIED="2013-10-11 13:24:29 +0200" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.44704126158075896" P_Z="0.2845747596579289" STUDIES="3" TAU2="0.0" TOTAL_1="262" TOTAL_2="250" WEIGHT="43.14765350656398" Z="1.0700990125386012">
<NAME>Italian trials</NAME>
<IV_DATA CI_END="2.010512280496049" CI_START="0.6450744415974338" EFFECT_SIZE="1.1388283833246218" ESTIMABLE="YES" ESTIMATE="0.13" LOG_CI_END="0.30330673017973103" LOG_CI_START="-0.1903901648848855" LOG_EFFECT_SIZE="0.05645828264742272" MODIFIED="2013-09-11 19:35:30 +0200" MODIFIED_BY="[Empty name]" ORDER="100" SE="0.29" STUDY_ID="STD-Brunello-2008" TOTAL_1="69" TOTAL_2="70" WEIGHT="20.88602250370808"/>
<IV_DATA CI_END="2.1779619528630585" CI_START="0.6988008002701454" EFFECT_SIZE="1.2336780599567432" ESTIMABLE="YES" ESTIMATE="0.21" LOG_CI_END="0.3380502887319911" LOG_CI_START="-0.15564660633262534" LOG_EFFECT_SIZE="0.09120184119968286" MODIFIED="2013-09-11 19:35:34 +0200" MODIFIED_BY="[Empty name]" ORDER="101" SE="0.29" STUDY_ID="STD-Giorgio-2011" TOTAL_1="143" TOTAL_2="128" WEIGHT="20.88602250370808"/>
<IV_DATA CI_END="45.82176985481562" CI_START="0.5462058811922451" EFFECT_SIZE="5.002811227833588" ESTIMABLE="YES" ESTIMATE="1.61" LOG_CI_END="1.6610718596970229" LOG_CI_START="-0.26264362796855173" LOG_EFFECT_SIZE="0.6992141158642354" MODIFIED="2013-09-11 19:35:50 +0200" MODIFIED_BY="[Empty name]" ORDER="102" SE="1.13" STUDY_ID="STD-Lencioni-2003" TOTAL_1="50" TOTAL_2="52" WEIGHT="1.3756084991478186"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.07537757252837317" CI_END="2.7514092879557217" CI_START="1.3813986947826042" DF="2" EFFECT_SIZE="1.9495623096466468" ESTIMABLE="YES" I2="0.0" ID="CMP-006.03.02" LOG_CI_END="0.439555198997188" LOG_CI_START="0.14031904132628822" LOG_EFFECT_SIZE="0.28993712016173806" MODIFIED="2013-10-11 13:24:34 +0200" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9630125976222906" P_Z="1.4580207856105103E-4" STUDIES="3" TAU2="0.0" TOTAL_1="228" TOTAL_2="175" WEIGHT="56.852346493436016" Z="3.798112619286127">
<NAME>Asian trials</NAME>
<IV_DATA CI_END="4.202111068780668" CI_START="1.0247134018746136" EFFECT_SIZE="2.0750806076741224" ESTIMABLE="YES" ESTIMATE="0.73" LOG_CI_END="0.623467527346722" LOG_CI_START="0.010602416232025747" LOG_EFFECT_SIZE="0.3170349717893738" MODIFIED="2013-09-11 19:37:30 +0200" MODIFIED_BY="[Empty name]" ORDER="103" SE="0.36" STUDY_ID="STD-Lin-2004-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="52" TOTAL_2="26" WEIGHT="13.553352566063653"/>
<IV_DATA CI_END="3.921160887551156" CI_START="1.0341835194059656" EFFECT_SIZE="2.0137527074704766" ESTIMABLE="YES" ESTIMATE="0.7" LOG_CI_END="0.5934146620253273" LOG_CI_START="0.01459761263922522" LOG_EFFECT_SIZE="0.3040061373322763" MODIFIED="2013-09-11 19:37:35 +0200" MODIFIED_BY="[Empty name]" ORDER="104" SE="0.34" STUDY_ID="STD-Lin-2005-_x0028_RFA-vs.-PEI_x0029_" TOTAL_1="62" TOTAL_2="31" WEIGHT="15.194762046382776"/>
<IV_DATA CI_END="3.0343310736053684" CI_START="1.1388386372277903" EFFECT_SIZE="1.858928041846342" ESTIMABLE="YES" ESTIMATE="0.62" LOG_CI_END="0.4820629645837301" LOG_CI_START="0.05646219297630215" LOG_EFFECT_SIZE="0.26926257878001614" MODIFIED="2013-09-11 19:37:39 +0200" MODIFIED_BY="[Empty name]" ORDER="105" SE="0.25" STUDY_ID="STD-Shiina-2005" TOTAL_1="114" TOTAL_2="118" WEIGHT="28.104231880989587"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-12-17 16:36:33 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram of the literature search as well as number and reasons of excluded studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAakAAALiCAYAAABjWylpAABLf0lEQVR42u2dD4QV3///PyRJkkiy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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies (survival outcomes).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAiIAAAEZCAMAAACdP77rAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2013-12-17 19:48:43 +0100" MODIFIED_BY="[Empty name]" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study (survival outcomes).</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZUAAAKfCAIAAAApSsKXAAAo+0lEQVR42u3dv27cSNbG4QYMGA46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</FILE>
</FIGURE>
<FIGURE FILENAME="Bildschirmfoto 2013-12-17 um 18.39.12.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2013-12-17 18:42:44 +0100" MODIFIED_BY="[Empty name]" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Trial sequential analysis for the comparison radiofrequency ablation versus hepatic resection on mortality in patients with hepatocellular carcinoma. </B>
</P>
<P>The diversity-adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the percutaneous ethanol injection group (PEI); a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. The cumulative Z-score never crossed the alpha-spending monitoring boundary for harm and did not reach the beta-spending monitoring boundaries (the area of futility), which was not even drawn by the program. Therefore, further randomised trials are needed.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA5oAAAKzCAIAAADwQ+WWAACAAElEQVR42uydB5hURfruwYBrdldX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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Bildschirmfoto 2013-12-17 um 18.36.15.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2013-12-17 18:42:44 +0100" MODIFIED_BY="[Empty name]" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>
<B>Trial sequential analysis for the comparison radiofrequency ablation versus percutaneous ethanol injection group (PEI) on mortality in patients with hepatocellular carcinoma. </B>
<BR/>
<BR/>The diversity-adjusted required information size (DARIS) was calculated based upon a proportion of deaths of 30% in the PEI group; a relative risk reduction (RRR) of 20%; an alpha of 5% (a); a beta of 20% (b); and an assumed squared diversity (D) of 30%. As it can be seen, the cumulative Z-score has never crossed the alpha-spending monitoring boundary for benefit and has not reached the beta-spending monitoring boundary (the area of futility). Therefore, further randomised trials are needed.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA3YAAAKaCAIAAAD9PlyXAACAAElEQVR42uydB9xeRZX/bwpBCIm0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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2010-12-25 21:57:34 +0100" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-12-17 19:51:39 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-12-17 19:51:39 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-10 01:34:50 +0100" MODIFIED_BY="[Empty name]">Search strategies</TITLE>
<APPENDIX_BODY MODIFIED="2013-12-17 19:51:39 +0100" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="6">
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Name of database</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Time spans</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Search strategy</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Hits</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Hepato-Biliary Controlled Trials Register</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>September 2012.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>(((radiofrequenc* or radio-frequenc* or 'radio frequenc*') AND (ablation* or therap* or treat*)) OR RFTA or RFA or RFT or RFCA) AND ((hepat* or liver) AND (carcinom* or tumour* or tumour* or neoplasm* or malign* or cancer*))<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>35</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>The Cochrane Central Register of Controlled Trials (CENTRAL) in <I>The Cochrane Library</I>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Issue 8 of 12, 2012.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 MeSH descriptor Catheter Ablationexplode all trees</P>
<P>#2 (radiofrequenc* or radio-frequenc* or radio frequenc*) AND (ablation* or therap* or treat*)</P>
<P>#3 (RFTA or RFA or RFT or RFCA)</P>
<P>#4 (#1 OR #2 OR #3)</P>
<P>#5 MeSH descriptor Carcinoma, Hepatocellularexplode all trees</P>
<P>#6 ((hepat* or liver) AND (carcinom* or tumour* or tumour* or neoplasm* or malign* or cancer*))</P>
<P>#7 HCC</P>
<P>#8 (#5 OR #6 OR #7)</P>
<P>#9 (#4 AND #8)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>94</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>MEDLINE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1946 to September 2012.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1. exp Catheter Ablation/</P>
<P>#2. ((radiofrequenc* or radio-frequenc* or radio frequenc*) and (ablation* or therap* or treat*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>#3. (RFTA or RFA or RFT or RFCA).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>#4. #1 or #2 or #3</P>
<P>#5. exp Carcinoma, Hepatocellular/</P>
<P>#6. exp Liver Neoplasms/</P>
<P>#7. ((hepat* or liver) and (carcinom* or tumour* or tumour* or neoplasm* or malign* or cancer*)).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>#8. HCC.mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>#9. #5 or #6 or #7 or #8</P>
<P>#10. #4 and #9</P>
<P>#11. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]</P>
<P>#12. #10 and #11<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>330</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>EMBASE (Ovid SP)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1974 to September 2012.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>#1 exp radiofrequency ablation/</P>
<P>#2 exp catheter ablation/</P>
<P>#3 (radiofrequenc* or radio-frequenc* or radio frequenc*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#4 (ablation* or therap* or treat*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#5 #4 and #3</P>
<P>#6 (RFTA or RFA or RFT or RFCA).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#7 6 or 1 or 2 or 5</P>
<P>#8 exp liver cell carcinoma/</P>
<P>#9 (hepat* or liver).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#10 (carcinom* or tumour* or tumour* or neoplasm* or malign* or cancer*).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#11 10 and 9</P>
<P>#12 HCC.mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#13 8 or 11 or 12</P>
<P>#14 7 and 13</P>
<P>#15 (random* or blind* or placebo* or meta-analysis).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]</P>
<P>#16 15 and 14</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>748</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>Science Citation Index Expanded (ISI Web of Science)</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>1900 to September 2012.</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P># 1 TS=(radiofrequenc* or radio-frequenc* or radio frequenc*)</P>
<P># 2 TS=(ablation* or therap* or treat*)</P>
<P># 3 #2 AND #1</P>
<P># 4 TS=(RFTA or RFA or RFT or RFCA)</P>
<P># 5 #4 OR #3</P>
<P># 6 TS=(hepat* or liver)</P>
<P># 7 TS=(carcinom* or tumour* or tumour* or neoplasm* or malign* or cancer*)</P>
<P># 8 #7 AND #6</P>
<P># 9 TS=HCC</P>
<P># 10 #9 OR #8</P>
<P># 11 #10 AND #5</P>
<P># 12 TS=(random* or blind* or placebo* or meta-analys*)</P>
<P># 13 #12 AND #11<BR/>
</P>
</TD>
<TD ALIGN="LEFT" VALIGN="TOP">
<P>801</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2010-12-25 21:57:34 +0100" MODIFIED_BY="[Empty name]">
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;11 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;12 studies included in qualitative synthesis&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;38 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1290 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1290 records after duplicates removed&lt;/p&gt;">
<FLOWCHARTBOX TEXT="&lt;p&gt;2008 records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;0 additional records identified through other sources&lt;/p&gt;"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1252 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;26 full-text articles excluded, with reasons&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1 included studies not analysed as it reported mid-term results of another included long-term trial&lt;/p&gt;" WIDTH="124"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>